Methods: Twenty boys with central precocious puberty treated with GnRHa at a dose of 60–80 μg/kg every 4 weeks for (20.5 +/- 6.7) months. At the beginning of therapy, mean chronological age and bone age was (11.2 +/- 1.0) y and (13.0 +/- 0.4) y, respectively. GnRH was discontinued when the boys reached the chronological age and bone age of (13.2 +/- 1.1) y and (13.7 +/- 0.6) y, respectively. At the conclusion of the study, all the boys had been followed up for (3.3 +/- 1.5) years and had achieved adult height. Comparisons were made among their final adult height (FAH), target height (TH), predicted adult height (PAH) at the start and the end of GnRHa treatment (PAH and PAHe).

Results: Final height was similar to the target height [(168.6 +/- 5.6) cm versus (167.8 +/- 4.6) cm] with no significant difference from the predicted adult height (PAH) [(168.6 +/- 5.6) cm versus (169.8 +/- 6.0) cm] based on the Bayley-Pinneau method, using a table for average bone age at the beginning of GnRH analogue therapy. Predicted adult height (PAH) at discontinuation of GnRHa therapy was significantly higher than predicted adult height at the beginning of GnRH analogue therapy [(172.5 +/- 7.0) cm versus (168.6 +/- 5.6) cm, P<0.05]. Ninety percent (90.0%) of the boys reached target height range (FAH>THt-1SD). The height gain in comparison with predicted adult height before the start of treatment was (-1.2 +/- 3.3) cm, with the residual growth capacity of (10.6 +/- 4.3) cm.

Conclusions: GnRHa treatment can improve final height into the range of target height in boys with central precocious puberty.

Background: Fanconi-Bickel syndrome (FBS) is a rare autosomal recessive disorder of carbohydrate metabolism caused by mutations in Glut2. To date there is no case has been reported from China.

Objective and hypotheses: To summarize the clinical characteristics of FBS by reviewing the 2 cases and published literature.

Methods: We reported the first two cases of FBS in China. We summarized the clinical characteristics of FBS by reviewing the 2 cases and published literature.

Results: The both cases presented similar manifestations as reported, including severe short stature, hypoglycemia, hepatomegaly secondary to glycogen accumulation, severe glycaemia secondary to proximal renal tubular dysfunction. And more points may help to differentiate FBS and type I glycogen storage disease(GSD I) including glucose intolerance with normal lactic acid and uric acid, possible and slightly glucose response to glucagon stimulation without accumulation of lactic acid, severe symptoms of hypophosphatemia and rickets, and metabolic acidosis caused by type II renal tubular acidosis. After receiving symptomatic treatment both children presented catch-up growth.

Conclusions: FBS is a rare inherited disease caused by mutations in Glut2. It should be carefully differentiated from GSD I and diabetes mellitus in clinical practice. Symptomatic treatment can be helpful.
Influence of birth brain size on newborn serum insulin-like growth factor-I: role of birth size beyond the presence of intrauterine growth retardation and of preterm birth

Cesare Terzi1, Raffaele Viridi1, Werner F. Blum2, Sergio Zani3, Marco Riani4, Gabrielle Tridoni5, Andrea Cerioli6, Elena Chesi5, Sergio Bernasconi1, Giacomo Banchini6

1University of Parma, Department of Pediatrics, Parma, Italy; 2University of Giessen, Department of Pediatrics, Giessen, Germany; 3University of Parma, Department of Economics, Parma, Italy; 4Saint Maria Nuova Hospital, Department of Obstetrics, Reggio Emilia, Italy; 5University of Parma, Department of Pediatrics, Parma, Italy

Background: The birth brain size - body size ratio has been related to fetal-neonatal stress.

Objective and hypotheses: The birth size - related predictor role of birth brain weight (BRW) on the ratio between serum Insulin-like Growth Factor Binding Protein-2 and -3 (resp. IB2 and IB3) in the human newborn (NWB) could not be completely explained by preterm birth (PT) and intrauterine growth retardation (SGA).

Methods: 78 NBWs 1) free of diabetes mellitus (DM)/life-threatening disease, 2) free of mother with DM and 3) with all of the following variables available were included in the study: gender (SEX), birth gestational age in completed weeks (GA), birth head circumference in cm and birth body weight in gr (resp. HC and BW), IB2 and chronologically corresponding IB3 measured in ug/dL at one of the first 5 postnatal days (x), 5 days after x (y) and 10 days after x (z) by radioimmunnoassay and postnatal age in completed days at x (PNA) (PT definition: GA≤35; SGA definition: BW<10th centile for GA and SEX; males, n=43; GA range=28-42; PT, n=46; SGA, n=20). BRW in gr was calculated according to the formula " BRW= 0.037 x HC " (McLennan JE, 1983; Lindley AA, 2000). An estimate of birth body size not represented by brain was obtained by subtracting BRW from BW (BW minus BRW, NBBW). IB2 was divided by the chronologically corresponding IB3, IB2/IB3, IB2/IB3x-ln, y-ln and z-ln were near-normally distributed. SEX, PT and SGA were dichotomized.

Results: Table 1 shows t value (t), partial correlation coefficient (r) and significance level (p) of partial correlations of BRW with IB2/IB3x-ln, IB2/IB3y-ln and IB2/IB3z-ln as outcome and, as predictors, either 1) BRW, SEX, PT, SGA and PNA (Table 1A), or 2) BRW, SEX, PT, NBBW and PNA (Table 1B).

Conclusions: A direct BRW relation to IB1 was observed in studied NBWs after controls including PT and SGA, which could be in part explained by peripheral, i.e., not BRW-related, birth size.

Table 1. vs. A) IB2/IB3-ln A) IB2/IB3-ln A) IB2/IB3-ln // B) IB1/IB3-ln B) IB1/IB3-ln B) IB1/IB3-ln
BRW t/p 2.506/2.83a .281/ .315b 2.211/2.52a // .059/ .007a .093ms .035ms
R2p 285c .459c .302c // .375c .486c .347c
Significances: a, p<0.05; b, p<0.01; c, p<0.001; ns, not significant.

Background: In this study, we investigated the changes of serum levels of Free T4 and T3, T3 resin uptake (T3RU) and TSH in epileptic children during chronic treatment with anti-epileptic drugs (carbamazepine, Primidone, phenobarbital and valproate) and 3 months later than prescription.

Material and method: This study consisted of four case-series comparisons, was accomplished on 115 (in 4 same groups) epileptic children who were involved 37 girls and 78 boys with ages between 2 months to 15 years (mean: 62.06 ± 44.97 months), who were taking either phenobarbital (n=29), PRM(n=28), CBZ (n=29), or VPA (n=29) at least for 3 months were evaluated T3, T3 resin uptake (T3RU), T4 and thyroid-stimulating hormone (TSH) levels in start and end of study.

Results: All patients were in euthyroid state, there were no clinical findings or laboratory results of hypothyroidism. In collation with thyroid hormones before of prescription in all bundles (Phenobarbital, CBZ, VPA and primidone), there was no significant distinctions in serum FT3, FT4, T3RU and TSH levels.

Conclusions: Thyroid function should be evaluated intermittently in epileptic children using AEDs specially in long term prescriptions.
Edema has been accepted as an uncommon complication occurring after initiating of insulin therapy in the absence of heart, liver or renal disease. In newly diagnosed type 1 diabetic children and adolescents insulin-induced edema should be considered after the initiation of insulin therapy.
Results: The study revealed that according to the glucometer’s readings the minimum glycemia level was 6.72±1.31 mmol/l; CGMS displayed 3.46±0.44 mmol/l (p < 0.001). The maximum glycemia level was 14.93±1.15 mmol/l (glucometer) and 18.18±1.48 mmol/l (CGMS) (p < 0.01). The mean glycemia level was 9.76 mmol/l (glucometer) and 10.8 mmol/l (CGMS). According to the CGMS results the patients were in the normoglycemia conditions during the 73% of the whole research period, hyperglycemia was registered at 24.68%; and hypoglycemia was registered at 3.47%. The readings of the regular glucometer showed normoglycemia at the 52% of the whole period, hyperglycemia at the 48%; hypoglycemia wasn’t revealed. The initial HbA1C level was 7.95%; after the three month it decreased to 7.41%(p > 0.05). The lack of accuracy may be caused by the limited sampling.

Conclusions: CGMS is able to reflect the adequate ratio of the hyper- hypo- and normoglycemia and helps to reveal the most serious latent hypoglycemias which are difficult to detect with the glucometer. CGMS helps to detect the actual glycemia variability in patients. CGMS shows more accurate results in the mean glycemia measuring and improves glycemic control quality.

Methods: Group 1 included 121 healthy children born in Italy or living in Italy since at least 1 year (78 females and 43 females, mean age 9.5±4.1 years). Group 2 included 168 adopted or migrant children living in Italy since less than 1 year (62 females, 106 males, mean age 5.45±3.1 years); the geographical area of origin were Sub-Saharan Africa (n=29), Latin America (n=36), Eastern Europe (n=37), Russia (n=24), Southeast Asia (n=25), Indian subcontinent (n=17).

Results: In group 1 mean serum level of 25(OH)D was 25.3±11.1 ng/mL; 34.7% of children was vitamin-D deficient and 39.6% was insufficient. In group 2 mean serum level of 25(OH)D was 29.0±17.9 ng/mL (significantly higher compared to group 1, p=0.04); 29.8% of children was vitamin-D deficient and 29.8% was insufficient. The subgroup from Southeast Asia had better levels of 25(OH)D (40.2±24.3 ng/mL) compared to the other subgroups. Comparing group 1 versus group 2 without subgroup from Southeast Asia (n=143), mean 25(OH)D 27.0±15.9 ng/mL, we found no significant differences (p=0.05).

Conclusions: Hypovitaminosis D is highly prevalent in both Italian (74.3%) and adopted or migrant children (59.6%); we exclude subgroup from Southeast Asia the prevalence in group 2 raises to 65.7%. We have no explanation for the higher levels of 25(OH)D found in this subgroup (Philippines, Cambodia and Vietnam).
Objective and hypotheses: The aim of the study is to assess the effect of physical activity on BMD, BMC and bone area (BA) in healthy Danish children. The study also aims to evaluate the relationship between fracture risk and BMD.

Method: The study is a three year controlled intervention study from August 2008-August 2011 in 10 public schools in the municipality of Svendborg, DK. Children aged 8 to 11 years were invited, 740 children accepted. Six schools were selected as intervention schools, where the children receive 6 lessons of physical education (PE) per week versus 2 lessons of PE at the four control schools. Blood samples were collected during September 2008 and September 2010. Biomarkers of bone health are measured. Whole-body DXA scans, (Lunar Prodigy) were performed at 718 children at baseline and BMD, BMC, and BA were measured. The DXA scans were repeated during the fall 2010 to February 2011. 684 children participated. Anthropometrics was registered every four month. X-ray of the left hand- wrist was taken at baseline and after the intervention for assessment of bone age. The children’s level of physical activity was recorded by accelerometers. Information about fractures was received through questionnaires and SMS-track.

Results and perspectives: Preliminary analysis has revealed that, the children in the two groups were similar regarding to anthropometrics, motor performance and aerobic fitness at baseline. Results from the DXA scans will be correlated to fracture risk and the two groups will be compared regarding BMD, BMC and BA values.

Conclusions: The data collection has just been completed and the results will be processed through the following months.

PAO-15

A peculiar cognitive and behavioural phenotype as the first clue to suspect Klinefelter syndrome in prepubertal males

Maria Francesca Messina; Fortunato Lombardo; Valentina Comito;
Tommaso Aversa; Danila Pecoraro; Mariella Valenzise; Filippo De Luca
University of Messina, Department of Pediatrics, Messina, Italy

Background: Klinefelter syndrome (KS) with the classic 47 XXY karyotype is the most frequent chromosomal aneuploidy with a prevalence of 1 in 700 males and, although the classical clinical picture is well-known and easily recognizable, most patients remain undiagnosed. The rate of diagnosis is extremely low in childhood and only 10% of cases are identified before puberty because the classical signs and symptoms of androgen deficiency appear only in late adolescence. A common element, often underappreciated, in these young boys is the peculiar cognitive and behavioural pattern.

Case report: We describe two patients who were diagnosed in prepubertal age, respectively at 7.1 and 10 years, due to a peculiar neurocognitive profile. Both of them showed on WISC III low-normal scores, i.e. FSIQ, PIQ and VIQ ranging between 80 and 85 and a behavioural profile characterized by immaturity, insecurity, shyness and low-self esteem, learning disabilities and academic difficulties. On clinical examination both of them showed a height taller than target height and a progressive growth acceleration between 5 and 7 years, and from the pubertal point of view they had prepubertal testes volume (< 2 cc) and one of them had hypoplastic scrotum with monolateral cryptorchidism. Hormonal pattern confirmed normal prepubertal basal levels of gonadotropins.

Conclusions: We believe that to achieve the goal of an early diagnosis in KS, it is necessary to increase medical awareness of the disease and in particular to augment paediatricians’ knowledge that in prepubertal age pathognomonic endocrinological features of KS are often lacking but a peculiar cognitive and behavioural pattern is always present, especially when accurately searched.

PAO-16

Effect of a large ventricular defect (VSD) on linear growth: a lesson from an affected baby who is one of triplets

Ashraf Soliman1; Amal Sabt; Ahmed Elawwa; Haytham Yassin2
1Hamad Medical Center and University of Alexandria, Pediatrics, Doha, Qatar; 2Hamad Medical Center, Cardiology, Doha, Qatar

Background: Large VSD may delay growth and compromise adult height. Objectives: Study the effect of large VSD on linear growth in a girl with large VSD, who was a part of triplet and compare it with her siblings’ growth.

Methods: This girl (C) was born as a part of triplet at 38 weeks of gestation. The other parts of triplet were a male (A) and female (B). The girl (C) birth weight = 1.82 kg, length = 41 cm. We compared girl C anthropometry, bone maturation and IGF-I level data with her normal siblings’ data.

Results: Clinical examination, CXR and echocardiography revealed a large-sized VSD with cardiomegaly and lung congestion. There was no cyanosis, pallor, jaundice or dysmorphic features. The girl was treated with folic acid and nutritional support. At the age of 3.5 years a complete corrective surgery was performed. At the age of 6.5 years the bone age of girl C = 5 years, girl B and boy A = 6 years. Their IGF-I were 85, 125 and 185 ug/L respectively. Analysis of growth data of girl C before and after surgery in comparison to the other parts of the triplet reflected the effect of VSD on linear growth as follows:

a) The VSD prevented catch-up growth in girl C which occurred in her 2 siblings (3SDS) during the first 3 years,

b) Correction of VSD accelerated growth for 2 years with a significant (2.2 SDS) but incomplete catch-up growth (still 1 SDS below mid-parental HtSDs),

c) catch-up growth stopped during the 3rd year after surgery,

d) in girl C, VSD was associated with delayed bone age (a year) and lower IGF-I versus her siblings.

Conclusions: In girl C, VSD prevented catch-up growth during the first 3 years of life with significant but incomplete catch-up growth for 2 years following surgical correction and lower IGF-I secretion. However, VSD was associated with a delay in bone age with a better potential for final adult height.
A three-week-old boy with normal male genitals pre-
the gonadal karyotype is congruent with lymphocyte karyotype.

to routinely performed on peripheral blood lymphocytes. The presence of Y
 Background: Cytogenetic analysis in disorders of sexual differentiation is routinely performed on peripheral blood lymphocytes. The presence of Y chromosome material in the gonads is of major interest because of the risk of gonadoblastoma development. However, there is a lack of evidence whether the gonadal karyotype is congruent with lymphocyte karyotype.

Patient and methods: A three-week-old boy with normal male genitals pre-

sented with left inguinal hernia and cryptorchidism. The inguinal hernia surgery revealed an unusual anatomic situation. His free testosterone was normal (23.21 pg/ml). Peripheral blood karyotype was mos 45,X(25)/46,X,i(Y)(p10). His identity(Yq11)(DXZ3+)(Y)[6]. An SRY duplication was detected by FISH. Histological examination found an immature testis on the left, a dysgenetic gonad on the right side and a uterus-like organ. Based on the different degree of differentiation of the two gonads and the normal hormone production we hypothesized that the mosaicism -namely the ratio of Y chromosome- may vary from loci to loci, moreover in some tissues might be significantly different from that of the peripheral lymphocytes. To test this hypothesis blood, gonad and subcutaneous fibroblast samples were analyzed by FISH and QF-

PCR. 

Results: The X:Y ratio was normal in the testis and nearly 2:1 in the blood, fib-
broblast and a dysgenetic gonad samples by QF-PCR. However, FISH analy-
sis in the testis have found one X centromere in 60% and presence of different mosaic SRY+ cell lines (with single or double SRY signals) in 40% of cells (inc.: int(DXZ1+)(SRY-)[20]/(DXZ1+)(SRY+)[8]/(DXZ1+)(SRY++)[52]/

(DXZ1+)(SRY+)[12]).

Conclusions: Our case underlines that peripheral blood lymphocyte karyo-
type might not provide a reliable representation of specific tissue karyotypes. Future studies may prove whether Y chromosome material present in the go-

nads would be completely absent or undetected in lymphocytes. Peripheral blood is an easy and reliable source of material for cytogenetic analysis, how-
ever, the interpretation of test results might require caution.

PAO-19

Complete catch-up growth in a neglected case of hypoaldosteronism a year after starting therapy

Noura Alhemaidi; Ashraf Soliman; Amal Sabt; Ahmed Elawwa

Hamad Hospital, Pediatric, Doha, Qatar

Background: Early growth impairment may be a sequelae of untreated hypo-
aldosteronism in infants.

Objective and hypotheses: To study the growth pattern of an infant with
neglected hypoaldosteronism after treatment for 3 years.

Methods: This boy presented at the age of one year, with recurrent vomiting and poor growth. He was a product of full-term pregnancy and normal vaginal delivery. Birth weight = 3.1Kg, length = 50 cm. His parents were first-degree cousins. He had five sisters and one brother, all were healthy. He was on formula feeds and started weaning at six months of age, with good appetite and normal bowel motion. He showed delayed gross motor milestones (can sit but can not stand at 1 y) with normal other developmental parameters. Examination revealed fair general condition, with mild dehydration with no pallor, jaundice, dysmorphic feauters or pigmentary changes. Vital signs including blood pressure were normal. His weight = 6Kg, length = 67.5cm (LDS = -3), HC= 41.5cm (all < 5th centile). The rest of exam was unrevealing.

Results: Showed hyperkalemia (K = 7mmol/L) (N 4-4.8), hyponatremia (Na = 126 mmol/L) (N 135-145), acidosis (HC03 = 17mmol/L) (N 24-30), BUN =10 mmol/L (N1-4.5), creatinine = 20umol/L, (N25-65), Cl = 90mmol/L ( N95-110), and normal blood glucose. Hormonal analysis showed: Aldoste-
58 children with DMT1 were included into this research and divided depending on gender and pubertal stage.

Background:
Diabetes mellitus type 1 (DMT1) can influence on life quality during the first year of life. Complete catch-up of growth was achieved during the first year of treatment.

Objective and hypotheses:
To define differences of IGF-1, IGFBP-3 and uGH values in various variants of short stature.

Methods:
We have examined 147 subjects (85 boys and 62 girls), aged 3-18 yrs (mean age 11±3.9 yr.) with short stature and 20 healthy children (10 boys and 10 girl). Serum levels of IGF-1, IGFBP-3 and uGH were measured by IRMA (Immunotech, Beckmand Coulter).

Results:
The obtained data of laboratory researches of levels of IGF-1, IGFBP-3 and uGH are given in the table. GH excretion and basal levels of IGF-1 and IGFBP-3 were lower in growth hormone deficiency, hypothyroidism and raised in case of familial short stature in compare with healthy children.

Conclusions:
Levels of IGF-1, IGFBP-3 and ursular GH are recognized by markers of GH deficiency and have diagnostic value in various variants of short stature.

Values of levels of IGF-1, IGFBP-3 and urinary GH to diagnose of short stature

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Total No. (%)</th>
<th>urinary GH, ng/ml</th>
<th>IGF-1,ng/ml</th>
<th>IGFBP-3, ng/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth hormone deficiency</td>
<td>53(36.0%)</td>
<td>0.6±0.8**</td>
<td>97±66.9*</td>
<td>1849.0±876.2</td>
</tr>
<tr>
<td>Constitutional growth delay</td>
<td>20 (13.6%)</td>
<td>1.4±0.9**</td>
<td>222±92.2***</td>
<td>3217.0±564.6***</td>
</tr>
<tr>
<td>Familial short stature</td>
<td>15 (10.2%)</td>
<td>2.3±1.2**</td>
<td>242±38.4***</td>
<td>3916.0±49.0**</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>15 (10.2%)</td>
<td>0.9±0.8</td>
<td>136±25.4**</td>
<td>3100.0±125.4***</td>
</tr>
<tr>
<td>Genetic syndromes</td>
<td>15 (10.2%)</td>
<td>1.2±1.5**</td>
<td>53±48.8***</td>
<td>1308.0±266.9</td>
</tr>
<tr>
<td>Other medical causes</td>
<td>14 (9.6%)</td>
<td>1.4±0.8</td>
<td>187±36.4***</td>
<td>2591.0±516.7</td>
</tr>
<tr>
<td>Turner syndrome</td>
<td>9(6.1%)</td>
<td>1.4±0.16**</td>
<td>69±7.3**</td>
<td>1728.4±98.5</td>
</tr>
<tr>
<td>Skeletal dysplasia</td>
<td>6 (4.1%)</td>
<td>1.6±0.9**</td>
<td>126±10.1***</td>
<td>2430.0±169.7</td>
</tr>
<tr>
<td>Healthy children</td>
<td>20</td>
<td>7.5±2.5</td>
<td>414±212.1**</td>
<td>1925.0±500.1</td>
</tr>
</tbody>
</table>

P - differences between group of healthy children:* p<0.001; ** p<0.01; *** p<0.05.
Descriptive study on growth of small for gestational age (SGA) babies in a multi-ethnic population

Sharon Lim
Broomfield Hospital, Paediatric, Chelmsford, United Kingdom

Background: The childhood population under study is approximately 200,000 with an annual birth rate of approximately 11,000.

Objective: In this prospective observational study, the aim was to collect data on parental ethnicity, educational attainments, social habits, medical history and auxology of SGA babies till the first birthday.

Methods: SGA babies were defined as birth weight or length less than the third percentile for gestation. Measurements were converted to SD scores. Mothers of SGA babies were interviewed by one of the authors using a standardised questionnaire. Babies were measured using a stadiometer and weighed using digital weighing scales.

Results: 24 mothers were interviewed. Growth data was available for all babies except 1 final measurement. Only 5 out of 24 mothers were Caucasian, 14 were Asian, 3 were mixed and 1 was African. Mean maternal age was 31 (range 21 - 40yrs). 2 admitted to smoking before and during pregnancy. 10 admitted to alcohol intake prior to getting pregnant, with 3 continuing to drink in pregnancy. Birth weight SDS ranged between -2.7 to -1.3, mean -1.8, weight SDS at 1 year ranged between -2.2 to 1.1, mean -0.7 (see chart).

Conclusions: It was possible but difficult to study this largely multiethnic group of families (hence the small numbers). Data obtained can be used in future to compare with other populations and with the comparisons, possible factors may be identified to be more strongly linked to having a SGA baby.
10q. The breakpoint located by CGH-array was in 2q37.1 (gene DIS3L2).

Objective and hypotheses: MC’s mother, carrying the balanced (2;10) translocation, has no loss of genetic material according to karyotype and CGH-array; but curiously she has the same phenotype than her son except mental retardation.

Method: AHO phenotype is present in two disorders: pseudohypoparathyroidism 1a (PHP 1a) where it is associated with hormone resistances especially to PTH; and pseudosyndrome of PHP (PPHP) where no resistance to PTH is observed. In most of the cases of PHP 1a and PPHP, patients have a gene GNAS (located in 20q13) mutation, responsible for a decrease of Gsα protein activity. This gene is controlled by genomic imprinting. In case of paternal transmission the patient has PPHP and inversely. However, some cases like MC have PPHP without gene GNAS mutation but are carrier of a 2q37 deletion. Then Gsα protein activity is normal.

Results: Some molecular investigations have tried to identify the gene responsible for the AHO phenotype in 2q37. Recently the gene HDAC4, located in 2q37.3, was found to be mutated in patients with AHO phenotype. However, the mother’s breakpoint is in 2q37.1 and HDAC4 is entirely translocated.

Conclusions: We propose a diagnostic flow chart in case of AHO phenotype in order not to forget 2q37 deletion as rare cause of short stature and obesity. Furthermore this familial case may be useful to understand the molecular pathways leading to AHO phenotype.

PAO-28

Diabetic ketoacidosis as initial presentation in children with type 1 diabetes mellitus in South Region of Saudi Arabia

Mohammad A Hareed Alqahwiri
MOH, Pediatric, Abha, Saudi Arabia

Background: Type 1 Diabetes Mellitus (DM) represents about 5-10% of total diabetes with more susceptibility to develop Diabetic Ketoadidosis (DKA) than Type 2 DM as the underlying cause is insulinopenia.

Objective: To study the percentage of patients with Type 1 DM that presents initially with DKA as this is a good indicator of public health knowledge about diabetes in the pediatric age group.

Method: A retrospective study to evaluate charts of patients seen regularly in Aseer Diabetes Center (ADC) over a period of 10 years from 1st Jan 2000 till 31 Dec 2009 whether they present initially in DKA or not.

Result: A total of 614 patients with Type 1 DM were registered. Among them 487 patients with completed data, 228 patients were seen in DKA as initial presentation (47%), whereas 259 patients were discovered before reaching DKA (53%). This percentage is higher than what have been published from the United States (25%) and in between if compared to the International figures (16-80%). In relation to age we found that 83% of patients who are less than 1 year of age had DKA as initial presentation. Beyond that age there was no much difference.

Conclusions: A relatively high percentage of DKA as initial presentation necessitates to follow up study to evaluate what can be the reason of this relatively high percentage, with suggestion to have more public health programs in the media and training courses for primary health care physicians in order to reach developed countries percentages.

PAO-29

Hypoglycaemia in a Nigerian paediatric emergency ward

Jerome Eluiyin, Ebunoluwa Adeyujibe, Oluwagbenga Adeodu, Obafemi Awolowo University, Paediatrics and Child Health, Ile-Ife, Nigeria

Background: Hypoglycaemia is a common problem in paediatric emergency admissions. It has not received enough attention in Nigeria. It has been shown to complicate many childhood illnesses.

Objective: This study aimed to determine the prevalence of hypoglycaemia in paediatric emergency admissions, describe clinical factors that commonly predispose to it and investigate its effect on outcome of management.

Method: Three hundred and ninety-two consecutively admitted patients were studied. Two milliliters of blood was obtained from each patient for plasma glucose determination. Hypoglycaemia was defined as plasma glucose 52.5 mmol/l (954 mg/dl).

Results: Out of these 392, twenty-five (25) of them were hypoglycaemic giving a prevalence of hypoglycaemia to be 6.4 per cent in our emergency ward. Hypoglycaemia was found to be associated commonly with severe malaria, septicaemia, pneumonia, and protein energy malnutrition. Interval of last meal and unconsciousness were the only two significant associated factors to hypoglycaemia. However, the likelihood of hypoglycaemia is increased with night admissions and prolonged duration of illness before admissions. Presence of hypoglycaemia at admission was also found to be significantly associated with death and dying within 24 hours of admission.

Conclusions: The prevalence of hypoglycaemia was found to be 6.4 per cent. It was found to complicate many childhood illnesses and it is associated with a higher mortality. It should be suspected in all very ill children, particularly when they are unconscious and have not eaten for over 12 hours.

PAO-30

Ethnic and gender inequities in the evaluation of referred short children

David Yardene, Neta Loewenthal, Yehuda Limony, Eli Herschkovitz
Soroka Medical Center, Pediatric Endocrinology and Metabolic Unit, Beer Sheva, Israel

Aims: To examine ethnicity and gender differences in the evaluation of referred children with short stature and to investigate adherence of the primary care evaluation to published guidelines.

Methods: Cross-sectional study in a referral center. 371 short patients aged 2 to 18 years were included. Outcome measures were patient’s growth characteristics, final diagnosis, and prevalence of pre-referral patient data.

Results: The study population was composed of 239 Bedouin children and 132 Jewish children (P <0.0001). More males (61.3%) than females were evaluated (P < 0.0001). There were no significant differences between males and females in age and growth parameters at the time of referral. Bedouins, males and females, were significantly shorter than their Jewish counterparts at the time of referral: Ht SD -2.44±0.73 and -2.62±0.55 versus -2.13±0.55 and -2.21±0.57, respectively (P > 0.05). There were no significant ethnic or gender differences in the final diagnosis. Significant deficiencies in the primary care evaluation of referred short children were found.

Conclusions: We demonstrated novel ethnic- and gender-based inequities in the evaluation of referred short children. We found that the current evaluation of short stature in our area does not comply with existing guidelines.

PAO-31

A novel mutation in EIF2AK3 gene associated with Wolcott-Rallison syndrome in a family from Saudi Arabia

Rahmat Alsafi1; Amr Alsafi2, Alia Alamer1
1MOH, Pediatric, Sa'awi, Saudi Arabia; 2King Faisal Specialist Hospital & Research Center, Genetic Diagnostic Lab, Riyadh, Saudi Arabia

Context: Wolcott-Rallison syndrome (WRS) is a rare autosomal recessive disorder characterized by neonatal diabetes mellitus, multiple epiphyseal dysplasia, osteoporosis, skeletal dysplasia and growth retardation. WRS is caused by mutations in EIF2AK3 gene.

Objective: The aim of the study is to describe a new case of Wolcott-Rallison Syndrome and define the underlying genetic defect.

Design: A WRS patient was followed up for the first 7 years of his life. DNA sequencing was performed to detect mutations in EIF2AK3 gene.

Setting: The patient was followed up in a pediatric hospital.

Patients: DNA analysis was performed on the index case, his parents and siblings.

Results: A child of first-cousin parents presented at the age of 38 days with hyperglycaemia. At the age of one year, x-rays showed skeletal deformities. He developed recurrent acute hepatitis during the follow-up time, the last one was associated with renal failure that resulted in his death at the age of 7 years. DNA sequencing showed homozygosity for a novel mutation (c.1262delA) in the EIF2AK3 gene.

Conclusion: A novel mutation c.1262delA was detected in a new case of Wolcott-Rallison syndrome.
PAO-32

Growth and weight-regulation disorders in children are not commonly associated with mutations of the ghrelin and GH secretagenous receptor (GHSR) genes

Ora Hess1; Gadir Elia2; Tal Almagor1; Osnat Admoni1; Morad Khayat3; Stavit Salev-Allon1; Yarden Tenenbaum-Rakover1

1Ha’Emek Medical Center, Pediatric Endocrine Unit, Afula, Israel; 2Ha’Emek Medical Center, Genetic Institute, Afula, Israel

Background: Ghrelin and its receptor, growth hormone secretagenous receptor, GHSR, play a major role in appetite control and growth regulation. To date, only four confirmed mutations in the GHSR gene have been identified in children with obesity and short stature, while no such mutations have been found in the ghrelin gene.

Objective and hypotheses: In the current study, we tested the hypothesis that mutations in ghrelin or GHSR will result in subjects being either over or underweight, and exhibiting abnormal growth.

Methods: Ninety-five subjects (37F/58M) were enrolled with FTT (10 pts), GHD (45 pts), ISS (18 pts) or obesity (22 pts). Both ghrelin and GHSR genes were sequenced.

Results: Seven different sequence changes were identified (66.3%) in GHSR, two of them novel and five described previously. None of the sequence changes identified in the GHSR gene changed the sequence of the encoded protein. The prevalence of these sequence changes did not differ between the subgroups. One previously described sequence change, Leu72Met, within the preproghrelin/ghrelin gene was identified in two patients (2%), one with FTT and the other with obesity and partial GHD. This sequence change, which had been identified previously in obese women, is located in exon 2 outside the coding region of the mature ghrelin.

Conclusions: Our results suggest that mutations of the ghrelin and GHSR genes are not commonly associated with growth and weight-regulation disorders in children.

PAO-34

A case of salt-wasting and virilizing form of congenital adrenal hyperplasia in a patient with male phenotype and 46,XX karyotype

Maia Rekhviashvilli1; Mariam Balakhadze1; Revaz Morgoshia1; Rolf Peter Willig1

1JSC “Vere XXI”, Department of Physical and Sexual Development of Children and Adolescents, Tbilisi, Georgia; 2Endokrinologikum Hamburg, Pediatrics, Hamburg, Germany

Background: In congenital adrenal hyperplasia (CAH) with 21-hydroxylase deficiency, furosemide and hydrocortisone treatment results in excess sex hormone precursors. Androgen predominance in these forms of CAH leads to virilization of affected females in utero.

Objective and hypotheses: We describe a patient with virilizing and salt-wasting form of CAH.

Methods: A case report.

Results: Patient 7.2 years old boy. The complaints were: Delay of physical and sexual development (anorchia), pubic hair since the age of 2 years. Anamnesis to 6 months postnatal period the child was frequently hospitalized due to intensive vomiting, diarrhea and weight loss. The patient was on symptomatic treatment. Auxology: HSDS 1.22. Sexual development stage P1 A1 G2; Testes not palpable. Bone age by Greulich and Pyle 10.5 years. Genetical research: karyotype - 46,XX; Laboratory research: 17OH Prog-50 ug/l, Potassium 4.1 mmol/l, Sodium-136 mmol/l, LH >0.1 U/l, FSH 2.8 U/l, Estradiol 10 ng/l, Androstendion 0.7 ug/l, ACTH 133 ng/l, Renin 241 ng/l. Abdominal MRI: In the pelvic cavity on both sides ovary like structure, with the size: 0.8X1.33 cm. At the posterior side of the urinary blade tubular mass with the size 27X7 mm (apparently vagina).

Conclusions: The diagnosis of children’s psychologist: The psychologic development of the child corresponds to male. Therapy: Hydrocortisone 15mg/day, Fludrocortisone 1 mg/day, Cyprowterone 10 mg/day. By substitutional therapy hormone concentration in the blood came down to the normal range and puberty stopped. The condition of the patient was explained to the parents and to an ethical committee for the decision, to raise the patient as a girl or as a boy by gender reassignment surgery (exstirpation of uterus and ovaries).

Conclusions: Continued excessive adrenal sex steroids in untreated CAH patient causes several problems which may reveal not only physical, but also psychological deviations.

PAO-33

The relationship between initial BMI and BMI change during 1-year of GnRH agonist therapy in girls with idiopathic central precocious puberty

JuYoung Yoon1; Sei Won Yang1; Young Ah Lee1; Min Jae Kang1; Sinmi Kim1; Jeon Lee1; Choong Ho Shin1

1Seoul National University Children’s Hospital, Department of Pediatrics, Seoul, Republic of Korea

Background: Childhood obesity is associated with early pubertal development, and early sexual maturation is associated with increased prevalence of obesity. Above-average BMI is frequent at diagnosis of central precocious puberty (CPP).

Objective and hypotheses: The purpose of this study is to evaluate the relationship between initial BMI and BMI after 1-year of GnRH agonist (GnRHa) therapy in girls with idiopathic CPP. We also compared the group in which BMI-standard deviation score (BMI-SDS) increased after treatment with the group in which BMI-SDS remained the same or decreased.

Methods: The subjects were ninety-nine CPP girls treated with GnRHa for more than 1 yr. We investigated chronologic age (CA), bone age (BA), BA advance (BA-CA), height, Ht-standard deviation score (Ht-SDS), BMI, BMI-SDS, predicted adult height (PAH), PAH-SDS before initiation of GnRHa treatment and 1 yr later.

Results: There was no difference in initial CA, BA, BA-CA, Ht-SDS, target height between normal BMI group and obesity/overweight BMI-SDS. BMI-SDS increased more in normal BMI group than in obesity/overweight obesity group (0.2 vs -0.1, P > 0.004), and initial BMI and delta BMI-SDS showed negative relationship (R2=0.251, P < 0.001). PAH-SDS increased less in normal BMI group than in overweight/obesity group (0.3 vs 0.7, P > 0.002), but there was no linear relationship between initial BMI and PAH-SDS. delta BA CA, delta Ht-SDS also was not different between normal BMI group and obesity/overweight obesity group. Comparing pts. in whom BMI-SDS increased or remained the same after treatment with those whose BMI-SDS decreased, there was no difference in delta BA, delta Ht-SDS, delta PAH-SDS. Delta BMI-SDS was related only with initial BMI SD, and showed no relationship with CA, BA, BA advance, height, drug dose.

Conclusions: In CPP girls treated with GnRHa for 1 year, BMI SDS increased in those with normal BMI. Delta BMI-SDS had negative relationship with initial BMI-SDS, but was not influenced by other factors such as initial CA, initial BA, initial BA-CA, initial Ht-SDS, initial PAH-SDS, target height, drug dose.

PAO-35

A hypothyroidistic hormatomata associated with precocious puberty

Mariam Balakhadze1; Maia Rekhviashvilli1; Revaz Morgoshia1; Rolf Peter Willig1

1JSC “Vere XXI”, Department of Physical and Sexual Development of Children and Adolescents, Tbilisi, Georgia; 2Endokrinologikum Hamburg, Pediatrics, Hamburg, Germany

Background: Gonadotropin-releasing hormone (GnRH) dependent, or central precocious puberty (CPP) results from early onset of pubertal hypothalamic-pituitary-gonadal activity. This occurs as a consequence of physiologic gonadotropin stimulation emanating from the GnRH secretion of hypothalamic origin. Both boys and girls with an organic etiology of CPP are more likely to present at a younger age, than those with idiopathic etiology.

Objective and hypotheses: We describe a child with hypothalamic hormatomata associated with precocious puberty on Triptorelin treatment.

Methods: A prismatic case report.

Results: We report 1 year 9 months old girl. Complaints: premature puberty. Sexual development stage: Tanner 3 (B3, P3, A2). Me at the age of 8 months) Anamnesis: from the age of 2 weeks till today vaginal discharge (white), at the age of 3 months pubic hair appeared, at the age of 6 months breast de-
Disorder of sexual differentiation can produce phenotype alteration. 

Background: Pyle: 4 years; Gynaecological Ultrasonography: Uterus: 23.6X17X26 mm; Endometrium thickness 4 mm; Ovaries: dex - 23X11 mm with cystic insertion 11X6 mm; sin - 14X9 mm with cystic insertion 2.5 mm; Adrenal Ultrasonography: Without pathology. Cerebral MRI: Disontogenic neoforumation of the hypothalamic area (Harmathoma). Hormonal research: FSH 9.6 IU/L (N < 1); LH 1.70 mIU/ml (N < 0.1); Estradiol 77 pg/ml (N < 15); Therapy: GnRH agonist – Triptorelin (Dosage 3.75 mg every 4 weeks). By the therapy hormone concentration in blood came to the normal range 0.06 mIU/ml (LH) and 0.19 mIU/L (FSH), patient had no menstruation since the beginning of the treatment. The puberty has stopped. 

Conclusion: CNS abnormalities causing CPP include redundant or excessive hypothalamic tissue (hypothalamic hamartoma). Treatment by suppression of gonadotropin secretion with Gonadotropin-releasing hormone agonist (GnRHa) is an appropriate and efficacious treatment of CPP.

Methods: Complementary tests TSH 1.98uU/mL FSH 51.6 U/L LH 33.2 U/L Estradiol 13.3 pg/ml Testosterone total 10.41 ng/mL SHBG 52.92 nmol/L DHEA-S 174 mcg/dL Free Testosterone 19.3 17 QHP 1.64 ng/ml Karyotype: (400 bands): 47,XY[28]/45,X[2]

Genital Echography: small size uterus (40x20x8 mm) and gonads (15 x 5 mm) without follicles Lineal endometrium. LHRH Test: positive respond for testosterone.

Gynecologic exploration through laparoscopy: Uterus and Fallopian tubes were normal. Left ovary compatible with testicle; with a similar form between fimbriaes in right side. Tissues biopsy: Compatible with testicular tissue. Karyotype of gonadal biopsy 47 XXY

Evolution: Quick estrogenization (etinilestradiol VO and combined progestagen). 6 months after quiriury, there was a reduction of basal testosterone, partial reduction of body hair, telarche development grade III and a substantial improvement of patient’ self-esteem. Clitoromegaly is lower too.

Background: Disorder of sexual differentiation can produce phenotype alterations. Some of them are imperceptible at birth. We present the case of a girl with a karyotype and internal/ external phenotype never described before. We present a large iconography of this peculiar case.


Methods:

Objective: The aim of this study was investigation of clinical features, pathogenesis, laboratory examination and early treatment of diabetes mellitus in patients with beta-thalassemia major.

Methods: Diabetes mellitus was observed in 6 of 53 patients with beta-thalassemia major. In this retrospective analysis study, patients were examined to determine their pubertal status and the standard deviation score for height for evaluation of short stature. Laboratory test index of blood were measured.

Results: The average age in the 6 patients was 13.36 years (11-18 years). Two patients, at onset of clinical diabetes, presented with an asymptomatic glycosuria and four with polydipsia, polyuria, weight loss and ketoacidosis. Serum ferritin was in the range of 4800-7148ug/L; Fasting blood glucose was in the range of 8.9-43.8mmol/L; Hba1c was in the range of 8.9-16.8%. 2 patients were detected high insulin level (>20mu/L), suggesting insulin resistance. 4 cases of ketocidosis were detected insulin level <2mu/L, C peptide mean 24pmol/L, suggesting lack of insulin secretion. Pancreas MRI showed the signal to reduce, which was related with iron deposition. The pubertal stage of 6 patients was in Tanner 1 to Tanner 2. 6 patients were all short stature, 4 cases of hypothyroidism, 2 cases of GHD. Mild liver function abnormalities(2 cases) and abnormal heart function (1 case) were detected. All patients treated with transfusion, deferoxamine, exercise, diet control, Glucobay and insulin.

Conclusions: Comprehensive therapy was good.

Diabetes in 6 patients of beta-thalassemia major

Zhe Meng; Li-Yang Liang; Li-Na Zhang; Li-Ping Hou
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Department of Pediatrics, GuangZhou, China

Objective: The aim of this study was investigation of clinical features, pathogenesis, laboratory examination and early treatment of diabetes mellitus in patients with beta-thalassemia major.

Methods: Diabetes mellitus was observed in 6 of 53 patients with beta-thalassemia major. In this retrospective analysis study, patients were examined to determine their pubertal status and the standard deviation score for height for evaluation of short stature. Laboratory test index of blood were measured.

Results: The average age in the 6 patients was 13.36 years (11-18 years). Two patients, at onset of clinical diabetes, presented with an asymptomatic glycosuria and four with polydipsia, polyuria, weight loss and ketoacidosis. Serum ferritin was in the range of 4800-7148ug/L; Fasting blood glucose was in the range of 8.9-43.8mmol/L; Hba1c was in the range of 8.9-16.8%. 2 patients were detected high insulin level (>20mu/L), suggesting insulin resistance. 4 cases of ketocidosis were detected insulin level <2mu/L, C peptide mean 24pmol/L, suggesting lack of insulin secretion. Pancreas MRI showed the signal to reduce, which was related with iron deposition. The pubertal stage of 6 patients was in Tanner 1 to Tanner 2. 6 patients were all short stature, 4 cases of hypothyroidism, 2 cases of GHD. Mild liver function abnormalities(2 cases) and abnormal heart function (1 case) were detected. All patients treated with transfusion, deferoxamine, exercise, diet control, Glucobay and insulin.

Conclusions: Comprehensive therapy was good.

Conclusions: Despite therapy with deferoxamine to treat iron overload, the risk of secondary endocrine dysfunction remained high. Diabetes in patients of beta-thalassemia major were often accompanied by other endocrine organ damaged, which occurs with iron deposition. The pathogenesis of diabetes in beta-thalassemia major may be similar to the development of type 2 diabetes. Early diabetes, it was insulin resistance, and finally lack of insulin secretion induced to insulin dependent diabetes mellitus.

Introduction: The craniopharyngioma is a cystic tumor, calcified, squamous-epithelial origin in the slow growth. Internationally, the incidence is 0.5-2/100.0. Mortality/morbidity: survival varies by age group, with a excellent prognosis in patients aged less than 20 years (99% at 5 years).

Clinical: The most common presenting symptoms are headache (55 - 86%), endocrine dysfunction (66-90%) and visual disturbances (37 - 68%). Endocrine abnormalities are found in 80 to 90% of craniopharyngiomas. In fact,
in 39% of patients shows impairment of 3-axis pituitary in 28% of 2 or more axes in 11% of 1 or more and 22% no axis compromise. [5]. The most frequent response is that of a GH deficiency present in more than 75% of cases, followed by a gonadotropine deficiency in 40% of cases and an ACTH and TSH deficiency in 25%. Despite craniohypophysealomas are usually of significant size already at diagnosis, the pituitary stalk is rarely interrupted, for which only 20% of patients presents hyperprolactinaemia resulting from the compression pedicle.

Our experience: In 25 children (16 males and 9 females) whose age at diagnosis was between 0.35 and 13.30 years with an average of 6.65 years (SD 3.04). Location of craniohypophysealoma. Suprasell 8 Sellar suprasellar 8 Saddle + 3rd ventricle 1 Suprasellar diencefal 1 Suprasellar + 3rd ventricle 1 Chiasmatic 2 3rd ventricle 1 Chiasmatic 2 3rd ventricle 1 Chiasmatic 2 3rd ventricle 1. Retrosellar 1 Suprasellar retrochiasmatic 1 Total 25 Audo-encephalic abnormalities at diagnosis. Growth retardation 4 / 25 (16%) Precocious puberty, 1 / 25 (4%) Delayed puberty 1 / 25 (4%) PU / PD 1 / 25 (4%) Overweight / obesity 5 / 25 (20%) Gigantism 1 / 25 (4%) Endocrine abnormalities detected after treatment. Diabetes insipidus 20 (80%) Precocious puberty 2 (8%) Hypothyroidism 18 (72%)

Conclusion:
- High incidence of short stature and / or = 2
- High incidence of obesity hyperpyagia
- marked hyperpyagia (binge eating) with difficulty in controlling appetite.
- Increased behavioral and psycho-social.

PAO-39
Is the level of anti TPO antibodies predictive for the course of Hashimoto thyroiditis?
Ana Ostojevic1; Jovana Obrenovic1; Silvija Sajic1; Ana Stankovic2; Vera Zdravkovic2
1University of Belgrade, Medical School, Belgrade, Serbia; 2University Childrens Hospital, Endocrinology, Belgrade, Serbia

Background: Hashimoto’s thyroiditis (HT), characterized by the presence of high serum thyroid auto-antibody titers and goiter, is one of the most common types of thyroiditis in children and adolescents. It is associated with a wide spectrum of thyroid functions, ranging from euthyroidism to overt hypothyroidism, with a variable clinical course.

Objective and hypotheses: To assess the thyroid hormone status during the long-term follow-up and to establish the prognosis of children and adolescents with HT.

Methods: We evaluated thyroid function (TF) in 77 children with HT. The patients were assessed at presentation and then followed up at 6-12 months intervals. We divided them according to the level of anti TPO antibodies into 2 groups: up to 10 fold elevated and above that level.

Results:

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>5-19, mean 14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M/F)</td>
<td>19/58</td>
</tr>
<tr>
<td>Puberty (no/yes)</td>
<td>8/69</td>
</tr>
<tr>
<td>TSH (high/normal)</td>
<td>28/49</td>
</tr>
</tbody>
</table>

Follow up period was 0.5 to 10, mean 1.9 years. We compared TF in 2 groups of patients and did not find that level of anti TPO antibodies was predictive.

Conclusions: In our group of patients we noticed female predomination, most patients were in puberty and majority of them are still euthyroid in follow up. We were not able to establish the connection between the level of anti TPO antibodies and thyroid function.

PAO-40
Prevalence of subclinical hypothyroidism in child cancer survivors and efficacy of levothyroxine treatment
Shinichiro Sano; Yuichi Nakagawa; Toshiki Nakashish; Rie Matushita; Eiichiro Satake; Yasuko Fujisawa; Eiko Nagata; Takehiko Ozeki
Hamamatsu University School of Medicine, Pediatrics, Hamamatsu, Japan

Background and objective: Child cancer survivors (CCS) have some complications. Although hypothyroidism in CCS has been well reported, little is known about subclinical hypothyroidism (SCH). The aim of this study was to investigate the prevalence of SCH and efficacy of levothyroxine (LT4) supplementation in CCS with SCH.

Methods: Twenty CCS were divided into two groups. The chemo group (n=8) was treated with chemotherapy alone and the radiated group (n=12) received chemotherapy plus radiotherapy. Control group was healthy children who showed short stature but normal hypothalamic-pituitary and thyroid function. TSH, FT3, and FT4 were measured in all patients. TRH stimulating test was performed only in the patients who were diagnosed with SCH. The definition of SCH is TSH > 5 µIU/ml, while FT3 and FT4 are within normal range. Lipid profile and QOL were evaluated after 2 or 3 month of LT4 supplementation in these patients.

Results: No patients in the chemo group showed SCH. Four patients in the radiation group (33%) were diagnosed with SCH. They received radiotherapy both in spine and brain. Their TRH stimulating test showed hyperresponse and persistence of high levels of TSH. Their cholesterol levels were significantly higher than those of the chemo group. Mild dose of LT4 administration improved their lipid profile and QOL.

Conclusions: High prevalence of SCH was seen in CCS with radiotherapy. Our findings suggest that irradiation of spine plus brain is high risk of SCH. Mild dose of LT4 can improve the lipid profile and QOL in SCH patients.

PAO-41
Adenohypophysitis in a boy with pan-sinusitis and meningitis
Mariella Valenzise1; Maioranza Wasniewska1; Francesca Granata2; Sabrina Cardile1; Maria Rosaria Velletri1; Filippo De Luca1
1University of Messina, Department of Pediatrics, Messina, Italy; 2University of Messina, Department of Neurosciences, Psychiatry and Anaesthesiology, Messina, Italy

Background: Although hypophysitis is usually thought as a primary process, it may occur secondarily in relation to infections or other processes such as Langerhans cell histiocytosis, Crohn disease.

Case report: We report the case of a 15-year-old boy who was admitted to our Clinic due to headache, fever, visual disturbances and rigor nucalis. A 3D-CT showed pansinusitis whereas CSF showed a pleiocytosis (500 cell/mm3); therefore, broad spectrum antibiotics therapy were administered. After 5 days of antibiotic therapy, headache, fever, rigor nucalis were resolved, but diplopia persisted. MRI demonstrated diffuse pansinusitis and extension of inflammation and infection into the adjacent cavernous sinuses and pituitary gland that, after gado-linum, presented asymmetrical enlargement in size. Basal concentrations of plasma ACTH, cortisol, PRL, FSH, LH, testosterone were very low; also TSH appeared very low but thyroid hormones were still within the normal limits. Anti-pituitary antibody was also negative. Corticosteroid treatment (1 mg/kg/die) was administrated for six months and after two months of discontinuation endocrinological investigations were repeated. There were normal responses of FSH and LH to appropriate stimuli, normal levels of T, ACTH, cortisol, TSH, FT4. Only GH secretion after stimulation tests appeared subnormal (Peak 3.71 ng/ml). Follow-up MRI showed that the pituitary had reduced in size.

Conclusion: On the basis of our case we may conclude that: a) pansinusitis can have devastating intracranial sequelae, as involvement of the adjacent pituitary gland and cavernous sinuses; b) endocrinological and radiological examination could be performed after pansinusitis in order to detect early involvement of pituitary gland; c) corticosteroid therapy can be effective in reducing the pituitary size, attenuating inflammation and restoring pituitary function; d) a pattern of pituitary hormone deficiency with early loss of ACTH and TSH and sequential loss of GH could be observed. Long term follow-up is mandatory to monitor other possible hormonal deficits.
PAO-42

Adrenal agenesis secondary to DAX 1 mutation in a newborn
Ignacio Diez-Lopez1; Ainhoa Sarasua Miranda1; Enrique Gonzalez Molina1; Mercedes Martinez Aycin2; Amaia Rodriguez Estevez1; Luis Castaño Gonzalez1; 1Txagorritxu Hospital, Paediatric Endocrinology Unit, Vitoria, Spain; 2Cruces Hospital, Paediatric Endocrinology Unit, Bilbao, Spain; 3Cruces Hospital, Paediatric Research Laboratory, Bilbao, Spain

Background: Agenesis or hypoplasia of adrenal glands associated to alterations of Gen DAX-1 (crom X) are a very unusual clinical subject, and could be accompanied of other hormonal and genetic alterations. We present a clinical case, supported with images.


Methods: Weight 3880 G (>2 SDS) Height 56,5 cm (<2 SDS) CP 37 cm Hypotonic, with labial sub cyanosis and general hyper pigmentation, Silverman score 3-4/10. Normo configured genitalia, except hyper-pigmentation. Appar 2/6/8. Requires RCP type II.

Results: Laboratory: pH 7.26, CO2H 19,4; EB -6. Sodium 119 mEq/L, potassium 7.3 mEq/L, PCR 23.8 mg/dl after 24 hours/ life Cultivates: Negative. Cortisol 2.86 mcg/dl. DHEA-S 8.32 mcg/dl (32-431), 170HP 3.73 ng/ml (0,4-3,3). ACTH 1.129, pp/ml (5-77), cholestero 177 mcg/dl (50-170), Noradrenaline, 5 mcg/24 horas (12 mcg/L); Ephinefrine: < 1 mcg/24 hours (<2 mcg/L); Dopamine: 65 mcg/dl (163 mcg/L). Abdominal ultrasound and MRI: There is no sign of adrenal glands. Genetic study: 46 XY (DAX-1 +) at index case, father not affected, mother 46 XX – (null/DAX +). Bone-age equivalent and the hyper-pigmentation were normal. Therefore we use supplementary dose of sodium too. After 3 months, the levels of ACTH were normal. Up to date patient is asymptomatic. His psychomotor and somato-metric development is according to his age. Bone-age equivalent and the hyperpigmentation has disappeared.

PAO-43

Bone mineral density and turnover in patients with idiopathic hypogonadotropic hypogonadism
Eeva-Maria Laitinen; Johanna Törmäla; Kirsi Vuoralahti; Tanelli Raitio Helsinki University Central Hospital, Hospital for Children and Adolescents, and, University of Helsinki, Institute of Biomedicine/ Physiology, Helsinki, Finland

Background: Patients with idiopathic hypogonadotropic hypogonadism (IHH) may have reduced peak bone mass in early adulthood, and increased risk for osteoporosis despite long-term hormonal replacement therapy (HRT). Objective and hypotheses: We investigated markers of short-term bone turnover, and the relationship between HRT history and bone mineral density (BMD) in patients with IHH.

Methods: 33 subjects (24 men, 9 women; mean age 39.8 yrs, range 24.0—69.1) with IHH (Kallmann Syndrome or normosmic IHH), were physically examined and measured for circulating PINP, ICTP, and sex hormone levels. 26 subjects underwent DEXA for BMD of lumbar spine, hip, femoral neck, and whole body.

Results: In men, serum PINP correlated with ICTP (R=0.61; p<0.002), but these markers correlated neither with circulating T, nor with serum E levels in women.

Treatment history had a clear impact on bone health in men: lumbar spine (LBMĐ), mean Z-score -2.0 SD, range -4.1—-1.4 was reduced in subjects with inadequate HRT (n=7), including those with long (≥5 yrs) treatment pauses, as compared to those with a history of adequate HRT (n=11); LBMĐ: -0.5 SD, -2.4—-0.7 (p<0.037).

The overall duration of treatment pause (range 0.15—-30 yrs) correlated negatively with lumbar and femoral neck Z-scores (R=0.42 and 0.61; p=0.039 and 0.001, respectively). Age, BMI, or age at onset of HRT did not correlate with BMDs. In addition, BMDs did not differ between subjects with KAL1 (n=3), FGF1R (n=5), or GNRRH (n=4) mutations (data not shown).

Conclusions: In patients with IHH, the prevailing sex steroid milieu does not affect short-term bone turnover. Our data suggest that both the quality and quantity of HRT influence BMD in IHH patients irrespective of age.

PAO-44

Two cases with HDR syndrome (hypoparathyroidism, sensorineural deafness and renal disease)
Mehmet Keskin1; Yılmaz Kor1; Ali Yalcın1; Hatice Uygur2; Ozlem Keskin1; Deniz Kor1
1Gaziantep University, Faculty of Medicine, Pediatric Endocrinology and Metabolism, Gaziantep, Turkey; 2Gaziantep University, Faculty of Medicine, Pediatrics, Gaziantep, Turkey

Background: HDR syndrome (hypoparathyroidism, sensorineural deafness and renal disease) was first reported by Barakat et al. described two brothers with steroid-resistant nephrosis with progressive renal failure, sensorineural deafness and hypoparathyroidism in 1977. Autosomal dominant disorder that is caused by mutations of the GATA3 gene, which is located on chromosome 10p15, has been identified recently. GATA3 is expressed in the developing parathyroids, inner ears and kidneys, together with thyms and central nervous system.

Objective and hypotheses: The patients with symptoms of hypocalcaemia must be evaluated carefully.

Results: Hypoparathyroidism, sensorineural deafness and renal anomaly were diagnosed in our two patients with symptoms of hypocalcaemia.

Conclusion: These cases are reported because of HDR syndrome is a very rare condition and the history of deafness in patients with hypocalcaemia for understanding of this syndrome.

PAO-45

Effects of growth hormone on muscle strength, tone and mobility of children with Prader-Willi syndrome
Shadab Salehpour1; Omid Aryani2; Farzaneh Rohani3
1Shahed Beheshti University of Medical Sciences, Pediatric Surgery Research Center, Pediatric Endocrinology, Tehran, Islamic Republic of Iran; 2Special Medical Center, Molecular Genetics, Tehran, Islamic Republic of Iran; 3Tehran University of Medical Sciences, Pediatric Endocrinology, Tehran, Islamic Republic of Iran

Background: Prader-Willi syndrome (PWS) is a genetic syndrome presenting with severe hypotonia and decreased agility. Growth hormone (GH) which is often used in these cases to treat short stature and obesity, seems to have some improvement in hypotonia, physical strength, activity, and locomotor developmental ability.

Objective: The aim of this study is to find the growth hormone effect on the agility and strength of these patients.

Material and methods: In a prospective, randomized controlled clinical trial, at an outpatient pediatric endocrinology clinic in Tehran, 21 PWS children (12 boys and 9 girls, 4 to 9 years old) were divided either in GH-treated or control groups and followed for two years. Agility run, sit ups, weight lifting, and inspiratory and expiratory strengths were considered as the main outcome measures.

Results: All the outcome measures of the GH treated group showed a significant improvement compared to those of the control (p<0.01).

Conclusions: GH causes a significant improvement in agility and strength of PWS children.
PAO-46
An unusually early diagnosis of 17-alpha-hydroxylase deficiency

Nicolin Datz1; Jens Siegel2; Felix Riepe3; Michaela Hartmann1; Stefan A. Wudy4; Sabine Heger1
1Children’s Hospital Bult Hannover, Department of Pediatric Diabetology and Endocrinology, Hannover, Germany; 2Children’s Hospital Bult Hannover, Department of Neonatology, Hannover, Germany; 3Christian-Albrechts University, Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, Kiel, Germany; 4Justus-Liebig-University, Steroid Research Unit, Center of Child and Adolescent Medicine, Giessen, Germany

Background: Mutations of the CYP17A1 gene result in 46,XY disorder of sex development, hypertension, hypokalemia and absent pubertal development. It is a rare, autosomal recessive form of congenital adrenal hyperplasia (CAH).

Objective and hypotheses: Usually, most patients are detected rather late as adolescents due to lack of puberty or hypertension.

Methods: We report about a neonate born to a 40 year old woman, 1st para, 1st gravida. Amniocentesis revealed a fetus with a 46,XY karyotype. At 20 weeks of gestation the development of male external genitalia was missing. Further molecular testing excluded an androgen receptor and SRY gene mutation. A phenotypically female child was born at 41st week of gestation. Gonads were palpable in the labia majora.

Results: Postpartal ultrasound revealed testes in both labia majora, absence of uterus and normal adrenal glands. Screening for 21-hydroxylase-deficiency was normal. Multisteroid analysis in serum showed reduced basal glucocorticoid, testosterone and androstenedione levels at the age of two weeks. The urinary steroid metabolome – assessed by GC-MS - showed excessive excretion of 17-desoxy-stereoids, decreased glucocorticoid metabolites and absent C19-stereoids. Such a metabolic constellation proves 17-alpha-hydroxylase-deficiency. Molecular analysis identified a novel mutation of the CYP17A1 gene: c.896T>A (p.L299N) in exon 5. Substitution with hydrocortisone was started at a moderate dose to prevent hypertension. The child is growing well so far.

Conclusion: Herein we report the unusually early diagnosis of a newborn with the rare CAH form of 17-alpha-hydroxylase-deficiency allowing installment of early treatment.

PAO-47
The effect of gonadotropin-releasing hormone agonists in Korean boys with idiopathic central precocious puberty and early puberty

Hae Sang Lee; Hong Kyu Park; Jin Soon Hwang
Ajou University School of Medicine, Pediatrics, Suwon, Republic of Korea

Background: Central precocious puberty (CPP) is less common in boys than in girls. There is little data available on the long-term safety and efficacy of GnRHa treatment in boys with CPP. The effects of GnRHa, with and without growth hormone, on the predicted adult height in boys with CPP and early puberty were evaluated after two years of treatment.

Methods: This study included nine boys with CPP and 13 boys with early puberty that were treated with depot leuprolide acetate. Anthropometry, bone age, the sexual maturity rating and predicted adult height (PAH) were assessed at baseline, and after 6, 12, 18, and 24 months.

Results: The PAH standard deviation score (SDS) in the GnRHa group of boys with CPP (n=9) was significantly increased (-0.23 ± 1.60 vs 0.49 ± 0.71; P=0.0014). The PAH SDS of the GnRHa group with early puberty (n=9) was significantly decreased to the pretreatment PAH SDS (0.57 ± 1.06 vs 0.36 ± 0.68; P=0.05). Multiple regression analysis revealed that height gain was influenced significantly by age at the start of treatment.

Conclusions: GnRHa treatment significantly improved the growth potential in boys with idiopathic CPP. However, GnRHa treatment alone did not affect the growth prognosis in boys with early puberty.
PAO-49
Medullary thyroid carcinoma in two children from a family with multiple endocrine neoplasia 2a syndrome - a case report

Gordana Stipancic1; Lavinia La Grasta Sabolic1; Marija Pozgaj Sepec2; Maja Radman2
1 University of Zagreb, School of Medicine, Department of Pediatrics, Zagreb, Croatia; 2 University of Zagreb, School of Medicine, Department of Pediatrics, Zagreb, Croatia

Introduction: All carriers of a point mutations in the RET proto-oncogene with multiple endocrine neoplasia type 2A (MEN2A) develop medullary thyroid carcinoma (MTC), while 50% and 30% of patients develop pheochromocytoma and hyperparathyroidism. MTC tends to disseminate early. It is chemoresistant and remains the cause of death in 15-20% of MEN2A patients. Consequently, early prophylactic total thyroidectomy is performed in all MEN2A patients.

Case report: A 32-year-old father presented with bilateral pheochromocytoma, MTC and parathyroid adenoma. Genetic analysis revealed a point mutation in codon 634 of exon 11 of the RET proto-oncogene. Genetic testing confirmed that both siblings were carriers of the same mutation. In a 10-y-old son ultrasound of the neck disclosed nodules in both thyroid lobes and enlarged paratracheal and left jugular lymph nodes. Laboratory examination revealed high calcitonin concentrations (437 pg/ml), while serum calcium and PTH levels were on the upper limit of normal values. In a 7-y-old 10-mo old daughter serum calcium level was slightly elevated (20.7 pg/ml), and plasma calcium and PTH levels were normal. On ultrasonography, a nodule in a right thyroid lobe, enlargement of the left jugular and right submandibular lymph nodes were observed. Both children underwent total thyroidectomy with neck dissection. Pathological examination showed bilateral MTC in a boy and MTC of the right thyroid lobe in a girl, with no lymph node metastatic disease. Laboratory examination showed no pheochromocytoma in siblings. After surgery both children began with thyroid replacement therapy. Due to the permanent hypercalcaemia in a boy, in treatment with calcium-carbonate and calcitriol it was initiated. Eighteen months after thyroidectomy, the children are doing well.

Conclusions: At present, genetic testing and prophylactic total thyroidectomy prevents the development of an invasive MTC in MEN2A patients. However, the risk of permanent hypoparathyroidism and the issue of thyroid replacement therapy remain a concern.

PAO-50
A case of adren al hypoplasia congenita caused by DAX1 deletion

Eun Young Kim-Kook1; Yang Ji Kang1; Hyun Woook Shin1; Han-Wook Yoo1
1 Kwangju Christian Hospital, Pediatrics, Kwangju, Republic of Korea; 2 Asan Medical Center, Pediatrics, Seoul, Republic of Korea

Background: Adrenal hypoplasia congenita caused by DAX1 (Doseage sensitive sex reversal-Adrenal hypoplasia congenita critical region on the X chromosome gene-1) mutation, is a rare disorder and presents usually acute severe adrenal insufficiency in the neonatal period and hypogonadotrophic hypogonadism. Because DAX1 is located on Xp21, the mutation affects primarily boys (X-linked). Associated with deletion of DAX1, the Duchenne muscular dystrophy, mental retardation-IL1RAPL1, glycerol kinase and ornithine transcarbamylase genes may also be deleted as part of a contiguous gene syndrome.

Case: We report an 1-month old male patient presenting with weight loss, dehydration, lethargy, poor feeding, and hypopigmentation. The first laboratory investigation showed hyponatremia (121 mEq/L), hyperkalemia (7.8 mEq/L), high ACTH (342 pg/ml), and high renin (24.6 ng/ml/hr), so he was diagnosed with primary adrenal insufficiency (PAI). He showed clinical improvement after glucocorticoid and mineralocorticoid treatment, but at present (12 months of age), shows mild motor developmental delay.

Conclusion: DAX1 mutation analysis should be considered in males with adrenal hypoplasia congenita.

PAO-51
Comparison of the efficacy of multiple daily insulin injection therapy and flexible intensive insulin therapy in children with type 1 diabetes mellitus

Gurul Gulvel1; Oplem Sangun1; Bumin Dundar2
1 Suleyman Demirel University, Department of Pediatrics, Sparta, Turkey; 2 Suleyman Demirel University, Department of Pediatric Endocrinology, Sparta, Turkey

Objective: To compare the effects of multiple daily insulin injection therapy (MDII) and flexible intensive insulin therapy (FIIT) on metabolic parameters and quality of life in children with type 1 Diabetes Mellitus (DM).

Method: Twenty eight patients who were followed regularly at least 1 year in our Pediatric Endocrinology outpatient clinic and being treated with MDII (three doses of pre-meal insulin aspart and a single daily dose of basal deglude/glargine insulin) were included in the study. All the patients were evaluated for Hba1c, BMI-SDS, hypoglycemia, mean fasting plasma glucose (FPG) levels, lipid profile, total daily insulin requirement and quality of life (QOL) before and after the 6 months of FIIT. Treatment periods of MDII and FIIT were compared. The Medical Outcomes Survey Short Form-36 (SF-36) was performed in order to assess QOL.

Results: Mean age of the patients was 12.9 ± 2.59 years old. The mean Hba1c and FPG levels of the patients during MDII treatment were found significantly decreased after switched to FIIT (p<0.001 and p=0.024). Insulin requirements, frequency of hypoglycemia, total cholesterol, low density lipo-protein (LDL), triglyceride levels, HDL levels and BMI-SDS of the patients were not significantly decreased with FIIT (p>0.05).

Conclusion: Hba1c and mean FPG levels significantly decrease with FIIT without causing significant difference in insulin requirements, frequency of hypoglycemia and lipid profiles. FIIT also improves mental health and is a reasonable choice in treatment of pediatric Type 1 DM patients.

PAO-52
Suspicious reflections and a solitary nodule in Hashimoto thyroiditis: finally carcinoma

D Mul1; J Kievit2
1 Haag teaching Hospital / Juliana Children's Hospital, Pediatric Endocrinology, The Hague, Netherlands; 2 Leiden University Medical Center, Surgery (section Endocrinology/Head & Neck), Leiden, Netherlands

Background: There is controversial literature on the association between Hashimoto thyroiditis (HT) and the incidence and course of papillary thyroid carcinoma (PTC) in children.

Case report: Our patient was first seen as a young girl at age 14 with a clinical picture of HT with positive antiTPO antibodies. Ultrasound revealed an inhomogeneous pattern in the left lobe with many reflections, mimicking microcalcifications, and Tc-99m-pertechnetate scan was inconclusive. Fine needle aspiration (FNA) suggested a benign etiology with lymphocytic thyroiditis as in HT. Levothyroxin supplementation was initiated. At age 16.5, our patient complained of a swollen neck and the thyroid gland was found to have increased in size. Ultrasound showed a 2 cm hypervascular solitary nodule in the left lobe near the isthmus. FNA again showed an HT picture. The risk for malignancy, given these repeated negative biopsies, was low and no surgical intervention was performed. Three months later the patient returned. On holiday abroad she had fallen ill and was seen at a hospital outpatient department. Complaints of further diameter increase of the thyroid led to another FNA, which this time suggested PTC. After her return from holiday, a total thyroidectomy was performed, showing a 3.5 cm diameter differentiated PTC (T2N0M0). No KRAS of BRAF mutations were detected in DNA analysis as markers of a malignant clinical course.

Conclusions: This case shows the co-occurrence of HT and PTC and the difficulties in diagnosis. In children it is not well defined whether HT increases the risk of permanent hypoparathyroidism and the issue of thyroid replacement therapy remain a concern.
and cell types in the blood. Young individual with CKD cope may be related to stress hormone levels.

The hypothalamic-pituitary-adrenal (HPA) axis is a normally well-tolerated degree of stress can become chronic for individuals in influence of internal conditioning factors, what might generally be called ‘a psychological and stressful under normal circumstances. Anxiety is a common psychological and physiological coping, well-being and overall quality of life.

Coping strategies (psychological and physiological):

- Weakness, glucose intolerance, reduced bone density; all leading to cardiovascular dysfunction, anaemia, malnutrition, muscle wasting, muscle weakness, glucose intolerance, reduced bone density; all leading to reduced stature from January 2000 to July 2010. Their medical records were retrospectively reviewed, and patients with obvious growth hormone deficiency were excluded. The main outcome measure was peak GH level of provocation test, and the height, weight, and serum IGF-1 levels were also recorded.

Results: Simple logistic regression analysis showed that body mass index standard deviation score (BMI SDS) had negative correlation with normal log value (Ln) of peak GH level (P=0.004), but gender, age, pubertal status, Ln IGF-1 had no correlation, respectively. In multiple logistic regression analysis, BMI SDS (P=0.042) and age (P=0.017) were suggested to be significant predictors of Ln peak GH level.

Conclusions: In children without overt GHD, a higher BMI SDS may have negative correlation with the peak GH level. Therefore, we can take BMI SDS into consideration when analyzing the results of growth hormone provocation test.

Paediatric nephrology; chronic kidney disease (CKD) & coping – psychology vs. immunology & neuroendocrinology; discussion paper

Background: The study of coping with Chronic Kidney Disease (CKD) in young people is a unique and challenging task because their circumstances are quite divergent from their adult counterparts. The aim of this article is to use a combination of retrospective and present literature to inform discussion linking psychology, immune and neuroendocrine systems to recognize a deeper perspective on coping in young people facing CKD.

Ckd in children and young people: CKD is a chronic illness and it is irreversible. Coupled with its devastating effects, CKD is associated with cardiovascular dysfunction, anaemia, malnutrition, muscle wasting, muscle weakness, glucose intolerance, reduced bone density; all leading to reduced coping, well-being and overall quality of life.

Coping strategies (psychological and physiological): The majority of young people with CKD would be expected to cope adequately with daily events and stresses under normal circumstances. Anxiety is a common psychological pattern of children/young people with CKD. Physiologically, due to the influence of internal conditioning factors, what might generally be called ‘a normally well-tolerated degree of stress’ can become chronic for individuals with vulnerable body systems, thus leading to long-term adapting/coping in young people with CKD.

Central mechanisms: The hypothalamic-pituitary-adrenal (HPA) axis is a major part of the neuroendocrine system, involving the interactions of the hypothalamus, the pituitary gland and the adrenal glands; thus how well a young individual with CKD cope may be related to stress hormone levels and cell types in the blood.

Conclusion: Overall, an integrated PNI approach is desirable to better understand coping. The immune system has a ‘means’ to signal and ready the body to respond to stressful challenges enabling it to cope. Understanding coping in children/young people with CKD should not be restricted to psychological/psychosocial research.

Breasts condition in adolescent girls with autoimmune thyroiditis

Objective: To study the prevalence of mammary glands (breasts) condition in adolescent girls with autoimmune thyroiditis (AT).

Population and methods: The study included 30 girls (aged 15-18 yrs) with AT (group I) and 30 girls without thyroid diseases (control group). AT was diagnosed on the basis of thyroid peroxidase antibodies level and typical picture of thyroid ultrasound. Mammary glands (MG) disease (mastopathy or dysplasia) was diagnosed on the basis of signs and typical picture of MG ultrasound.

Statistical analysis was performed using Mann-Whitney Test.

Results: Thyroid function was normal in all these girls. TSH levels in girls of group I and control group were 2.9±0.9 and 1.7±0.5 mIU/L respectively. The investigation shows that only 2 girls without AT and all girls (100%) with AT had MG diseases. Among the patients with MG disease the diffuse fibrous dysplasia was found in 26 (87%) in group I and 2 girls – in control group. The cystic diffuse dysplasia was diagnosed only in girls with AT (in 2 patients). The study demonstrated that all adolescents with AT and MG disease had cyclic (premenstrual) mastalgia, 27% girls – persistent mastalgia and 45% girls – cyclic and persistent mastalgia. The investigation shows that only 2 girls with MG disease of in control group had premenstrual mastalgia.

Conclusions: This study has shown a high frequency of mastopathy (38%) among the examined adolescent girls with AT. The AT is risk factor for the mastopathy and the indication for observation and examination of MG.

Computer diagnostics of diabetic cardiac autonomic neuropathy in children

Objective: To study the possibilities of apparatus programmed test in diagnostics of DCAN in children. Population and methods. There were examined 40 children with DMTI, at the age from 7 to 16 yrs. 12 children have the deforming form of diabetes (I group), 16 children have suffered the disease from 1 to 5 yrs (II group) and 12 children have had the disease more than 5 yrs (III group). To diagnose DCAN there was used cardiac vegetative test by means of apparatus programmed complex «VNS - spectrum» (Neurosoft), with program analysis «Poly-spectrum». The evaluation of cardiac rhythm variability (5 cardiac vascular tests on Ewing) was used as the basis of investigation. Each one is estimated from 0 to 2 points.

Results: In all patients of I group there was revealed compensation of carbohydrate metabolism; subcompensation in 6 patients of II group and in 5 patients of III group; decompensation in 10 patients of II group and in 7 patients of III group. DCAN of I degree (5-7 points) was revealed in 20 children with DM: 4 patients of I group; 8 – of II group, 8 – III group. DCAN of 2 degree (8 – 10 points) was revealed in 5 children with DM: 1 from I group; 4 from III group. There was detected the correlation of DCAN with the age of children at the debut of the disease, duration of the disease, degree of compensation.

Conclusions: Cardiac vegetative test allows to diagnose DCAN in children and administer the treatment at early stage, when there is no irreversible death of the nerve fibre.
**Failure to thrive and the diencephalic syndrome**

**Background:** Diencephalic syndrome is a rare condition which typically presents with severe failure to thrive despite preservation of normal linear growth. This is associated with tumours involving the hypothalamus and/or optic chiasma, with the majority being astrocytoma.

**Objective and hypotheses/method:** We describe 3 patients seen at our centre who were diagnosed with diencephalic syndrome over the past 20 years.

**Results:** Initial differential diagnoses for failure to thrive included celiac disease; isolated hypothyroidism; and generalised lipodystrophy and Russell Silver syndrome in one patient who was short. Only one patient presented with nystagmus, which suggested an intracranial pathology. After extensive workup for failure to thrive, Computed Tomography of the brain eventually revealed the presence of a suprasellar tumour in all 3 patients, which were subsequently confirmed to be inoperable hypothalamic astrocytomas. The age of diagnosis ranged from 9 to 18 months old. There was one death, with the other two patients demonstrating a more protracted course. The child who died presented at the earliest age and had the largest tumour which recurred within 1 month of surgery, suggesting a more aggressive course. Of the other two patients who have survived into adulthood, one underwent cranial irradiation before the age of 5 years, and suffered the consequences of late onset endocrinopathies and mental retardation. Both surviving patients have reached adulthood, with minimal increase in tumour size, suggesting a more indolent course. In diencephalic syndrome, the overall mortality rate is 55% with death ranging from 8 months to 13 years.

**Conclusions:** Diencephalic syndrome must always be considered in any child with failure to thrive from no other apparent reason. This peculiar syndrome provides a unique model of partial growth hormone resistance (elevated growth hormone levels) with normal linear growth, and suggests that there are hypothalamic-pituitary factors in the feedback mechanisms of appetite regulation and metabolism.

**Profile of iron metabolism in pediatric age: clinical and epidemiological impact on our environment**

**Introduction:** Iron deficiency is a significant public health problem in terms of epidemiology and potential comorbidities. Its prevalence and easy diagnosis and treatment, put into question the relevance of performing screening programs or targeted screening in high risk populations or suspected cases.

**Objectives:** Determine our environment and the existence of iron deficiency or iron-deficiency anemia in children previously diagnosed between 2 months and 11 years, analyzing their clinical implications.

**Material and methods:** Cross-sectional study in a sample of 900 children seen in primary care. They have no diagnosis or suspicion of iron deficiency or anemia. Simple systematic sampling was conducted to recruit 30 children.

**Results:** We found 46.6% of cases of hyposideremia and 40% of iron-deficiency anemia. Of the latter, we observed more frequently in men (83%) and predominant age group (53.3%) fell between 12-36 months. It was also observed more frequently in cases of low birth weight and/or exclusive feeding of formula.

**Conclusions:** Iron deficiency anemia is a common disease in our environment. Our largest case series was in children under 16 months, which disagrees with results of other authors. To obtain guidance on the diagnosis and etiology, sufficient medical history, physical examination and a small number of laboratory tests. Based on the foregoing, we propose the establishment of a hypothetical program of mass screening of iron deficiency or anemia in children, assessing their potential economic impact on the public health system in terms of cost-effectiveness.

**Implications of bone metabolism in pediatric patients with inflammatory bowel disease**

**Introduction:** Alterations of bone metabolism in patients with inflammatory bowel disease (IBD) have a high prevalence. Among the known factors leading to this comorbidity are: corticosteroid therapy, the activity of IBD and duration of symptoms and lifestyle.

**Objectives:** To study the potential impact of IBD in mineral metabolism in pediatric patients, evaluating clinical, biochemical, densitometric and radiographic parameters.

**Material and methods:** Cross-sectional study in children with IBD. We collected anthropometric and clinical data (cumulative dose of corticosteroids, index of IBD activity, nutrition survey and lifestyles). It was carried out a blood analysis. It included CBC and serum biochemical study on the levels of glucose, urea, creatinine, sodium, potassium, calcium, phosphorus, alkaline phosphatase, urate, magnesium, PTH, osteocalcin, TSH, T4, CRP, albumin, prealbumin, total protein, total cholesterol, HDL-cholesterol, triglycerides, iron, ferritin, transferrin, orosomucoid and C-telopeptide. The urine analysis included: glucose, urea, creatinine, ions, calcium, inorganic phosphate, total protein, microalbuminuria and urate. We performed bone densitometry (DEXA) of spine and hand-wrist radiograph. Multiple linear regression was performed in successive steps, using as dependent variable bone mineral density (BMD) quantified by the z score value obtained from the DEXA.

**Results:** Preliminary there are 8 patients (4 boys and 4 girls) aged between 3 and 17. About 25% had a BMD below the normal range for age and sex. Another 25%, an IBD activity index higher. About 37.5 had increased CRP. The C-telopeptide was increased in all cases. There was only one case of overweight. We found a significant relationship (ρ <0.02) between BMD and IBD activity index.

**Conclusions:** The index of activity of the IBD had a negative impact on BMD of the child. Iatrogenic corticosteroid did not result in a detriment of the BMD of pediatric patients and so we propose to prioritize good rate control IBD activity. The C-telopeptide is consistently high in children with IBD.

**Gonadal mosaicism 45X/46XY resulting in a Turner phenotype with mixed gonadal dysgenesis: a report of two cases**

**Background:** Mixed gonadal dysgenesis is regarded as the most common manifestation of 45X/46XY mosaics, associated with a wide spectrum of phenotypic manifestations.

**Objective and hypotheses:** We describe two cases with a Turner phenotype associated with mixed gonadal dysgenesis. One of the two cases presents a mosaicism 45X/46XY and one a 46XY karyotype.

**Methods:** We describe a 16 year old girl who presented with short stature and puberty delay. She had female external genitalia, an urethral opening on the posterior vaginal wall and some clinical features of Turner syndrome (widely spaced nipples, cubitus valgus, low hairline, multiple nevi). Endocrine studies showed levels of sex hormones consistent with primary gonadal failure. The
pelvic ultrasound revealed the presence of an uterus. At laparotomy a uterus, fallopian tubes and small gonad-like tissue masses in the region of the Fallo-pian fimbria were found. Histological analysis revealed no organized testicu-lar or ovarian morphology, fallopian tubes on the right side and epididymis on the left side. The second case is a 10 year old girl presenting with features of Turner syndrome (broad chest, mouth abnormalities, cubitus valgus), short stature, and primary gonadal failure. The pelvic ultrasound reveals the presence of an uterus and fallopian tubes with streak gonads. Results: In the first case G-bandning analysis of blood lymphocytes confirmed a 46XY karyotype while in the second there was a mosaicism 45XO/46XY. FISH analysis for the eventual presence of isodicentric Y chromosome, as well as gene sequencing for SRY, SRY, AMH and AR are in progress. Conclusions: Comprehensive cytogenetic, endocrine, histological and molec-ular studies on the gonads are further needed in order to explain the cau-sality between the genetic profile and the phenotype in these two particular cases.

PAO-62
The experience of recombinant growth hormone treatment in a secondary endocrine referral centre in Saudi Arabia
Suzanne Elholy; Sulaiman AlMuhaeamd
King Fahad Military Medical Complex, Paediatrics, Dhrhan, Saudi Arabia

Background: King Fahad Military Medical Complex is a secondary referral centre for paediatric endocrinology for the eastern province in Saudi Arabia. Recombinant Growth Hormone has been used for many years as a treatment option for children and young adults with many endocrine disorders mainly short stature resulting from growth hormone deficiency or insufficiency.

Objective and hypotheses: The aim of the present study is to evaluate the use of R-GH treatment use, indication, dose, effect on height as well as effect of discontinuation of treatment due to compliance or lack of supply issues.

Methods: We have identified over 50 patients who are receiving R-GH and performed a retrospective chart review to assess the effect of treatment of GH.

Conclusions: Most patients were diagnosed with growth hormone deficiency followed by children with Turner syndrome, then other genetic disorders, and ideopathic short stature. Doses used were generally less than recommended and periods of treatment interruption were noted. The study results will help shape protocols for future growth hormone doses, compare different protocols used in the past with current national and international protocols as well help guide the newly published growth curves for children from Saudi Arabia.

PAO-63
Rapid increase of serum TSH level in an infant on amiodarone treatment: a case report
Alessandr Peet; Vallo Tillmann
Children’s Clinic of Tartu University, Department of Paediatrics, University of Tartu, Tartu, Estonia

Background: Amiodarone is widely used as an effective and relatively safe anti-arrhythmic drug. Amiodarone-induced hypothyroidism is well described and close monitoring of thyroid function in all patients receiving amiodarone is recommended. For the first control of serum TSH level is usually recom-mended 10 to 60 days after starting the treatment.

Objective and hypotheses: We present a case of term infant who rapidly developed increased TSH level after starting amiodarone treatment.

Results: Male infant from normal pregnancy and uneventful delivery was born from 40 gestational week with the birth weight of 3210 g. Supraventricular tachyarrhythmia, severe combined congenital heart diseases (coarctation of aorta, ventricular septal defect, and foramen ovale apertum), and congestive heart failure were diagnosed at the first day of life. In order to control frequent episodes of supraventricular tachycardia paroxysms, treatment with amiodarone was introduced at the age of 10 days. During the following days the amiodarone dose ranged from 2.5 to 18.75 mg/kg/day (mean 7.2 mg/kg/day). Neonatal screening for hypothyroidism was normal (TSH 1.7 mU/l). On the 9th day of amiodarone treatment (at the age of 18 days) serum TSH level increased to 17.6 mU/l and for the 12 day to 28.6 mU/l. During that period treatment with L-Thyroxine was not initiated because of normal serum free T4 level (18.8 pmol/l). Amiodarone treatment was gradually withdrawn.

Conclusions: In infants receiving amiodarone treatment the thyroid function should be monitored more frequently than the recommended intervals, parti-cularly at the beginning of the follow-up, since the serum TSH level may increase in few days after commencing the treatment.

PAO-64
A case of Liddle’s syndrome in an 8-year old girl with argininosuccinic acidemia and childhood absence epilepsy
Jan Marquard; Thomas Meissner
University Hospital Duesseldorf, Department of General Pediatrics, Duesseldorf, Germany

Background: Liddle’s syndrome, also called pseudohyperaldosteronism, is a rare autosomal dominant disorder caused by an activating mutation of the renal epithelial sodium channel. Affected patients typically show hypertension, hy-pokalemia and metabolic alkalosis.

Case report: We report on an 8-year old girl with argininosuccinic acidemia and childhood absence epilepsy who developed arterial hypertension. Initial diagnosis was worked up a slight hypokalemia, serum aldosterone was not in cap-able of measurement. 24-hour urinary potassium excretion, serum creatinine, arterial blood gas analysis, blood catecholamines and steroid levels, abdominal and renal ultrasound, echocardiogram and renal magnetic reso-nance angiography were without pathological findings. The family history was unremarkable. An essential hypertension was assumed and the girl was treated with propranolol which failed to control the elevated blood pressure as well as the combination of captopril and spironolactone. Additionally, the girl developed a metabolic alkalosis, hypokalemia worsened. Serum and urine aldosterone levels as well as plasma renin activity were abnormally low. Liddle’s syndrome was suspected and treatment with amiloride was started. After 4 weeks of uncomplicated treatment blood pressure returned to normal levels and blood gas analysis was in a normal range. Gene-sequencing for liddle’s syndrome was negative.

Discussion: Despite a negative gene-sequencing for liddle’s syndrome (molec-ular detection rate around 40%) the diagnosis could be established by typical laboratory findings and a good response to amiloride. Neither argininosuc-cinic academia nor childhood absence epilepsy seems to be related to liddle’s syndrome since there are no comparable reports in literature. In retrospect the initial slight hypokalemia in combination with hypertension was already indicative for liddle’s syndrome but in fact the clinical course provided the diagnosis.

Conclusion: Children with hypertension and lack of therapeutic response to first-line antihypertensive agents should be worked up for secondary causes.

PAO-65
Side effect profile of diazoxide in children with congenital hyperinsulinism. A retrospective study
Jan Marquard; Laura Huberman; Thomas Meissner
University Hospital Duesseldorf, Department of General Pediatrics, Duesseldorf, Germany

Background: Diazoxide is the first-line drug for long-term treatment of con-genital hyperinsulinism (CHI). However, the use of diazoxide is often limited by side effects, e.g. hypertrichosis, fluid retention and feeding problems. Up to now the frequency of these side effects is based on estimation.

Objective: To precisely determine the frequency of major side effects of diazoxide in children with CHI.

Patients and methods: Interviews on side effects were performed with the parents of CHI patients who received diazoxide. In addition, patients’ records were retrospectively searched for side effects of diazoxide.

Results: So far we identified 24 patients (13 female, 11 male) with CHI who are or had been treated with diazoxide. Preliminary data shows that 92% of them developed hypertrichosis. The treatment of 16 patients is still ongoing, for 25% of these patients hypertrichosis has been regressive in the course of the treatment. In 8 cases the diazoxide treatment has ended because of remission of the disease. In all of these patients hypertrichosis regressed completely. Hypertrichosis was most distinctive along the spine (48%) followed
by the face (30%) and the extremities (13%). In 54% of patients feeding difficulties were reported during the diazoxide treatment, 40% of them had a verifiable weight loss. 37% of the patients developed edema, nearly all of them had facial edema. Tachycardia was rarely reported (4%), hyperuricemia and leucopenia were not reported during diazoxide treatment.

**Conclusions:** The most common reported side effects of diazoxide in patients with CHI are hypertrichosis (92%) followed by feeding problems (54%) and facial edema (37%).

**PAO-66**

**Ambiguous genitalia – a 15 years overview**

**Abiola Odusola:** Rolil Nwodo; Elizabeth Ebechirh Oyenusi; Chris Bode; James Rennie

Lagos University Teaching Hospital, Paediatrics, Surulere, Lagos, Nigeria

**Background:** The term ambiguous genitalia or indeterminate sex is a terminology that parents fear to hear. This is most devastating within the African continent were being in the 21st century the sex of a child is of utmost importance. Fortunately this disorder is uncommon. Classifying the cases into different groups is formidable especially when investigative support is minimal.

**Objective:** To determine the prevalence of ambiguous genitalia, categorizes patients, the mean length of time for completion of investigation and therapy outcome.

**Methodology:** This is a review of all patients referred with ambiguous genitalia to the clinic over 13 years. Assessment criteria were based on clinical presentation, hormonal and biochemical estimations, sonogram of the abdomen, genitogram and karyotype / baccal smear. Stimulation with human chorionic gonadotropin (hCG) and ACTH (adrenocortical hormone) stimulation tests were performed as required.

**Results:** Reviewed were 44 out of 245 patients with endocrine disorders (1997 to 2010) had ambiguous genitalia. They were categorized as genetic females with virilisation or FPH (15, 34 %) all of them had the V281L mutation. The gender distribution showed 92% was female with the other one patient had rapid progressive early puberty and developed male pseudohermaphroditism (0,2%).

**Conclusions:** Most patients who were female presented with CPP known as CPP (30%), all of them had the V281L mutation. The one of the patients with V281L heterozygous mutation developed true precocious puberty and the other one patient had rapid progressive early puberty and developed polycystic ovary syndrome.

**PAO-68**

**Continuous subcutaneous insulin infusion (CSII): a successful mode of therapy for neonatal diabetes (experience in Qatar)**

Fawzya Alkhalife; Maryam Al Ali; Asraf Tawfeq; Mohamoud Zyoud; Noura Alheamadi; Amal Sbat; Ahmed Alawa

Hamad Medical Corporation, Pediatric, Doha, Qatar

**Background:** Neonatal diabetes is defined as persistent hyperglycemia occurring in the first months of life that lasts more than two weeks and requires insulin for management.

**Objective and hypotheses:** Although pediatricians face numerous difficulties in managing insulin therapy at this age, very few data are available on possible methods of insulin delivery in neonatal diabetes.

**Methods:** We report our experience over 3 years of continuous subcutaneous insulin infusion (CSII) in cases of neonatal diabetes requiring insulin therapy (n = 5). Two neonates were negative for ABCCR-ve KCNJ11, two had pancreatic ageness and one has Wolcott-Rallison syndrome. CSII therapy in neonatal diabetes allows easy adaptation of insulin delivery, closely following the current feeding regimen (a basal infusion needed with very minimal dose; prreappendental boluses being started with intermittent bottle feeding).

**Results:** Management using very small insulin doses (e.g. bolus = 0.20 U and basal rate = 0.02 U/h) was required and was only possible after insulin dilution (5-10 U/ml) and is more accurate with CSII than with using syringes. CSII allows easy delivery of such small doses without dilution errors. CSII achieved good glycemic control for all neonates (mean HbA1c = 8 %) with few hypoglycemic events; which are particularly frequent and dangerous at this age. Neonates tolerated the subcutaneous infusion lines well without any local side effects.

**Conclusions:** During the neonatal period, and under the supervision of an experienced team, CSII is safe, more physiological, accurate and easy to manage than using syringes or pens.

**PAO-67**

**Characteristics and prevalence of non-classical congenital adrenal hyperplasia with a v281l mutation in patients with premature pubarche**

Senay Sivas Erdem1; Merih Berberoglu1; Nuket Yurur Kutlay1; Zeynep Siklar1; Bulent Hacihambagoglu1; Aijan Tukur1; Gonul Ocal1

1Ankara University School of Medicine, Department of Pediatrics, Division of Pediatric Endocrinology, Ankara, Turkey; 2Ankara University School of Medicine, Department of Medical Genetics, Ankara, Turkey

**Background:** The frequency of NCCAH with V281L among children presenting with premature pubarche (PP) is variable.

**Objective and hypotheses:** To determine the prevalence, clinical and laboratory characteristics of NCCAH with the V281L mutation in patients with PP.

**Methods:** The study group was composed of 159 unrelated patients with PP. ACTH stimulation test was performed in 14 of the 159 patients with PP who had basal 17-OHP levels ≥2 ng/ml. Patients whose stimulated 17-OHP level on the ACTH test was ≥10 ng/ml underwent a mutational analysis of the CYP21 gene, and those with the mutation were considered to have NCCAH.

**Results:** NCCAH was defined in nine (5.7%) among 159 patients with PP. The gender distribution showed 92% were female and all of them had the V281L mutation. The one of the patients with V281L heterozygous mutation developed true precocious puberty and the other one patient had rapid progressive early puberty and developed polycystic ovary syndrome.

**Conclusions:** ACTH stimulated > 17-OHP 10 ng/ml in PP patients is load star to mutation analysis and heterozygote patients should be followed for clinical and biological hyperandrogenism up to completion of the whole gen sequence.

**PAO-69**

**Complete catch-up growth in a case of Johanson Blizzard syndrome with severe postnatal growth retardation**

Amal Sbat; Ashraf Soliman; Noura Alheamadi; Ahmed Elawa; Nadra Abdelmajeed

Hamad Medical Center, Pediatrics, Doha, Qatar

**Background:** Patients with Johanson Blizzard syndrome (JBS) have significant postnatal growth retardation.

**Objective and hypotheses:** We report the growth pattern of a boy with the JBS who was born at term with aplasia of the alae nasi and severe congenital sensori-neural deafness.

**Case:** At the age of 1.5 years the boy presented with features of JBS and sensori-neural deafness.

**Results:** Investigations revealed mild pancreatic exocrine insufficiency and oral Pancrex V (lipase) was initiated. Despite some improvement in weight, his linear growth was still slow. At 2 years of age, endocrine evaluation proved growth hormone deficiency (glucagon test) with low IGF-I level, primary hypothroidism (low free T4 and high TSH) and cortisol deficiency. MRI of the brain, showed hypoplastic pituitary gland. The child was started on human
growth hormone (GH), L-thyroxine and hydrocortisone replacement. Marked improvement of linear growth occurred with complete catch-up to his mid-parental height SDS occurred in 2 years. He maintained normal linear growth during the following 3 years.

Conclusions: Our case represents the first report of complete catch-up growth in a case of Johansen blizzard syndrome after severe postnatal growth retardation during infancy.

Linear Growth JBS on Therapy

![Graph showing linear growth in JBS on Therapy](attachment://graph.png)

PAO-70

Pediatric Graves ophthalmopathy in association with thyroid autoantibodies

Dae Kyun Koh1; Won Kyung Cho2; Min Ho Jung2; Byung Kyu Suh2; So Hyun Park2

1The Catholic University of Korea, Pediatrics, Seoul, Republic of Korea; 2The Catholic University of Korea, Endocrinology, Seoul, Republic of Korea

Background: As pediatric Graves disease is an uncommon condition, Graves ophthalmopathy should be more unusual. Graves ophthalmopathy has been reported to be associated with high titers of thyroid autoantibodies. Nevertheless, studies on children are not abundant.

Objective and hypotheses: We aimed to compare the thyroid autoantibody levels in Graves disease patients with ophthalmopathy to those in patients without ophthalmopathy.

Methods: The subjects were 60 patients under the age of 18 years diagnosed with Graves disease from January 2000 to December 2010 at the Catholic University Saint Vincent Hospital. We reviewed the medical records retrospectively.

Results: Among them, 20 patients associated with Graves ophthalmopathy (33.3 %) were compared with 40 patients without ophthalmopathy (66.7 %). TSH Receptor antibody levels were higher in patients with ophthalmopathy than in patients without it (111.25±140.50 U/L vs 57.52±103.08 U/L, p = 0.024), and the percentage of elevated anti-microsomal antibody level was also higher in patients with ophthalmopathy (80 % vs 45 %, p=0.013).

Conclusions: Pediatric Graves ophthalmopathy was associated with high titers of thyroid autoantibodies in our study. Nevertheless, large-scale studies with more patients are required.

PAO-71

Intestinal malabsorption and dark skin caused elevated parathormone levels

Rolf Peter Willich1; Nunu Mitskevitch2

1Endokrinologikum Hamburg, Pediatrics, Hamburg, Germany; 2Tbilisi State University, Immunology and Microbiology, Tbilisi, Georgia

Background: Hyperparathyroidism is a rare finding in children. It is a typical sign of vitamin D-deficiency caused by different reasons. It may also be due to calcium wasting syndromes, and it can rarely be induced by adenomas of the parathyroid glands and in parathormone receptor mutations (pseudohyperparathyroidism).

Objective and hypotheses: To show how celiac disease can mimic hyperparathyroidism followed by rheumatic complaints.

Patient: A 12-year old Gambian girl living in north Europe was developing abdominal and joint pain. Serum analysis revealed low serum-calcium, significantly elevated parathormone and decreased vitamin D. Immigrant rickets was assumed. Because of abdominal pain and iron deficieny, lambliaisis was ruled out. Celiac disease was demonstrated by gladin- and tissue transglutaminase-antibodies as well as by intestinal mucosa biopsy. Despite of a gluten-free diet the joint pains persisted. They were declared by rheumatologists to be caused by a chronic juvenile arthritis (sister disease of celiac disease). However, there were no positive inflammation signals and no clear elevated rheuma-immunology.

Follow up: Gluten-free diet and additional treatment with calcium and active vitamin D did not stop increasing parathormone levels, did not stop abdominal and joint pain, and did not stop increment of positive celiac disease antibodies. Assuming compliance problems the patient was then treated with vitamin D injections, which caused decreasing parathormone levels and vanishing joint pain.

Conclusion: Celiac disease can cause intestinal rickets with elevated parathormone levels mimicking chronic juvenile arthritis, if gluten-free diet is not strictly performed by compliance problems. Parenteral supply of depot-vitamin D is the therapy of choice in these patients exhibiting normalization of parathormone and vitamin D25 levels with disappearance of rheumatoid joint pain.

PAO-72

Pituitary hyperplasia in primary hypothyroidism

Roberto Francone1, Maria Bellizz2; Vittoria Cauer1; Umberto Rozzanigo2; Riccarda Fiallo2; Annunziata Di Palma1

1S.Chiara Hospital of Trento, Pediatrics Unit, Trento, Italy; 2S.Chiara Hospital of Trento, Diagnostic Imaging Unit, Trento, Italy

Background: Despite recent progress in imaging techniques, it is not possible to distinguish between TSH-producing macroadenoma and hyperplasia of pituitary thyrotroph cells on CT and MR scans. In such cases, repeat MRI after therapy with thyroxine may provide a definitive diagnosis and eliminate unnecessary surgery.

Objective and hypotheses: We describe an example of reactive pituitary hyperplasia from primary hypothyroidism that mimicked a pituitary macroadenoma in a child.

Case report: A 10 year old boy presented with occipital headache over the last three months and height growth arrest. Cranial Magnetic Resonance Imaging (MRI) detected an intrasellar and suprasellar pituitary mass. Endocrine evaluation revealed a severe primary hypothyroidism (TSH 589 mU/L, free T4 1.5 pmol/L, mild hyperprolactinaemia (1.23 mmol/L) and low IGF-1 (8.6 mmol/L). Thyroid ultrasound showed normal thyroid size with markedly heterogeneous echo texture and hypo-echoic areas. Thyroid peroxidase and thyroglobulin antibodies were high. The patient was started on levothyroxine at 50 μg/day. Three months later IGF-1 and thyroid hormone had returned to the normal range and height growth velocity had increased. MRI study documented resolution of the mass effect.

Conclusions: Primary hypothyroidism should be considered in the differential diagnosis of solid mass lesions of the pituitary gland. Examination of thyroid function in patients with sellar and suprasellar masses revealed by MRI may avoid unnecessary operations which can cause irreversible complications.

PAO-73

Familial non autoimmune hyperthyroidism- a family

Gul Yesilpepe Mutlu; Filiz Mine Cizmecoglu; Sukru Hatun; Elif Ozsu

Kocaeli University, Pediatric Endocrinology and Diabetes, Kocaeli, Turkey

Objective: Familial nonautoimmune hyperthyroidism which is inherited autosomal dominant, that caused by activating mutations of the thyrotropin receptor gene (TSHR). Recent studies have shown that FNAH, toxic adenoma and sporadic congenital hyperthyroidism are in fact facets of the same disease, genetic hyperthyroidism due to TSHR mutations.

Printed Abstracts Only
Methods: Case 1: Eleven -year-old male patient was admitted to our clinic with complaints of a neck swelling, weight loss, irritability, sweating. In his physical examination his weight and height were in the normal range, cardiac rate was 100/min above the upper limit. Thyroid examination revealed grade 2 goiter. The patient’s laboratory examination: TSH:0.199uIU/ml (0.5 - 4.8), free t4: 1.23ng/ml(0.8-2.3), free t3:3.92pg/ml(2-4), anti-TPO:175IU/ml, anti-TG:21.6U/ml(0-134), anti-TSH receptor was negative. Imaging of the thyroid gland both thyroid glands and isthmus thickness increased, 3mm colloidal nodule was seen in right lobe. The patient’s mother also had goiter with hyperthyroidism which was resistant to treatment so radioactive iodine treatment was applied. Also autoantibody and anti-TSH receptor were found negative in mother.

Case 2: Ten-year-old female patient was admitted because of goiter with his (casel) older brother. Beside intolerance the heat, she had no symptoms. In her physical examination her weight and height were in the normal range, cardiac rate was 104/min above the upper limit. The patient had grade 2 goiter whose laboratory examination: TSH:9.3uIU/ml (0.5-4.8), free t4:1.43ng/dl (0.8-2.3), free T3: 4.66pg/ml (2-4), anti-TPO:12.8 IU/ml(0-134), anti-TG:19.7 IU/ml (0-134) and anti-TSH receptor was negative. Imaging of both thyroid glands and isthmus thickness increased TSHR gene mutations were sent for genetic analysis because of known two-generation family affected and hyperthyroidism no autoimmunity.

Result: TSHR activating mutations as the cause of subclinical hyperthyroidism may be more common and should be considered in the differential diagnosis especially if familial.

Background: Hypothalamic obesity is one of the most important effects of central nervous system damage. Generally lifestyle modification and diet are ineffective to treat the hypothalamic obesity. Sandostatin has been trying in pediatric hypothalamic obesity with short period in a few study. The results were promising but some are inconclusive.

Objective and hypotheses: To evaluate sandostatin treatment a case with hypothalamic obesity in a child.

Methods: A 5.1 year old male patient admitted to our clinic with complaint of a neck swelling, weight loss, irritability, sweating. In his physical examination his weight and height were in the normal range, cardiac rate was 160/min above the upper limit. Thyroid examination revealed grade 2 goiter. The patient’s laboratory examination: TSH:0.199uIU/ml (0.5 - 4.8), free t4: 1.43ng/dl (0.8-2.3), free T3: 4.66pg/ml (2-4), anti-TPO:12.8 IU/ml(0-134), anti-TG:19.7 IU/ml (0-134) and anti-TSH receptor was negative. Imaging of both thyroid glands and isthmus thickness increased TSHR gene mutations were sent for genetic analysis because of known two-generation family affected and hyperthyroidism no autoimmunity.

Result: TSHR activating mutations as the cause of subclinical hyperthyroidism may be more common and should be considered in the differential diagnosis especially if familial.

Conclusions: The high TNF-α, ucrP and fibrinogen levels confirm a proinflammatory state associated with abdominal obesity in the studied population.

Background: Non-alcoholic fatty liver disease (NAFLD), the most common cause of liver disease in children, is associated with obesity.

Objective: The aim of the study was to examine the prevalence pattern of NAFLD in obese children and adolescents and analyze the anthropometric, biochemical and metabolic factors related to it.

Methods: We retrospectively reviewed the charts of 2007 obese children and adolescents (BMI >95th centile) who attended our Department between January 2000 and January 2010. A total of 114 obese subjects were found with elevated (>40U/L) serum alanine (ALT) and/or aspartate (AST) aminotransferases, considered as surrogate marker of NAFLD, since other causes of hepatitis and alcohol consumption were excluded. Variables studied included BMI, pubertal status, and fasting levels of glucose, insulin and lipids. Insulin resistance was evaluated by means of HOMA-IR and Quicki.

Results: Presumed NAFLD was present in 5.8% of the obese pediatric population but, predominantly in boys (boys vs girls : 8.4%vs 3.9%, p=0.001). They were 63 boys and 51 girls aged 3.15 to 16.4 (mean age 9.8 ± 3.0) with BMI ranging from 1.62 to 5.11 (mean 3.17 ± 1.6). 48% of them were prepubertal and had significantly lower serum ALT levels compared with pubertal children (p<0.001). Hypersulinsinemia was present in 77(67.5%). Insulin resistance as estimated with HOMA-IR-3 or Quicki >0.31 were equally prevalent in pre- and post pubertal children. In multiple logistic regression models BMI<50s and male gender were strongly associated with NAFLD.

Conclusion: Elevated transaminases is a common finding among obese children even in younger ages, strongly associated with insulin resistance. Their evaluation is recommended as a screening parameter in obese pediatric population.
PAO-77

The first documented case of Wolcott-Rallison syndrome in Serbia
Tatiana Milenkovic; Sladiana Todorovic; Dragana Zdravkovic; Anke Pyper; Andrea Naeke; Jayne Houghton; Sian Ellard; Katarina Mitrovic

1Mother and Child Healthcare Institute of Serbia, Endocrinology, Belgrade, Serbia; 2Klinik fur Kinder und Jugendmedizin, Endocrinology, Dresden, Germany; 3Peninsula Medical School, Universities of Exeter and Plymouth, Genetic laboratory, Exeter, United Kingdom

Background: Wolcott-Rallison syndrome (WRS) is a rare autosomal recessive disease. Its main characteristic is permanent neonatal diabetes mellitus (PNDM) associated with skeletal epiphyseal dysplasia.

Clinical report: The female infant was born from unrelated parents. Pregnancy was uneventful and delivery was at term. Birth weight was 2100 g (below 5th centile) and length was 48 cm. At 3 months of age, the diagnosis of NDM was established and insulin treatment was introduced. From the very beginning, diabetes was difficult to control. At the age of 1.5 years she was admitted to the hospital for vomiting, edema and hepatomegaly. Laboratory workup showed extremely high levels of liver enzymes. This episode of hepatitis resolved spontaneously within 4 weeks. By that time, she was also diagnosed a hypothyroidism and was started on L-thyroxine. Eight months later, when investigated for steatorrhoeas, pancreatic hypotrophy was found on abdominal ultrasound.

After exocrine pancreatic insufficiency has been confirmed, therapy with pancreatic enzymes was initiated. At the age of 2.6 years an episode of liver failure (requiring hospitalization) reappeared. She had seizures soon after and was put on Phenobarbital. The etiology of seizures was unrevealed. Mutation analysis of the EIF2AK3 gene showed that the child is homozygous for a nonsense mutation, R902X, in exon 13. This result confirmed the diagnosis of WRS. After the diagnosis had been established skeletal X-ray was performed. It revealed multiple epiphyseal dysplasia affecting long bones, vertebrae and pelvis.

Conclusions: WRS is a very rare disease. However, it should be considered in any child with NMD and associated disorders, especially if skeletal changes are detected. The diagnosis of WRS in our patient delayed since genetic testing had not been performed at the time of making the diagnosis of NDM and hypothyroidism.

Although genetic diagnosis of WRS does not alter therapeutic approach, it might help in predicting the outcome, as well as offering informed genetic counseling.

PAO-78

Obesity in Greek children: a meta-analysis of data from the last decade
Eleni Kotanidou; Maria Grammatikopoulou; Bessie E. Spiliotis; Christina Kanaka-Gantenbein; Maria Tsigara; Assimina Galli-Tsinopoulou

1Faculty of Medicine, Aristotle University of Thessaloniki, 4th Department of Pediatrics, Thessaloniki, Greece; 2Alexander Technological Educational Institute, Department of Human Nutrition and Dietetics, Thessaloniki, Greece; 3University of Patras School of Medicine, Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, Patras, Greece; 4University of Athens, First Department of Pediatrics, Division of Endocrinology, Diabetes and Metabolism, Athens, Greece

Background: The obesity epidemic has reached children in Europe, including Greece. National epidemiological data and trend monitoring are of extreme interest in order to be able to provide a burden to this epidemic.

Objective and hypotheses: The aim of the present study was to review all available data published last the decade on objectively measured weight status in prepubertal (1-12 years old) Greek children and therefore to estimate an updated accurate prevalence of obesity in this age group according to sex, after controlling for publication bias.

Methods: We reviewed all published available citations from January 2001-December 2010, reporting the prevalence of childhood obesity (ages 1-12 years old) according to the International Obesity Task Force Criteria, in Greece. Pooled analysis and Der-Simonian Laird analysis was performed.

Results: The pooled analysis revealed that among 219996 boys, 11.8% were obese, whereas in the girls the prevalence of obesity was 10.6% (total n=210772). When forest plots were plotted for identification of studies with publication bias, the prevalence of obesity was 10.9% in the boys and 10.2% in the girls (total n=216168 boys and 208637 girls). Overall the boys demonstrated increased odds for being obese compared to the girls (OR:1.14, CI:1.11-1.12). Between pooled and meta-analysis, the girls demonstrated a significantly lower prevalence of obesity in the second (p<0.001).

Precise conclusions: According to the analysis, one out of ten prepubertal Greek children appears to be obese. The results also demonstrate the existence of publication bias in pediatric obesity research.

PAO-79

Prevalence of obesity and overweight in the primary school children and their relationship with some life style factors, Iran, 2010
Shahla Vaziri Esfarjani; Samin Vafa; Maryam Razaghy-Azar

1Jondi-Shapour University of Medical Sciences, Social Medicine, Ahvaz, Islamic Republic of Iran; 2Tehran University of Medical Sciences, Pediatric Endocrinology and Metabolism, Tehran, Islamic Republic of Iran

Background: Currently obesity is a major health problem throughout the world and a risk factor of many chronic diseases such as cardiovascular disease, hypertension, diabetes mellitus and cancer. Prevalence of obesity and overweight has been rapidly increased in both children and adults. Most of the obese children (80%) will be obese in adulthood.

Objective and hypotheses: The aim of this study presents the prevalence of childhood overweight, obesity and their relationship with factors which focused on watching TV, using the computer or playing video games, fast foods consumption, breast feeding and birth weight.

Methods: In this cross sectional study 960 (480 male and 480 female) primary school aged children aged 6-12 years old were selected by a two stage cluster sampling method. Height and weight were measured by the standard methods. Additionally BMI was calculated based on the weight, height and obesity; overweight were defined based on the BMI scores using CDC chart. Obesity, overweight and normal weight were defined as BMI<95th percentile and BMI=85-95th; BMI=85th respectively. The other data were collected by questionnaire that completed by parents. Data were analyzed by using chi square and fisher exact test(ANOVA).

Results: According to our findings 11.9% of the subjects were overweight and 6% were obese. The results have shown a positive significant relationship between BMI and the mean time of watching TV, using computer or playing video games and fast food consumption during childhood (p<0.001). There was no relationship between BMI and gender, birth weight and breast feeding.

Conclusions: In this study the prevalence of overweight and obesity was compared to the same study in the last seven years which showed increasing in this community. Several studies have shown breast feeding is a protective factor for obesity, but this study has shown fast foods consumption, the mean time of watching TV and using computer or playing video games during childhood in spite of breast feeding in infancy period can be more effective on obesity.

PAO-80

Growth patterns in 100 short children receiving GH therapy – a retrospective study
Cristina Dumitrescu; Corina Chirita; Camelia Procopiuc; Anda Dumitrascu

1National Institute of Endocrinology, Pediatric Endocrinology, Bucharest, Romania; 2Anina Specialty Medical Services, Endocrinology, Bucharest, Romania; 3National Institute of Endocrinology, Radiology, Bucharest, Romania

Background: The goal of growth hormone (GH) therapy is to promote linear growth in children with GH deficiency and to improve the short stature associated with other causes of GH deficiency. GH promotes both growth and the conversion of protein from fat into lean tissue, and is thus important for normal growth and development.

Aim: To present the evolution of height and metabolic parameters in 100 short children treated with daily doses of growth hormone for up to 3 years.

Methods: The children were divided into four groups: group 1 - 58 children with GH deficiency: 19 girls and 39 boys, mean age 8.8 yrs +/-3.4; group 2 - 21 girls with Turner syndrome, mean age 8.2 yrs +/-3; group 3 - 17 children born SGA, 8 girls and 9 boys, mean age 7.8 yrs +/-3.4 and group 4 - 14 children with idiopathic short stature: 5 girls and 9 boys, mean age 7.4 yrs +/-3.2. The SDS for height and growth velocity (GdV) were calculated using the Prader standards from 1988 and statistical relevance was calculated using test.
Results: In group 1, the average height was -3.1 SD +/- 1SD (between -6.1 and -1.5 SD). In the first year, the height gain was of 0.8 SD with an average GV of 3.9 SD (0.6 cm/year). In the second and third years of treatment the height gain and GV were 0.9 SD and 3.3 SD (8.5 cm/year) respectively 0.4 SD and 2.3 SD (7.4cm/year). In group 2 the initial growth deficit was -2.7 SD +/-1.2 SD (between -5.0 and -1.1 SD), with a gain of 0.5 SD in one year. The GV was 2.5 SD – 8.6 cm/year (p=0.02 compared with the 1st group) but dropped to 1.2 SD (6.9 cm/year) in the second year (p=0.05), with a further gain of 0.5 SD in height. Group 3 had a -3.3 +/-0.7 SD height deficit with a gain of 0.5 SD in the first year and of another 0.4 in the second year. The GV was 2.7 SD – 9.1 cm/year (compared with the group 1 p= 0.15) respectively 1.2 SD – 6.8 cm/year (p=0.1). In the 4th group, the initial growth deficit was -3.3 +/-0.5 SD, with a growth of 6.6 SD in the first year of treatment. The GV was 1.4 SD, (8.5 cm/year) significantly lower than in the first group (p=0.01). There was an increase of blood glucose levels (p=0.03), but the values remained normal.

Conclusion: GH therapy in short children is effective, especially in children with GH deficiency. The maximum of catch-up growth is obtained in the first year of treatment. The therapy is safe, but clinical and biochemical follow-up is necessary.

Conventional adrenocortical hyperplasia – still an undiagnosed condition with serious consequences

Corina Chirita1; Cristina Dumitrescu2; Margarita Matei2; Anda Carageorgheopol1; Camelia Procopiu1
1Anima Specialty Medical Services, Endocrinology, Bucharest, Romania; 2National Institute of Endocrinology, Pediatric Endocrinology, Bucharest, Romania; 3National Institute of Endocrinology, Endocrinology, Bucharest, Romania

Introduction: Classic congenital adrenal hyperplasia is one of the causes of virilisation of the female fetus and can have dramatic implications if it is not diagnosed in time.

Case presentation: We present the case of a 4 yrs 8 month old boy, who was admitted for bilateral cryptorchidism and pubic hair development. The patient had been surgically investigated for cryptorchidism at the age of 2.6 yrs, but no tests were found. He had been admitted to various pediatric hospitals for repeated episodes of severe dehydration with low levels of sodium (Na – 128.8 mEq/L, normal range 136-145) and hyperkalemia (K – 6.1 mEq/L, normal range 3.3-5.1) and was treated for salt wasting nephritis. The clinical exam revealed a patient with normal height (+0.37 SD) and weight with a well developed penis, and no evident testes. The pubic hair was P3-4. The rest of the clinical exam was unremarkable and the patient was not dehydrated. The hormonal panel revealed: Testosterone – 2.23 ng/mL; LH – 0.87 mU/mL; FSH – 3.11 mU/mL; cortisol – 3.92 µg/dL (normal range 4.3-22.4); ACTH – 173 pg/mL (normal range 8-60); 17 OH Progesterone – 533 ng/mL (normal range 0.07-1.7). The abdominal CT exam showed adrenal hyperplasia and a uterus. The pelvic ultrasound revealed fluid in the uterus and 2-3 follicles in each ovary. The bone age was 11 years. The cardiotype was 46 XX. The diagnosis was of virilizing congenital adrenal hyperplasia, probably due to 21-hydroxylase deficiency, with female pseudohermaproditism and secondary central precocious puberty. Treatment with hydrocortisone was initiated. Triphroline 3.75 mg/month i.m. was administered for precocious puberty.

PAO-81

Results: FSH – 3.11 mUI/mL; cortisol – 3.92 µg/dL (normal range 4.3-22.4); ACTH – 128.8 mEq/L, normal range 136-145) and hyperkaliemia (K – 6.1 mEq/L, normal range 3.3-5.1) and was treated for salt wasting nephritis. The clinical exam was unremarkable and the patient was not dehydrated. The patient was admitted for bilateral cryptorchidism and pubic hair development. The patient had been surgically investigated for cryptorchidism at the age of 2.6 yrs, but no tests were found. He had been admitted to various pediatric hospitals for repeated episodes of severe dehydration with low levels of sodium (Na – 128.8 mEq/L, normal range 136-145) and hyperkalemia (K – 6.1 mEq/L, normal range 3.3-5.1) and was treated for salt wasting nephritis. The clinical exam revealed a patient with normal height (+0.37 SD) and weight with a well developed penis, and no evident testes. The pubic hair was P3-4. The rest of the clinical exam was unremarkable and the patient was not dehydrated. The hormonal panel revealed: Testosterone – 2.23 ng/mL; LH – 0.87 mU/mL; FSH – 3.11 mU/mL; cortisol – 3.92 µg/dL (normal range 4.3-22.4); ACTH – 173 pg/mL (normal range 8-60); 17 OH Progesterone – 533 ng/mL (normal range 0.07-1.7). The abdominal CT exam showed adrenal hyperplasia and a uterus. The pelvic ultrasound revealed fluid in the uterus and 2-3 follicles in each ovary. The bone age was 11 years. The cardiotype was 46 XX. The diagnosis was of virilizing congenital adrenal hyperplasia, probably due to 21-hydroxylase deficiency, with female pseudohermaproditism and secondary central precocious puberty. Treatment with hydrocortisone was initiated. Triphroline 3.75 mg/month i.m. was administered for precocious puberty.

PAO-82

Pituitary hyperplasia caused by primary hypothyroidism: clinical presentation and follow up

Mirjana Kocovs; Elena Sukarova-Angelovska
Univeristy Pediatric Clinic, Endocrinology and Genetics, Skopje, Macedonia, FYrom

Background: Pituitary thyrotroph hyperplasia secondary to primary hypothyroidism is a rare cause of pituitary enlargement. Clinical presentation is variable.

Objective: To present a clinical presentation and evolution in 5 cases (4 girls) of pituitary hyperplasia appearing as a result of longstanding hypothyroidism.

Methods: Clinical appearance was variable (Table 1). Common finding in all children was growth delay during months or years before the diagnosis. All had moderate clinical hypothyroidism. Diagnosis was made by measuring T4, TSH, thyroid antibodies and ultrasonographic examination of the thyroid gland. Pituitary function was revealed by measuring GH, FSH, LH, Prolactin and ACTH. MRI of the pituitary was performed.

Results: TSH was very high, and T4 low in all patients. Ultrasound finding of the thyroid gland was typical for Hashimoto thyroiditis. GH deficiency, as well as FSH, LH deficiency were revealed in two patients. One girl had elevated levels of prolactin. Magnetic resonance imaging revealed symmetrical pituitary enlargement associated with contrast enhancement simulating macroadenoma. After introduction of therapy with levothyroxine, both symptoms and pituitary hyperplasia regressed within a period of 1.5 - 13 months. Children were followed for 2-9 years. Growth resumed in all patients, and puberty followed regularly.

Conclusion: Pituitary tumor associated with elevated thyroid stimulating hormone and low levels of free T4 is most frequently caused by Hashimoto thyroiditis and should always be treated with thyroxine replacement before other diagnostic tests are ordered. Careful follow up is warranted.

PAO-83

Retrospective analysis of effectiveness of growth hormone therapy: identification of poor responder

Klaus Karl Paul Hartmann
Inst. of Pediatric Endocrinology & Diabetology, Pediatric Endocrinology, Frankfurt, Germany

Background: Growth hormone (GH) therapy is well established for more than 20 years including experience in different indications as insufficiency of GH secretion, Ulrich Turner and Small for Gestational Age (SGA) Syndrome.

Objective and hypotheses: The aim of this study was to identify Poor Responder after one year of GH Therapy and to find out possible reasons as GH effect on IGF-1 or IGF-BP3 secretion.

Methods: For 197 children (136 male/61 female) at the age of 9.2 +/- 7.7 years GH therapy was started with the average daily dose of 0.029 +/- 0.004 mg/kg for the first and of 0.030 +/- 0.005 mg/kg for the second year.

Results: Average growth velocity increased from 4.6 +/- 1.9 cm/year to 7.6/cm/year.
fatty liver and testosterone levels in adult survivors.

Methods: We reviewed the clinical records of 34 patients who received autologous SCT at Tokai University Hospital. The median age of the 34 patients at SCT was 10.0 years, the median age at the last evaluation was 25.5 years, and the median follow-up duration after SCT was 15.9 years. The study population was categorized into 4 groups: CRT (cranial radiotherapy) + TBI (total body irradiation) group, TBI group, TAI (thoraco-abdominal irradiation) group, and Chemo groups.

Results: Among the 34 patients, 1 patient treated with only chemotherapy had a greater than 25 kg/m2 BMI. On the other hand, 11 patients had a BMI less than 18.5 kg/m2. No patient satisfied the criteria for metabolic syndrome. Fatty liver was diagnosed in 15 patients during the follow-up period. Concerning the mode of irradiation, a greater number of patients who received CRT+TBI developed fatty liver compared among other groups. Patients in CRT+TBI group were statistically associated with decreased testosterone levels, increased LH and FSH levels compared among other groups (P<0.001, respectively), although testosterone levels in all patients were within normal range during follow-up period. Moreover, severe fatty liver was statistically associated with decreased testosterone levels compared among moderate, mild and non-fatty liver (P<0.001, median 273ng/dL, 333ng/dL, 345ng/dL, and 530ng/dL, respectively).

Conclusion: Even patients who are not overweight/obese may develop fatty liver, and degree of fatty liver was associated with decreased testosterone levels in adult survivors.

PAO-84
Clinical characteristics of subclinical rickets in infants less than two years of age

Ji Young Seo; Ji Hyun Yoon
Eulji General Hospital, College of Medicine, Eulji University, Pediatrics, Seoul, Republic of Korea

Background: In young children, cases with both of vitamin D deficiency and iron deficieny anemia(IDA) are common.

Objective and hypotheses: To evaluate the clinical characteristics of vitamin D deficiency and its association with IDA.

Methods: A total of 261 children aged <2 years underwent 25-hydroxyvitamin D3 tests between January 2007 and July 2009. The study cohort was classified into two groups: normal and vitamin D deficient, by their 25-hydroxyvitamin D3 levels.

Results: In total, 171 children were in the normal group (mean age, body weight and height 12.5±7.0 months, 9.3±0.9 kg and 76.8±11.1 cm), and 51 children in the vitamin D deficient group (9.9±5.4 months, 9.0±0.9 kg and 75.1±0.9 cm). Vitamin D deficiency was most commonly diagnosed in the spring (44%). The proportion of complete breast-feeding was higher in the deficient group (92%), and 25.5% of the children in the deficient group also experienced vitamin D deficiency anemia compared that 12% of normal group. Wrist radiographs showed findings suggestive of rickets in 7 children in the normal group. Nine children in the deficient group experienced persistent bony changes. Six children received calcitriol medication in the normal group, by their 25-hydroxyvitamin D3 levels.

Conclusion: This study demonstrated that approximately 30% of children aged <2 years experienced vitamin D deficiency associated with subclinical rickets. Many children also experienced concurrent iron deficiency anemia. Guidelines for vitamin D supplement in such children must therefore be established.

PAO-85
Decreased serum testosterone levels in long-term adult survivors with fatty liver after childhood stem cell transplant

Hirokazu Ishiguro1; Yuichiro Tomita2; Hiromi Hyodo1; Takashi Kojima3; Takashi Shimizu1; Tsuyoshi Morimoto1; Hiromasa Yabes2; Miharu Yabes3
1Tokai University, Pediatrics, Kanagawa, Japan; 2Tokai University, Clinical Laboratory, Kanagawa, Japan; 3Tokai University, Transplantation and Regenerative Medicine, Kanagawa, Japan

Background: Fatty liver and gonadal dysfunction have been identified as potential late effects of therapy in adult survivors treated with SCT. Obesity and metabolic syndrome are also associated with low testosterone levels in general population.

Objective: The purpose of this study was to investigate the short-term effect of the diabetes education program with intensified treatment in diabetic children and adolescents and to assess the necessity of regular and structured education and support in diabetic children and adolescents.

Methods: Thirty patients (10.0—18.9 years) with type 1 diabetes mellitus (T1DM), attending the diabetes clinic in Seoul National University Children’s Hospital, were included in the diabetes education program with intensified treatment. A six—day—course program was provided by a diabetes care team with doctors, a specialist diabetes nurse, a clinical dietitian, and a social worker. Patient data of disease duration and complication studies at the time of enrollment were reviewed and changes in HbA1c levels before and after the education program were analyzed.

Results: In 28 of 30 patients, significant decrease of average HbA1c levels (average 0.9%, median 0.8%, P<0.001) was observed after education. The changes in average HbA1c levels were prominent in patients who were educated for the first time. On follow—up, HbA1c level at 3 months was significantly increased (P<0.009) but after 9 months, it tended to increase again. The decrease of average HbA1c levels after education was negatively correlated with disease duration (r=−0.60, P=0.001).

Conclusion: Short—term effect of the diabetes education program with intensified treatment in diabetic children and adolescents was optimistic but regular education and support in these patients should be sustained.

PAO-86
Abstract withdrawn.

PAO-87
Short—term effect of the diabetes education program in children and adolescents with type 1 diabetes mellitus

Min Jae Kang; Shin Mi Kim; Young Ah Lee; Jieun Lee; Juyoung Yoon; Sei Won Yang; Choong Ho Shin
Seoul National University Children’s Hospital, Pediatrics, Seoul, Republic of Korea

Background: Diabetes mellitus is a chronic disorder and strict glycemic control, which cannot be successfully obtained without behavior modification, is the most important factor in prevention and management of complications.

Objective and hypotheses: The purpose of this study was to investigate the short—term effects and associated factors of the diabetes education program and to assess the necessity of regular and structured education and support in diabetic children and adolescents.

Methods: Fifty patients with type 1 diabetes mellitus (T1DM), attending the diabetes clinic in Seoul National University Children’s Hospital, were included in the diabetes education program with intensified treatment. A six—day—course program was provided by a diabetes care team with doctors, a specialist diabetes nurse, a clinical dietitian, and a social worker. Patient data of disease duration and complication studies at the time of enrollment were reviewed and changes in HbA1c levels before and after the education program were analyzed.

Results: In 28 of 30 patients, significant decrease of average HbA1c levels (average 0.9%, median 0.8%, P<0.001) was observed after education. The changes in average HbA1c levels were prominent in patients who were educated for the first time. On follow—up, HbA1c level at 3 months was significantly increased (P<0.009) but after 9 months, it tended to increase again. The decrease of average HbA1c levels after education was negatively correlated with disease duration (r=−0.60, P=0.001).

Conclusion: Short—term effect of the diabetes education program with intensified treatment in diabetic children and adolescents was optimistic but regular education and support in these patients should be sustained.
PAO-88

Phenotypic and metabolic characteristics in non-obese adolescents with PCOS

Hae Soon Kim1; Hye Jin Lee2; Ji Young Choi3; Young Sun Hong4; Yeon-Ah Sung1

1Ewha Womans University School of Medicine, Pediatrics, Seoul, Republic of Korea; 2Ewha Womans University Mokdong Hospital, Internal Medicine, Seoul, Republic of Korea

Purpose: Polycystic ovary syndrome is characterized by hyperandrogenemia, insulin resistance, and dyslipidemia. We evaluated the clinical characteristics and metabolic components of non-obese adolescent girls with PCOS.

Subjects and methods: Thirty-six non-obese (BMI<25kg/m2) adolescent girls (16-18years) with PCOS were compared to thirty-two control group girls in similar age and BMI with regular menstrual cycles and were evaluated for anthropometric data and blood pressure. Fasting glucose, triglyceride, HDL-cholesterol, LDL-cholesterol, GOT, GPT were measured.

Results: BMI and waist circumference of the PCOS group were not different to the control. Frequency of menstruation and FG score of the PCOS group were significantly lower than the control. Blood pressures of the PCOS group were not different compared to the control. Fat mass and fat percents were higher in the PCOS group but were not significantly different to that of the control. AST ALT, triglyceride, total cholesterol, HDL-cholesterol, fasting glucose were not significantly different between the two groups. LDL-cholesterol was significantly higher in the PCOS group compared to the control. Frequency of abnormal components in metabolic syndrome was not different between the two groups.

Conclusion: In non-obese adolescents with PCOS, metabolic derangements were not remarkable.

PAO-89

Does gonadotrophin-releasing hormone analogue affect of the body mass index in the girls with idiopathic precocious puberty?

Ayla Guven
Goztepe Educational and Training Hospital, Pediatric Endocrine Clinic, Istanbul, Turkey

Background: To assess whether Gonadotrophin-releasing hormone analogue (GnRHa) affects body mass index in children with idiopathic central precocious puberty (ICPP).

Patients and methods: At least 12 months follow up 41 girls (mean age 8.66±1.3years) with CPP were included in the study. 34 girls with ICPP were followed up 18 months. Complaints had been begun before 8 years old. 28 girls underwent GnRH stimulation test. All children were treated with Leuprolide acetat (LA) 3.75 mg/q4wk and the dose was increased only if there is inadequate suppression of LH. The dose had to be increased 7.5 mg/q4 wk in 13 patients. Body mass index (BMI) of the children with ICPP was calculated before the initiation of therapy (PRE) and at 3rd, 6th, 12th and 18th months of the GnRHa therapy.

<table>
<thead>
<tr>
<th></th>
<th>Mean±SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone age, year</td>
<td>10.3±2</td>
</tr>
<tr>
<td>Right ovary volume, mL</td>
<td>2.62±1.6</td>
</tr>
<tr>
<td>Left ovary volume, mL</td>
<td>2.76±1.6</td>
</tr>
<tr>
<td>Uterine length, cm</td>
<td>40.4±8.1</td>
</tr>
<tr>
<td>Basal LH, mIU/mL</td>
<td>2.18±1.8</td>
</tr>
<tr>
<td>Basal FSH, mIU/mL</td>
<td>4.31±2</td>
</tr>
<tr>
<td>Basal Estradiol, pg/mL</td>
<td>29.6±22</td>
</tr>
</tbody>
</table>

Table 1

Results: Pelvic ultrasound findings and basal hormone levels were given in Table 1. At the admission thearchae was a major complaint (32/41) and 5 girls had menarche. PRE-BMI was significantly more correlated with BMI at 3rd, 6th, 12th and 18th months of therapy (r: 0.879; r: 0.896; r: 0.909; r: 0.887, respectively). PRE-BMI significantly differed from BMI at 3rd, 6th, 12th and 18th months of therapy (F:69.808, p<0.0001). BMI gradually increased after 6 th months of therapy (Figure1). LA dose was significantly correlated with all body mass indexes during therapy. Bone age was correlated with volume of right (r:0.404; p:0.015) and left (r:0.360;p:0.034) ovary and uterine length (r:0.447;p:0.05).

Conclusions: An initial dose of LA 3.75 mg/4wk was efficient in most girls with ICPP. Unfortunately if this dose would be increased, patients would have a tendency having increased BMI. Clinicians should be alert of obesity risk in children treated with LA.
PAO-91

Comparison of antithyroid antibodies in type 1 diabetic children and control group in 2010
Fateme Saffari1, Ali Asgari2, Tahereh Sadeghi3, Neda Esmailzadehehar4, Qazvin university of medical sciences, pediatric endocrinology, Qazvin, Islamic Republic of Iran; 1Qazvin university of medical sciences, pediatrics, Qazvin, Islamic Republic of Iran; 2Qazvin university of medical sciences, Nursing and Midwifery Faculty, Qazvin, Islamic Republic of Iran; 3Qazvin university of medical sciences, Children hospital clinical research center, Qazvin, Islamic Republic of Iran.

Background: Type 1 diabetes is the most common metabolic disease worldwide. thyroid autoimmune diseases accompany with type 1 diabetes is the most common endocrinopathy. Therefore, thyroid function tests and antithyroid antibodies in patients suffering from Type 1 diabetes is essential to diagnosis of thyroid autoimmune disorders.

Objective: To compare the anti-thyroid antibodies in patients with Type 1 diabetes and healthy individuals.

Methods: In this descriptive-analytic study, 65 children with Type 1 diabetes and 65 healthy children were selected using simple sampling. Anti-TG, Anti-Tpo, TSH and T4 hormones were measured. The amount of antibodies in both groups compared by using Chi-square statistical analysis, t-independent, Kruskal Valis.

Results: There was not significant difference between two group of samples (case and witness group) in case of sex and age but BMI percentile of two group was significantly different. Positive Anti-TG in patients was 10.8% and in controls was 1.5% and the difference was statistically significant (p=0.029). 16.9% of patients and 3.1% of controls had positive Anti-Tpo that was significantly different between two groups (p=0.024). 10.8% of patients had overt hypothyroidism and 4.6% of controls had subclinical hypothyroidism. The difference was not significant statistically.

Conclusions: According to the results of research, it seems that the prevalence of Hashimoto thyroiditis in patients with type 1 diabetes is more than healthy people. Hence, thyroid function tests (TFT) and antithyroid antibodies (Anti-Tpo) in patients with Type 1 diabetes is necessary in order to early diagnosis of autoimmune thyroid disorders, prevention of their complications and timely treatment.

PAO-92

Maturity onset diabetes of the young (MODY) 2: clinical and genetic spectrum in five children
Maria Joao Oliveira; Cristina Couto; Manuel Oliveira; Joana Freitas; Helena Cardoso; Teresa Borges
Centro Hospitalar do Porto, Paediatrics Department - Paediatric Endocrinology Unit, Oporto, Portugal

Background: MODY is a genetically heterogeneous form of diabetes (DM) characterised by early onset, autosomal dominant inheritance and a primary defect in pancreatic β-cell function. MODY2, caused by mutations in the glucokinase (GCK) gene, is one of the most common types. The authors describe 5 cases of MODY2 diagnosed in paediatric age.

Case report:

<table>
<thead>
<tr>
<th>Case</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age of detection of diabetes (years)</td>
<td>5</td>
<td>5</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Family history of type 2 diabetes mellitus and/or hyperglycaemia</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Body mass index (Kg/m2) at 1st exam (percentile)</td>
<td>12.8 (3)</td>
<td>19.4 (85)</td>
<td>15.8 (40)</td>
<td>24.1 (90.5)</td>
<td>14.2 (11)</td>
</tr>
<tr>
<td>Fasting glucose &gt;126 mg/dl</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Initial Hba1c (%)</td>
<td>7.3</td>
<td>6.5</td>
<td>5.3</td>
<td>6.1</td>
<td>5.9</td>
</tr>
<tr>
<td>Serum insulin (µU/ml)</td>
<td>&lt;2</td>
<td>9.4</td>
<td>&lt;2</td>
<td>8</td>
<td>6.6</td>
</tr>
<tr>
<td>Serum C peptide (ng/ml)</td>
<td>0.9</td>
<td>1.2</td>
<td>1.1</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>Antibodies: anti-TG, anti-Tpo</td>
<td>negative, negative, negative, negative, negative, negative</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose at 0h and 2h in oral glucose tolerance test (mg/dl)</td>
<td>0</td>
<td>116, 157</td>
<td>130, 189</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Genetic testing (GCK)</td>
<td>mutation c.579+1_579+30del683 in intron 5</td>
<td>mutation c.579+1_579+30del683 in intron 5</td>
<td>mutation c.616A&gt;C in exon 6 (not previously described)</td>
<td>mutation c.1268T&gt;A in exon 10 (not previously described)</td>
<td>mutation c.616A&gt;C in exon 6 (not previously described)</td>
</tr>
<tr>
<td>Age at genetic diagnosis (years)</td>
<td>7</td>
<td>11</td>
<td>12</td>
<td>14</td>
<td>8</td>
</tr>
<tr>
<td>Treatment</td>
<td>diet measures</td>
<td>diet measures</td>
<td>diet measures</td>
<td>metformin before MODY2 diagnosis; diet measures</td>
<td>diet measures</td>
</tr>
<tr>
<td>Complications</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
</tbody>
</table>

1. 5-year-old boy with random hyperglycaemia detected during hospitalization due to gastroenteritis. Hba1c was 7.3% and spot urine analysis was normal. The initial diagnosis was the early presentation of type 1 DM.
2. 11-year-old asymptomatic boy with fasting and random hyperglycaemia since 5 years.
3. 9-year-old asymptomatic boy with fasting hyperglycaemia during the previous year.
4. 8-year-old girl, obese, with fasting hyperglycaemia detected during co-morbidity study. Clinical insulin resistance signs were absent. The initial diagnosis was type 2 DM.
5. 8-year-old asymptomatic girl with fasting hyperglycaemia during the previous 7 months. Evolution Patient 4 was treated with metformin and the other patients didn’t start pharmacological treatment. During follow-up, patients 1, 2 and 3 maintained occasional fasting hyperglycaemia; mean Hba1c was 6%. In case 4, despite treatment with metformin, evolution was similar and Hba1c didn’t improve. Genetic testing for MODY2 was performed after few months to several years of follow-up. Any of the patients started or maintained pharmacological treatment.

Conclusions: GCK-MODY is characterized by non-progressive mild hyperglycaemia, rare microvascular complications and unnecessary pharmacological treatment. The authors describe 5 patients with mild asymptomatic hyperglycaemia and mildly elevated Hba1c. All presented family history of DM or untreated hyperglycaemia. Genetic testing detected heterozygosity for mutations in GCK gene, 2 previously described and 3 apparently novel variants. This is a vital clinical tool in selected cases since it confirms a diagnosis, predicts clinical course, defines family risk and determines treatment.
**PAO-93**

**Persistent pubertal gynecomastia: an unusual presentation of a steroid 17-alpha-hydroxylase deficiency**  
**Francoise Paris**, Marianne Ribotton, Yves Morel, Charles Sultan  
**1 CHU and UMI, Hormonologie and Unité d'Endocrinologie Pédiatrique, Montpellier, France; 2 Centre de Biologie et pathologie Est, Service d'Endocrinologie Moléculaire et Maladies Rares, Bron, France

**Background:** Pubertal gynecomastia is a frequent reason for consultation in pediatric endocrinology. Although it is usually idiopathic, hypogonadism, hyperprolactinemia, hyperthyroidism and rare testicular or adrenal tumors must be considered. Most often, idiopathic pubertal gynecomastia regresses at the end of puberty when the testosterone (T) level increases.

**Objective and hypotheses:** We report a case of persistent pubertal gynecomastia revealing a mutation of steroid 17-alpha-hydroxylase (CYP17).

**Methods:** This 15-year-old boy was referred to our pediatric endocrinology clinic because of bilateral gynecomastia, stage III with pigmented and developed areolae. Pubertal development was P3,G3 with a normal penis (length = 7 cm). Basal LH and FSH were 7.5 mIU/ml (N=1.5-8.5 and 3-8, respectively). Plasma T=5.5 nmol/l (N=12-38), DHEA=1.8 nmol/l (N=10-19) and 17OHP=11 nmol/l (N=15). E2 level was 175 pmol/l (N<180). Basal PRL level was 230 μIU/ml (N<500). Plasma TSH and T4L levels confirmed euthyroid status. Plasma βCG and αP were negative. Testicular sonography found normal testicular testis structure. The low plasma T led us to evaluate other steroid precursors. Plasma progesterone (P) level was 10.9 nmol/l (N=0.7-2) with low and non-ACTH-stimulated plasma cortisol deficiency (154.6→2123.2 μmol/l).

**Results:** The discordance between the high P level and the low values of other 17OH steroid precursors suggested 17OHP deficiency. Sequencing of the CYP17a gene identified an heterozygous composite mutation: p.Pro35Thr and p.Arg239X. Substitution by testosterone enanthate was introduced.

**Conclusions:** This report points out the usefulness of investigating adolescents with persistent pubertal gynecomastia to identify a specific cause and thus propose adequate management.

**PAO-94**

**Congenital hypothyroidism in a neonate born to a mother with autoimmune thyroid disease**  
**Malgorzata Kumrowsicz-Czoń**, Dorota Tylek-Lemanska  
**1 Polish-American Institute of Pediatrics, Collegium Medicum, Jagiellonian University, Department of Pediatric and Adolescent Endocrinology, Krakow, Poland; 2 University Children’s Hospital in Krakow, Division of Screening and Inborn Errors of Metabolism, Krakow, Poland

**Background:** Congenital hypothyroidism (CH) induced by maternal TSH receptor-blocking antibodies is responsible for approximately 2% of all CH cases.

**Objective:** A case report of a newborn with CH born to mother with autoimmune disease.

**Methods:** TSH in blood on filter paper, serum TSH, FT4 and TSH receptor antibodies (TRAb) tests, imaging pictures.

**Results:** A female newborn is presented pregnancy 1, delivery 1, terminated by a cesarean section at 40 weeks of gestation, birth weight 3150g, length 54cm, Apgar score 8 and 10 at 1 and 5 minutes, respectively). Maternal medical history indicated hyperthyroidism treated with thiamazol for 5 years, followed by hypothyroidism supplemented with L-thyroxin (LT4) for 3 years prior to conception and during pregnancy.

Available data suggested LT4 substitution during pregnancy to be insufficient, resulting in periodic hypothyroxinaemia. Suspected fetal arrhythmia led to a cesarean section at 40 weeks of gestation, showing regular, but rather slow heart action (112-120/min). In mass screening for CH, TSH concentration in blood on filter paper was 130.5 mIU/ml (N<15). Serum levels of TSH =600 mIU/L [N:0.4-9] and FT4 9.6 pmol/l [N:10-26] determined in the 4th day of life confirmed the diagnosis of CH. A high neonatal TRAb value [67.8 IU/L, N<1] was correlated with maternal TRAb [68.5 IU/L]. Ultrasound showed the thyroid situated normally and normal in size, yet no marker uptake by the gland was demonstrated by Tc99m scintiscan.

On day 7 of life, the neonate received LT4 substitution at the dose of 12 μg/kg/d, the dosage being modified based on serum FT4 and TSH levels. A decreasing demand for LT4 was seen along with normalization of TRAb concentration; at 4 months of life, TRAb was 0.7 IU/L. At 13 months of life serum FT4 and TSH levels during LT4 substitution (1 μg/kg/d) were normal.

**Conclusions:** The presented case confirms the diagnostic importance of TRAb determinations in newborns with CH born to mothers with autoimmune disease, additionally pointing to maternal hypothyroxinemia in pregnancy as a significant CH risk factor in newborns.

**PAO-95**

**Central precocious puberty in a female child of very young age**  
**Kim Jong-Duk**, Choi See-Seung  
**1 Wonkwang University Hospital, Pediatrics, Iksan, Republic of Korea; 2 Wonkwang University Hospital, Radiology, Iksan, Republic of Korea

**Background:** Central precocious puberty under age of 6 years old is rarely related to morphological abnormality of hypotalamus and pituitary gland, and the type of abnormality was variable.

**Objective and hypotheses:** We report a case that a two year and 10 month aged female child was diagnosed central precocious puberty with pituitary intermediate cyst.

**Methods:** This child was visited the pediatric out-patient clinic due to breast budding and progressively increased size of breast for three months. Physical examination with laboratory and radiological study for precocious puberty of this patient was done.

**Results:** On visiting day, breast size was 3 x 3 cm and pubic hair was not noticed. Head circumference of this patient was 98.6 cm (95-97 percentile) and 16 kg (90-95 percentile). Head circumference of this patient was 49 cm (50-75 percentile).

This patient was born by the full term normal spontaneous vaginal type delivery and birth weight was 3,200 gm, and height 49 cm. Bone age was 5 years old but chronological age was two years and 10 months old. The basal serum level of E2 and LH was 25.58 pg/mL and 7.8 mIU/mL respectively, but the maximum serum level of LH was 43.8 pg/mL after GnRH stimulation. Brain MRI shows pituitary cyst between anterior and posterior pituitary lob. Breast size of this patient regresses to 2 x 2 cm and sustained after GnRH agonist therapy.

**Conclusions:** We report a case of central precocious puberty that is very young age with intermediate cyst of the pituitary gland and respond well to GnRH agonist therapy. However, careful follow-up will be needed in this patient.

**PAO-96**

**The association of thyroid autoimmunity with statural development in a group of type 1 diabetes mellitus children**  
**Aura Diana Regina**, Alice Albu, Nicoleta Petre  
**1 Polish-American Institute of Pediatrics, Collegium Medicum, Jagiellonian University, Department of Pediatric and Adolescent Endocrinology, Krakow, Poland; 2 University Children’s Hospital in Krakow, Division of Screening and Inborn Errors of Metabolism, Krakow, Poland

**Background:** Type 1 diabetes mellitus is frequently associated with other endocrine autoimmunity and the risk is increased by the duration of diabetes. These associations may have a negative impact on diabetes control and children development.

**Aim:** The aim of the study was to evaluate the impact of thyroid autoimmunity on statural growth of children with type 1 diabetes mellitus.

**Material and method:** We examined a group of children with type 1 diabetes mellitus. We collected demographic data; we performed general physical examination, height, weight, thyroid gland, and laboratory data: glycated hemoglobin, thyroid peroxidase antibodies (TPOAb). The score of standard deviation (SDS) was calculated as the difference of actual height and mean height for age and gender divided by standard deviation value. We defined short stature as a SDS under -2 DS. An informed consent was obtained from children’s parents or legal tutors.

**Results:** We studied 68 patients (36 boys) with mean age 11.2±2.0 years, mean duration of diabetes 3.43±2.55 years and mean glycated hemoglobin...
8.94±1.9%; 16 patients (23%) had thyroid autoimmunity. None of our pa-
tients had short stature.
We found a significant association between thyroid autoimmunity and lower
SD score: 0.26 SD vs 0.98 SD (p=0.043). Mean glycated hemoglobin was
significantly higher in patients with thyroid autoimmunity 9.7% vs 8.6%
(p=0.05), but BMI did not differ significantly between the two groups.
Logistic regression analysis revealed that low SDS (SDS under 0) was inde-
pendently associated with duration of diabetes (p=0.049), but not with birth
weight, glycated hemoglobin, and TPOAb.
Conclusion: Our data suggest a significant association between thyroid auto-
immunity and height in children with type 1 diabetes mellitus, but this seems
to be explained by other factors such as diabetes duration.

PAO-97

Pattern of presentation and management when
neonatal screening for congenital adrenal
hyperplasia is not available
Suzanne Elkhol
King Fahad Military Medical Complex, Paediatics, Dhahran, Saudi
Arabia

Background: We present the presenting features and management of sixteen
cases of congenital adrenal hyperplasia following up in the paediatric endo-
crine clinic at King Fahd Military Medical Complex, Dhahran, Saudi Arabia.
Cases were diagnosed at our centre or referred from other hospitals.

Objective and hypotheses: The aim of the study is to highlight the different
presentations and on rare occasions delay of management even when family
history exists. The different treatment regimens and follow up plans were also
evaluated and compared with current guidelines.

Methods: Retrospective chart reviews of sixteen patients diagnosed with
congenital adrenal hyperplasia.

Results: Family history was positive but was denied or concealed by some
families which delayed diagnosis for some cases. Salt loss and ambiguous
genitalia was the main presenting feature in neonatal period. Genetic diagno-
sis was performed for some cases and new mutations were identified. Doses
of steroids were adequate according to current guidelines but follow up was
hindered by lack of local laboratory evaluation of urinary and serum steroid
precursors.

Conclusions: We conclude that laboratory support needs to improve as well as
parents' education about need to disclose important medical information.

PAO-98

Endocrine disorders in 62 children with Turner
syndrome
Ruimin Chen; Xiaohong Yang; Ying Zhang; Xiangquan Lin
Fuzhou Children's Hospital of Fujian, Endocrinology, Fuzhou, China

Background: Turner syndrome (TS) is a common genetic disorder, is asso-
associated with reduced adult height and with ovarian failure. However, it is
becoming increasingly evident that patients with TS are also susceptible to a
range disorders.

Objective and hypotheses: Explore the endocrine disorders in Chinese chil-
dren with TS.

Methods: 62 patients with TS diagnosed in our clinic in 1999–2010 by karyo-
type, FSH, LH, growth hormone stimulation, IGF-1, TPO and Tg antibodies,
TSH, FT3, FT4, fasting glucose (GS), A1c (if GS high), ultrasound (varian,
uterus and thyroid), bone age, pituitary MRI (if Growth hormone deficiency).

Results: Chronological mean age: 10.9(0.2~18) years, mean height z
score (HtSDS): -3.96 (-0.39~7.3)SD, >13.5 years no puberty signs (15/17,
88.2%), Distribution of karyotypes: X monosomy-45,X (27/62, 43.6%);
Hyperthyroidism (3/60, 5%), Hypothyroidism (8/60, 13.3%), growth hor-

PAO-99

A case of myasthenia gravis with graves
disease
Order Aslan; Aycan Zehra; Senma Cetinkaya; Havva Nur Peltek
Kendirci; Sebahat Yilmaz Agladioglu; Veyssel Nijat Bas
Ankara, Pediatric Endocrinology, Ankara, Turkey

Background: Thyrotoxicosis due to autoimmune thyroid disease (AITD) oc-
curs in % 5-10 of patients with Myasthenia Graves (MG) whereas MG has a
frequency of % 0.2 among the patients with AITD. MG and AITD can also
be seen together in Autoimmune Polyglandular Syndrome (APS) type 2 and
type 3.

Objective and hypotheses: Hereby, we report a patient with MG and Graves
diseases.

Methods: A 15 years old male patient was referred to our clinic for hyper-
thyroidism. He had hyperthyroidism since 8 months and pituitis since 3 months.
His height was 169.5 cm, weight was 64 kg, blood pressure was 130/80 mmHg
and he had a heart rate of 132/minute. He had unilateral pititis and diffuse
enlarged thyroid gland. Laboratory findings were as follows: TSH: <0.004
mIU/ml, free T4: 4.4 ng/dl, free T3: 13.7 pg/ml, anti thyroglobulin antibody:
2175 IU/ml, anti microsomal antibody: >1000 IU/ml, TSH receptor antibody:
36.9 UI. He had a positive response when we performed prostigmine test.

Results: Our case was diagnosed with MG and Graves diseases. He started
to receive methimazole, propranolol, pridostigmine.

Conclusions: We found that plasma cortisol was 10 µg/dl, ACTH was 23 pg/ml,
c ANCA, p ANCA, anti dsDNA, ANA, anti Ro, anti La and anti tissue transglutaminase
antibodies, anti GAD, anti insulin antibody, islet cell antibody were negative.
Vitamin B12 was 175 pg/ml and parietal cell antibody was positive. So, we
started to give B12 vitamin replacement. We regulated methimazole dosa-
g, beta- blocker therapy was terminated and there was a decline in TSH re-
ceptor antibody levels. His dyspila was recovered on the second month of
pridostigmine treatment.

Conclusions: Autoimmune thyroid diseases should be investigated in the
presence of Myasthenia Gravis. Further exploration about Autoimmune Poly-
glandular Syndrome type 2 and type 3 is needed in the association of Myas-
thenia Gravis and Graves diseases.

PAO-100

Abstract withdrawn.

PAO-101

Recombinant GH treatment in a female
patient with Seckel-like syndrome and a novel
homezygous mutation 7055 – 7056insC in the
PCNT gene
Natalya Velevodz; Elena Hennessy; Louise Bicknell;
Andrew Jackson
1Endocrinology Research Centre, Institute of Paediatric Endocrinology,
Moscow, Russian Federation; 2Western General Hospital, MRC Human
Genetics Unit, Edinburgh, United Kingdom

Background: Seckel syndrome is a rare autosomal recessive disorder, charac-
terized by pre- and postnatal growth deficiency, microcephaly, mental re-
tardation, and characteristic facial appearance beaklike protrusion of the
mid-face (bird-headed). This disorder is associated with defective ATR-dependent
DNA damage signaling. Mutations in ATR gene and also gene encoding peri-
centin (PCNT) cause Seckel syndrome.

Objective and hypotheses: We describe rGH treated patient with confirmed
Seckel-like syndrome.

Methods: We report a female patient, 1,5 years old, who has classic features of
the syndrome Seckel: height at birth -3,3SD, postnatal growth retardation
-10,5SD, OFC -9,9SD, bird-head phenotype, mental retardation. She also has

Conclusions: Endocrine disorders are common in Chinese children with TS.
Children with TS are at risk for growth hormone deficiency, Hashimoto thy-
roiditis, thyroid dysfunction, diabetes, which require treat early.
micrognathia, face asymmetry, low-fitting ears, disproportionately large eyes, clinodactyly of fifth finger. The patient’s tooth system is at the initial stage of eruption. She does not have haematological and bone abnormalities.

Results: The girl had treatment of recombinant growth hormone “Saizen” 0.05 mg/kg/day. After six months of treatment height was -9.52SD, height velocity 5.5 cm/6 months (+0.53SD), the level of IGF-1 increased to 80.2 ng/ml (before growth hormone treatment IGF-1 was 46.9 ng/ml). Molecular-genetic researches confirmed Seckel-like syndrome in our patient: a novel homozygous mutation in the PCNT gene 7055 – 7056insC. Her unaffected parents and two brothers are heterozygous for this mutation.

Conclusions: We described a positive effect of GH treatment in patient with Seckel-like syndrome with a novel homozygous mutation (7055 – 7056insC) in the PCNT gene.

Conclusions: The fearsome consequences of polycystic ovary disease in the short term are present in most of the young patients, which is a personal, familial and social tragedy, considering the low age of the affected. We propose educational and preventive measures to avoid the potential torpid progress of polycystic ovary syndrome in short, medium and long term.

**PAO-104**

**Final height in patients with type 1 diabetes mellitus (DM1)**
Maria Claudia Schmitt-Lobe; Raisa Rodrigues Weber; Thaisa Silva Glic; 
FURB-Faculty of Medicine, Pediatric Department, Blumenau, Brazil

Background: Final Height (FH) could be compromised in DM1 pediatric patients. Poor control, growth retardation secondary to celiac disease, chronic acidosis and hypothyroidism are possible causes that could compromise FH in these patients. A retrospective study with 130 patients was performed between 1993-2010.

**Objectives:** To evaluate FH in patients who have DM1 at childhood or adolescence and to compare with their target height (TH). To identify factors that could compromise FH.

**Material and methods:** FH was considered when growth velocity was < 1 cm/year at last year and/or Bone age (Gredich-Pyle atlas) > 15y for girls, and, > 16y for boys. The FH was compared with their TH; mother and father height were obtained from each patient. Were analysed: chronological age (CA) at diagnosis; time of disease (TD) is the time since diagnosis until FH; numbers of hospitalization due to ketoacidosis and hypoglycemia since the diagnosis and, glycosylated hemoglobin (HbA1c) mean during follow up. In addition autoimmune disease: Hashimoto Tiroidites was considered with positives antibodies TPO and/or TG and elevated TSH; Graves Disease was considered with positive antibody anti-TRAB, low TSH and elevated T4free; Celiac Disease was considered with positive antibody antiendomysium IgA and intestinal biopsy confirmed. Presence of microalbuminuria during the follow up were analysed. The HSDS was used for statistical analysis. A p value less than 0.05 was considered statistically significant.

**Results:** 55 patients (34 girls reached FH.

<table>
<thead>
<tr>
<th>Group</th>
<th>Median</th>
<th>Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>-0.14 (-2.08 - +2.02)*</td>
<td>-0.16 (-0.81)</td>
</tr>
<tr>
<td>Group B</td>
<td>-0.27 (-2.28 - +0.96)*</td>
<td>-0.34 (-0.78)</td>
</tr>
</tbody>
</table>

In Table 02 are show the findings of overall and the comparison of two groups of patients. We separated and compared two groups of patients; Group A: HSDS-FH minus HSDS-TH ≥ zero (0.54 [0.05 - 1.99]), and; Group B: HSDS-FH minus HSDS-TH ≥ zero (0.54 [0.05 - 1.99]), p=0.01 (Mann-Whitney).

**Conclusion:** The patients reached FH according their TH. None of the factors evaluated compromised FH in these patients.
PAO-105

Growth hormone excess in two children with neurofibromatosis type 1 and optic pathway glioma
Patrizia Bruzzi; Assunta Albanese
Royal Marsden Foundation Trust, Paediatric Endocrine Unit, Sutton, United Kingdom

Background: In children with neurofibromatosis type 1 (NF1) growth hormone excess (GHE) is extremely rare, but reported in the presence of optic pathway glioma (OPG). GHE can be the result of hypothalamic regulatory defect due to OPG infiltration of somatostatinergic pathways reducing somatostatin tone and leading to GHRC-mediated overproduction of GH.

Objective and hypotheses: We present 2 cases of children with NF1, OPG and GHE.

Methods: It is a case-report.

Results: First case: A pre-pubertal 5 years old girl with NF1 and a diffuse suprasellar low grade glioma involving the optic pathway was referred for tall stature. After completion of chemotherapy, GHE was documented by failure of GH levels to suppress during a standard OGTT and elevated age-adjusted plasma IGF1 levels. She was started on long acting somatostatin analogue (SSa) therapy which normalized her growth velocity and plasma IGF1 levels. Six months after starting SSa she developed central precocious puberty (CPP) and from the age of 7.5 years she also received LRHHa therapy. However, following an episode of acute pancreatitis at the age of 10.2 years SSa was stopped. IGF1 levels and growth velocity remained normal while off SSa and subsequently when at the age of 13.5 years LRHHa was also discontinued. This is the first reported case in the literature documenting spontaneous resolution of GHE after treatment with SSa in a child with NF-1 and OPG.

Second case. A tall 7.3 years old girl with NF1 and OPG treated with chemotherapy was referred for precocious puberty. CPP was confirmed and treated with LRHHa. Despite documented biochemical and clinical suppression of puberty, growth velocity remained accelerated with raised IGF1 age-adjusted plasma levels. GHE was suspected and then confirmed by a failure of GH levels to suppress in response to an OGTT. Treatment with SSa was started with a normalization of both auxological and biochemical data.

Conclusions: Tall stature and growth acceleration in children with NF1 and OPG require investigation for both precocious puberty and GHE.

PAO-106

Screening results for vascular complications and associated autoimmune diseases in children and adolescents with type 1 diabetes
Fatma Damgic; Derya Tepe; Ozlem Kara; Devin Essen
Ankara Child Diseases Hematology and Oncology Education and Research Hospital, Pediatric Endocrinology Department, Ankara, Turkey

Background: Diabetes-related microvascular complications, as retinopathy, nephropathy and neuropathy are life-threatening complications in children and adolescents with type 1 diabetes mellitus (T1DM). Longer duration of diabetes, older age and puberty are the risk factors for the development of complications. Further risk factors include smoking, hypertension, higher body mass index and dyslipidemia. Therefore prevention and screening for complications is an important part in the care of children and adolescents with T1DM.

Objective and hypotheses: Our aim was to investigate diabetic complications and associated autoimmune diseases in children and adolescents with T1DM of more than 5 years duration.

Methods: The study included 46 children and adolescents with T1DM (18 male, 28 female), mean aged 14±2.8 years, with a T1DM duration of 8.4±2.9 years. Forty-two (91.3%) cases were adolescent and 4 (8.7%) cases were in prepubertal age.

Results: Insulin treatment consisted of four daily injections in all of the patients. Treatment in the mean HbA1C level was 8.3% (range 5.9%-12.4%). The prevalence of microalbuminuria was 32.6%, dyslipidemia was 21.7%, hypertension was 17.4%, and peripheral neuropathy was 2.2%. None of the patient had diabetic retinopathy. Prevalence of autoimmune thyroiditis and celiac disease were found to be 21.7% and 6.5% respectively. Despite intensive insulin treatment, 47.8% (n:22) of patients with T1DM developed at least one detectable diabetic complication after approximately 8 years of diabetes. Microalbuminuria was the most common complication and the strongest risk marker was high blood pressure.

Conclusions: Annual complication screening should be done after diabetes duration of 5 years in patients with T1DM. Additionally screening at an onset and repeated measurements for autoimmune thyroiditis and celiac disease are recommended.

PAO-107

Cushing’s disease in a 14-year old female: difficulties of diagnosis
Violette Csakvary1; Zoltan Locsé2; Gyorgy Oroszlian3; Zita Halasz3; Miklos Toth3; Sandor Czirjak4; Karoly Raczy1
1Markusovszky Teaching Hospital, Department of Pediatrics, Szombathely, Hungary; 2Markusovszky Teaching Hospital, 1st Department of Internal Medicine, Szombathely, Hungary; 3University of West Hungary - Savaria Campus, Institute for Health Promotion, Szombathely, Hungary; 4Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary; 5Semmelweis University, 2nd Department of Internal Medicine, Budapest, Hungary; 6National Institute of Neurosurgery, Department of Neurosurgery, Budapest, Hungary

Background: Cushing’s disease (CD) is rare in childhood and remains a difficult condition to diagnose and treat. Although the diagnosis of CD is crucial importance in effective diagnosis and treatment. Sometimes it is difficult to confirm the location of microadenoma in CD.

Objective and hypotheses: We report the case of 14-year old girl, who was referred to our hospital because of growth retardation with muscle weakness and rapid onset weight gain. On admission, she had typical Cushingoid appearance with Tanner pubic hair stage 3.

Endocrinological examinations showed elevated levels of serum cortisol, and 24-h urinary free cortisol (UFC), and plasma ACTH. Lack of diurnal variation of ACTH and cortisol was observed. Serum cortisol levels were not suppressed by low and high dose dexamethasone as well. We established ACTH dependent CD. Perifoming the corticotrophin-releasing hormone (CRH) test, increased cortisol response confirmed the diagnosis of CD. Gonadotropin levels were subnormal suggesting a suppressive effect of chronic hypercortisolism. Although, on 3.0 Tesla brain MRI, no microadenoma was detected in the pituitary gland. Considering the patient’s age, hormonal findings compatible with pituitary ACTH production and the possible complications the bilateral inferior petrosal sinus sampling for ACTH was not performed.

Results: Despite of the lack of positive radiomorphological MRI signs, the patient underwent successful and curative transphenoidal pituitary surgery and a 2 mm microadenoma was removed. The histopathological features–ACTH secreting microadenoma-was consistent with the diagnosis.

Conclusions: Hypercortisolism was resolved after pituitary surgery. Possessing the typical clinical presentation and endocrinological investigation of CD in special cases –lack of detected microadenoma- the transphenoidal surgery is henceforward a safe and effective procedure in children.

PAO-108

Noonan syndrome: clinical phenotype and response to GH treatment
Yuliya Makarava; Julia Boiko
State Center of Medical Rehabilitation, Pediatric Department, Endocrinology Group, Minsk, Belarus

Background: Noonan syndrome (NS) is a disorder characterized by congenital heart defects, facial dysmorphism, skeletal malformation and short stature.

Objective and hypotheses: The aim of the study was to describe a cohort of patients with NS in Belarus, evaluate the effect of rGH treatment for 24 months on metabolic, clinical and cardiac status in patients with NS.

Methods: Since 2008 at the State Endocrinology Center 8 NS patients (5m, 3f) were observed. Median age was 13.7yr (11.0-17.8). All but one were in puberty Tanner stage 2-3 at the first observation. One boy had early puberty, a gonadal atrophy was found in one boy also. Two patients had a mild growth retardation (mean height SDS -2.9 (from -4.8 to -2.0SDS)) according to population standards. Means birth weight and length were normal. Typical face dysmorphology were found in all patients. 3/8 were diagnosed with pulmonary valve dysfunction.
Case report: A 5.5 year-old girl admitted to our clinic with mutism caused by coarsening of the voice and unwillingness to speak. Her previous history revealed that pubic and axillary hair appeared at the age of 1 year and she was admitted to another hospital. However, the parents could not have brought the child to the regular follow up because of economic deprivation. During subsequent years, clinical progression of virilization has resulted in deepening of voice and ultimately a voluntary mutism have occured which was chief complaint for admission to our clinic. At the time of presentation, in physical examination there were signs of virilization(deepening of voice, hyperpigmentation in genitalia and areola, acne, cliteromegaly, axillary and pubic hair). Laboratory examination revealed elevated adrenal hormones(17-OH-progesterone: 62ng/ml(N<20), DHEA-S:1543 µg/dl(N:15-60), cortisol:35.9 µg/dl(N:5-15), ACTH:9.2 pg/ml(N:0-46). Abdominal ultrasonography and CT showed a large(13x11,4 cm) cystic heterogeneous mass on right adrenal localization. There was no sign of metastasis.

Results: At 12 and 24 months of treatment mean height SDS elevation was found (A1 height SDS = 0.43 and A2 height SDS = 0.64, respectively). Basal serum IGF-1 levels normalized after 1st yr of rhGH therapy: -0.48SDS. No significant difference was observed in lipids profiles, fast glyceria, fast insulin levels and clinical cardiac status during two years of rhGH treatment.

Conclusions: Cohort of patients with NS in Belarus showed the typical clinical phenotype as well as in other researches. Effect of rhGH treatment starting at the age of puberty in NS is minimal. Early genetic analysis is required to be helpful in selecting the appropriate patients for rhGH therapy.
BS measurement at school. The classmates and teachers of the patient know that they were diabetic in %95 and %94 respectively. 30% of the children were avoiding injections at school, 33% were injecting at classroom, 15% at infirmary, 11% at cantina and 11% at restrooms. There was no school nurse in 80% of the schools. 18% of the children reported severe hypoglycemia in the last year. Glukagon was present at 19% of the schools and 72% of the homes of diabetic children.

Conclusions: This survey demonstrated a need for a more vigorous education and organisation for diabetes-care (especially for blood sugar measurement, insulin injections and glucagon) at school environment in Istanbul. It also demonstrates importance of a specialist (pediatric endocrinologist) in care of children with T1DM.

PAO-112

Wolcott Rallison syndrome (WRS): a case report of a rare genetic disorder presenting with permanent neonatal diabetes mellitus

Vagias Imran Khan1; Muhammad Waqar Rabbani2; Sian Ellard3; Sara Flanagan3
1Children’s Hospital & Institute of Child Health, Department of Endocrinology, Multan, Pakistan; 2Children’s Hospital & Institute of Child Health, Department of Paediatric Medicine, Multan, Pakistan; 3Royal Devon & Exeter NHS Hospital, Molecular Genetics, Exeter, United Kingdom

Introduction: WRS is the most common genetic cause of Permanent Neonatal Diabetes Mellitus in consanguineous families. Much information can be gained by the identification of a susceptible gene in a particular disorder. WRS is a rare autosomal recessive disorder resulting from mutations in EIF2AK3 (or PEK), the gene encoding the eukaryotic translation initiation factor 2 α kinase 3 (eIF2α kinase).

Description: We report a case of 35 days old female, who presented with seizures, hepatic dysfunction and diabetes mellitus and diagnosed as WRS on the basis of genetic studies with identification of mutations in the gene EIF2AK3. The baby was born an uneventful 36 weeks pregnancy from healthy consanguineous parents with birth weight of 1700 gms. Initial glucose level was 1020mg/dl, insulin needs dropped gradually from 4u/kg to 0.5u/kg until adequate glycemic control was achieved.

Result: Sequencing analysis has shown that she is homozygous for the nonsense mutation, L425X, in exon 7 of the EIF2AK3 gene. This mutation is a T > A substitution at nucleotide 1274 (c.1274T>A) resulting in a premature termination codon (p.Leu425X). This result confirms a diagnosis of Wolcott Rallison syndrome. Her mother is heterozygous for the EIF2AK3 nonsense mutation L425X and her father, heterozygous for a nonsense mutation in exon 7 of the EIF2AK3 gene.

Discussion: WRS results from the lack of trans-membrane enzyme activity which leads to the cell death by apoptosis in a number of different tissues. The development of early onset diabetes mellitus and skeletal dysplasia in almost all patients of WRS explains the high level of expression of EIF2AK3 in both pancreatic β cells and bone tissues. However the gene is expressed at a lower level in several other tissues, which determines the variability of the clinical manifestations observed in this syndrome. The clinical features of variable intensity found in different tissues include mental retardation, hepatic and renal dysfunction, cardiac abnormalities, exocrine pancreatic dysfunction and neutropenia.

PAO-113

Terms of diagnostics of 21-hydroxylase deficiency at performance of neonatal screening

Oleg Malievsky1; Dilara Nurmukhametova2; Rushana Basharova2
1Bashkir State Medical University, Department of Pediatrics, Ufa, Russian Federation; 2Republican Children Hospital, Department of Endocrinology, Ufa, Russian Federation

Background: Before introduction of neonatal screening there was observed a great many cases of late diagnostics of the 21-hydroxylase deficiency (21-OHD), especially in boys. This led to premature sexual development in the simple virilizing form (SV) and to salt-losing crisis at the salt-wasting form (SW). Objective and hypotheses. To evaluate age of patients with 21-hydroxylase deficiency, at which the disease was diagnosed, during performance of the neonatal screening.

Population and/or methods: In 2006-2010, in Republic of Bashkortostan, by using the neonatal screening the 21-hydroxylase deficiency was revealed in 15 newborns. To evaluate efficiency of the neonatal screening, we determined terms of performance of each screening stage, age (median, minimal and maximal age) at making out the diagnosis of SW and SV 21-OHD in boys and girls.

Results: Age at making out the diagnosis of SW 21-OHD in girls after introduction of screening did not essentially change (medians 11 and 8 days, respectively). SV 21-OHD in girls in all cases began to be diagnosed at the neonatal period (median 15 days, min-max 0-21 days). In boys, all cases of the SW 21-OHD after the beginning of screening were revealed at the neonatal period as early as before development of the salt-wasting crisis (median 20 days, min-max 14-28 days). After introduction of screening, median of the age, at which the diagnosis was finally established, were 43 days. SV 21-OHD in boys was diagnosed later as compared with SW 21-OHD in boys and with both forms in girls. This is accounted for by that due to a large amount of the increased 17-hydroxyprogesterone values in boys the repeated study of this marker was performed every 2 weeks.

Precise conclusions: Neonatal screening has allowed decreasing essentially the time of diagnostics of the 21-hydroxylase deficiency, especially in boys.

PAO-114

Following up plasma LH and estradiol in overweight children with idiopathic precocious puberty during GnRH agonist therapy

Se-Min Lee
Hanyang University, College of Medicine, Pediatrics, Seoul, Republic of Korea

Background: They have reported that obesity was associated with development of idiopathic precocious puberty (IPP).

Objective and hypotheses: We compared suppression of plasma LH and estradiol between overweight girls and nonoverweight group to evaluate whether overweight is associated with suppression of plasma LH and estradiol during GnRH agonist therapy in patients with idiopathic precocious puberty.

Methods: We measured plasma LH and estradiol of overweight girls (n=16) and nonoverweight group (n=27) before and after 3 months of GnRH agonist therapy.

Results: Follow-up plasma LH and estradiol were not significantly different between overweight group (0.57 ± 0.31 mIU/mL, 7.77 ± 3.55 pg/mL, respectively) and nonoverweight group (0.4 ± 0.29 mIU/mL, 7.80 ± 4.91 pg/mL, respectively). Significant suppression of plasma LH (<0.6 mIU/mL) was observed in 62.5% of overweight group (n=10) and in 70.4% in nonoverweight (n=19). Significant suppression of plasma estradiol (< 10 pg/mL) was observed in 81.3% of overweight group (n=13) and in 81.3% in nonoverweight (n=22).

Conclusions: In 3 months of GnRH agonist therapy, suppression of plasma LH and estradiol was not significantly different between overweight and control group.

PAO-115

The analysis of the CYP21A2 gene in children with 21-hydroxylase deficiency from Republic Bashkortostan (Russia)

Vita Akhmetova1; A. Rakhimkulova1; Oleg Malievsky2; Elza Khusnutdinova1
1Institute of Biochemistry and Genetics, Department of Molecular Genetics, Ufa, Russian Federation; 2Bashkir State Medical University, Department of Pediatrics, Ufa, Russian Federation

Background: Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders of adrenal steroidogenesis in which 21-hydroxylase deficiency (21-OHD) accounts for over 95% of cases.

Population and methods: We studied 87 patients with 21-OHD from Republic Bashkortostan with salt wasting (SW) (n=42) and simple virilizing (SV) (n=45) forms. Mutations of the CYP21A2 gene were revealed in 71.82% of
the studied CAH-chromosomes with the following frequencies: delA2orL-GC (27.6%), R356W (16.02%), I2splice (11.6%), I172N (7.18%), Q318X (4.97%), V281L (2.76%), P30L (1.11%) and P453S (0.55%).

Results: The mutations frequency distribution in the CYP21A2 gene in 2 groups of patients with classical disease forms showed statistically significant differences. SW 21-OHD patients demonstrated delA2orLGC of the gene CYP21A2 twice more often than patients with SV (37.65%) and 19.32%, respectively, \( \chi^2 = 6.28, p = 0.012 \), mutation R356W - 2.6 times higher (23.53% and 9.09% respectively, \( \chi^2 = 5.62, p = 0.018 \), mutation I2splice - 2.9 (16.47% and 5.68%, respectively, \( \chi^2 = 4.1, p = 0.043 \)), and mutation Q318X - 8.3 (4.41% and 1.14% respectively, \( \chi^2 = 0.044, p = 0.004 \)).

The mutation I172N, on the contrary, was more typical for SV patients than SW patients (3.64% and 1.18%, respectively, \( \chi^2 = 7.95, p = 0.005 \)). Mutations P30L and V281L were detected only in SV patients.

Thus, we have been able to detect the spectrum of diagnostic significant CYP21A2 gene mutations typical for SW and for SV forms in CAH patients. We found 6 21-OHD patients who carried 3 mutations, two of which formed a cluster. Q318X=R356W (2.87%, 5/174), I172N=Q318X (0.57%, 1/174).

Precise conclusion: The studying of molecular-genetic nature of 21-OHD represents the doubtless scientific and practical importance in respect of use of the received data for differential diagnostics of its various forms, medical and genetic consultation and prenatal diagnostics.

PAO-116
A rare case of adiposogenital puberal obesity
Susanne Frick-Otto1; Reinhardt Mühlenberg1; Katrin Held2
1Helios Clinic Krefeld, Department of Endocrinology, Krefeld, Germany; 2Helios Clinic Krefeld, Children’s Department, Department of Endocrinology, Krefeld, Germany

Background: We present a girl with the diagnosis of a growth hormone producing tumour of the pitutary gland.

Objective: We would like to present the case of a 14.11/12-year-old girl who was referred to our outpatient clinic for endocrine evaluation of obesity. The auxology findings showed a body weight of 97.6 kg, a BMI of 32.8 (≈ 99.8 Perc.) and a body height of 172.6 cm (≈ 90. Perc.) with familiar aim size of 156 cm. X-ray of the left hand showed a retardation of the bone age of 1.6 J, the prospective final size was calculated at 177 cm. 2.3 years ago, at the beginning of the first puberty signs remarkable changes of the physical development and the appearance were noted for the first time.

The patient increased extremely in weight and showed a persistent growth push by shoe size at last 45. Clinically she suffered from occasional episodes of headaches, strong sweating and a primary amenorrhoe.

Because of the clear discrepancy between informal aim size and prospective final size, the external appearance of the patient and her distinct obesity we performed detailed endocrinology analysis incl. chromosome analysis, cerebral MRI and ophthalmologic investigation and could diagnose a growth hormone producing tumour of the pituitary gland.

Methods: Clinical history and clinical findings, measuring of height, familiar aim size and prospective final size, x-ray of the left hand to calculate bone age and MRI of the brain, especially the pitutary gland.

Result: After diagnosis of a growth hormone producing tumour of the pituitary gland, the patient was transferred to a specified neurosurgery for transphenoidal tumor extirpation.

Conclusion: If you see a clear discrepancy between informal aim size and prospective final size in a patient you have to search after a tumor in the pitutary gland.

PAO-117
Delirium in diabetic ketoacidosis
Ayse Nurcan Cebeci; Ayla Guven
Goztepe Educational and Research Hospital, Pediatric Endocrinology, Istanbul, Turkey

Background: Neurologic changes during the course of diabetic ketoacidosis (DKA) should be considered as early signs of cerebral edema and should be treated immediately. Yet, delirium is not a usual neurological complication of DKA and has not been reported in pediatric DKA so far. We report our experience with a teenage girl who developed hyperactive delirium during the treatment of DKA.

Case report: A 15-year-old female patient with known type 1 diabetes mellitus of two years duration was referred because of fatigue and symptomatic hyperglycemia. She had abdominal pain for the last 24 hours, could not eat her meals appropriately and had hypoglycemia in the morning of admission. Due to appetite loss and hypoglycemia, she omitted the insulin dose at lunch time.

On physical examination she was alert, had dehydration, deep sighing respiration and a smell of ketones. Her height was 168 cm (+1.02 SDS), weight 68 kg (+1.66 SDS), respiratory rate was 38/min, pulse 80/min. She had normal body temperature and blood pressure. Blood glucose was 414 mg/dl (23 mmol/l), capillary pH: 6.99 and bicarbonate: 5.0 mmol/l. Base excess was -25.2 mmol/l and anion gap was 29.8 mmol/l. Blood urea, liver enzymes and electrolytes were within normal limits. At the sixth hour of treatment the acidosis with administration of fluid and insulin, the patient became delirious. The delirium persisted despite the normalization of acidosis and was difficult to manage.

Brain imaging studies revealed neither brain edema nor other intracranial pathologies. No evidence of intoxication could be found. The patient gradually regained consciousness and “merely” suffered from massive DKA associated with infection.

Conclusions: We did not find any similar case in childhood period in the literature thus we thought that clinicians should be aware that delirium can be seen in DKA due to severe acidosis.

PAO-118
Differences in clinical features and responses to treatment in different age groups of children with diabetic ketoacidosis and ketosis
Ayse Nurcan Cebeci; Ayla Guven; Heves Kirmizibekmez; Metin Yildiz; Fatma Dursun
Goztepe Educational and Research Hospital, Pediatric Endocrinology, Istanbul, Turkey

Objective and hypotheses: To compare clinical features and responses to a certain treatment protocol in different age groups.

Material and methods: Hospital records of patients with diabetic ketoacidosis (DKA) and ketosis (DK) who admitted to our hospital between January 2007 and December 2009 were reviewed. Symptoms, clinical and laboratory findings of all patients were recorded. Patients were divided into subgroups regarding to age (Group 1 (<5.0 years), Group 2 (5.1-10.0 years), Group 3 (>10.1 years)). All patients with DKA were treated with a standardized intravenous fluid and insulin therapy while patients with DK were treated with subcutaneous insulin. The therapy protocol was analyzed in terms of amount and duration of fluid therapy, dose of insulin infusion and complications of therapy.

Result: 132 episodes in 107 patients with DKA (101 episodes) and DK (31 episodes) were studied. 64 patients (%60) were female, 43 (%40) were male, 81 (%60) were in new onset, 51 (%40) were in established diabetes. There were 22 episodes in group 1 (16.7%), 30 episodes in group 2 (22.7%) and 80 episodes in group 3 (60.6%). Patients in group 1 and 2 reported more polydipsia and polyuria than patients in group 3 involving patients mostly with established diabetes. Blood glucose and corrected Na levels, as well as pH and osmolality did not differ between groups. HBAlc was found significantly higher with age. Children in group 1 had significantly lower HCO3 levels compared to group 2 (P=0.047) and group 3 (P=0.014). Duration and amount of fluid therapy did not differ between groups. Patients in group 3 received significantly higher doses of insulin and patients in group 1 received significantly more bicarbonate therapy. Only one patient experienced cerebral edema which recovered without any sequel owing to appropriate therapy.

Conclusion: Children less than five years of age are at higher risk of acidosis and require more attention and closer monitoring during treatment.
Long term longitudinal evaluation of overweight and insulin-resistance in patients treated for acute lymphoblastic leukaemia during childhood

Background: Cranial radio-prophylaxis (CR) and total body irradiation (TBI) for hematopoietic stem cell transplantation are risk factors for obesity and insulin resistance (IR) in long term childhood cancer survivors.

Objective and hypotheses: To evaluate overweight and IR in a group of childhood acute lymphoblastic leukaemia (ALL) survivors who received or not radiotherapy (RT).

Methods: We evaluated 74 patients (pts) treated for ALL at our Centre, at mean age 5.2±3.1 years (yrs), follow-up 7.8±3.4 yrs. They were subdivided in 3 groups according to RT: group 1 (CR 1800 cGy) 17/74 pts, group 2 (TBI 800-1800 cGy) 16/74, group 3 41/74 pts not irradiated. In each group BMI SD and HOMA were evaluated yearly. HOMA was normal if < 2.5 in adults and children, <4 in adolescents.

Results: The prevalence of obesity was 9% in group 1 (after the 5th year), 7% in group 3 (in the first 5 years), 0% in group 2. 18% of pts in group 1, 14% in group 2 and 20% in group 3 were overweight. In the first 3 yrs, group 2 pts showed lower mean BMI SD (p=0.03) than the others. HOMA was abnormal in 9.5% of all pts and in 39% of overweight and obese pts. HOMA improved during follow-up in group 1 and 3. In group 2 IR was found in 47% of pts, increasing after the 4th year of follow-up. HOMA was abnormal also in some lean pts (8.3% from group 1, 27% from group 2 and 18.5% from group 3).

Conclusions: Obesity is rare in our pts. CR seems to be a risk factor for late obesity onset. TBI showed some protective effect on BMI SD while it negatively affected insulin sensitivity. HOMA should be evaluated in ALL survivors regardless BMI SD, in particular in pts who underwent TBI.

Comparison of efficacy of growth hormone (GH) treatment in short children with neurosecretory dysfunction (NSD) and partial GH deficiency - 3 years of observation

Background: Improvement of height velocity (HV), related to an increase of insulin-like growth factor-I (IGF-I) secretion, is the most important index of growth hormone (GH) therapy effectiveness.

Objective and hypotheses: The aim of the study was an assessment of the efficacy of 3 years GH treatment by estimation of HV, IGF-I secretion and IGF-I to IGF binding protein-3 (IGFBP-3) molar ratio.

Methods: The analysis comprised 54 children (40 boys) with short stature and: partial GHD (pGHD – GH peak in 2 stimulating tests 5-10 ng/ml), and neurosecretory dysfunction (NSD – GH peak in stimulating tests >10 ng/ml but after falling asleep <10 ng/ml, decreased IGF-I secretion). All the patients were treated with GH in a dose of 0.18±0.02 mg/kg/week for – at least – 3 years. Before GH administration and after following years of therapy HV, IGF-I secretion and the IGF-I-IGFBP-3 molar ratio were compared.

Results: There were no significant differences in any of the analysed parameters between the groups either before the therapy or at any time of treatment, except for the significantly lower (p=0.01) IGF-I-IGFBP-3 molar ratio in NSD group before treatment. For detailed data see the Table.

Conclusions: The effectiveness of treatment presented similar in NSD and pGHD groups. It seems that normal GH results of stimulating tests should not be a reason for disqualifying short children with disorders of spontaneous GH secretion from GH therapy.
PAO-122
Multiple endocrine complications of allogeneic hematopoietic stem cell transplantation
Anna Wêdrychowicz; Agata Zygmunt-Górakta; Joanna Wojtyr;
Marta Ciechanowska; Aleksandra Krąsowska-Kwiecien;
Jerzy Starzyk
1Polish-American Children’s Hospital, Medical College, Jagiellonian University, Department of Pediatric and Adolescent Endocrinology, Department of Transplantation, Cracow, Poland; 2University Children’s Hospital, Pediatric and Adolescent Endocrinology, Cracow, Poland; 3Polish-American Children’s Hospital, Medical College, Jagiellonian University, Department of Pediatric and Adolescent Endocrinology, Cracow, Poland

Background: Since the 1980s, hematopoietic stem cell transplantation (HSCT) has been performed for malignant and non-malignant disorders leading to increasing numbers of long-term survivors. Some of them have endocrine complications that arise many years after the end of the initial disorder treatment.

Objective and hypotheses: We present the 16.5 year-old girl with endocrine complications after treatment of acute lymphoblastic leukemia diagnosed at the age of 10.

Method: First chemotherapy was complicated with an acute pancreatitis after L-asparaginase. Eight months after diagnosis an allogeneic HSCT from HLA-matched sibling donor was performed. In the conditioning regimen fractionated total body irradiation and high-dose etoposide were used. After HSCT several early and late complications occurred: bacterial and mycotic infections, engraftment syndrome with renal and respiratory failure, graft versus host diseases (GVHD) and pancreatitis.

Results: We observed multiple endocrine complications successively appearing after HSCT: i) transient carbohydrates metabolism disorders in first days, followed by regular diabetes requiring insulin therapy, ii) euthyroid sick syndrome in first months, then an overt primary hypothyroidism treated with L-thyroxin, iii) transient hypoglycemia due to SIADH syndrome, iv) growth hormone deficiency supplemented with recombinant human growth hormone since second year after HSCT until the age of 16 according to the patient’s decision, v) delayed spontaneous puberty followed by secondary amenorrhea requiring an estrogen-progesterone replacement therapy, vi) low bone mineral density detected in repeated densitometry examination, in spite of calcium and vitamin D supplementation, vii) some elements of metabolic syndrome in spite of diabetes with insulin resistance, as high blood pressure, and dyslipidemia.

Conclusions: The significant endocrine complications of HSCT in the presented patient were associated with radiation exposure, but were also related to some chemotherapeutic agents, GVHD, and prolonged corticosteroid exposure.

PAO-123
Central hypothyroidism following chemotherapy for acute lymphoblastic leukemia
Federico Baronti; Laura Battisti; Giorgio Radetti
Regional Hospital of Bolzano, Pediatrics, Bolzano, Italy

Background: Thyroid dysfunction is frequently reported in patients treated with radiotherapy for childhood cancer. However, it has been suggested that chemotherapy per se might also impair the hypothalamus-pituitary-thyroid axis.

Objective and hypotheses: We examined 8 patients, out of a cohort of 31 subjects treated for acute lymphoblastic leukemia (ALL) with chemotherapy alone, who, showed, during the follow-up, thyroid findings consistent with central hypothyroidism (CH).

Methods: The patients were diagnosed with ALL at a mean age (range) of 3.8 (0.3-6) years and were, at the time of the study, for 6 years (range 6-13) off therapy. Auxological data were recorded and TSH, FT4, thyroid peroxidase and thyroglobulin antibodies, cortisol and IGF-I were evaluated and a thyroid ultrasound was performed. Four subjects, who gave their consent, underwent a TRH test and a MRI scan of the hypothalamic-pituitary region.

Results: All subjects showed basal TSH above the normal range, while FT4 was abnormally low in two patients only. FT3 was always in the normal range. After TRH infusion, an increase in TSH serum level was observed; however, 2 patients showed an exaggerated TSH increase while 3 patients showed a slow TSH decline. Two patients showed an impaired FT3 net increase.

Conclusions: Our study shows that central hypothyroidism could arise at any time after childhood leukemia following only chemotherapy treatment. Although overt hypothyroidism was detected in only two patients, a careful follow-up of the thyroid function is recommended also for not irradiated ALL survivors.

PAO-124
Hyponatremia, hypothyroidism and metabolic acidosis
Ozlem Korkmaz; Damla Goksen; Gulgun Yermen; Afig Berdeli; Sukran Durcan
1Ege University, Faculty of Medicine, Pediatric Endocrinology, Izmir, Turkey; 2Ege University, Department of Pediatrics, Izmir, Turkey

Background: Severe hyponatremia with hyperkalemia and dehydration is an uncommon but life-threatening occurrence in infancy.

Objective and hypothesis: To highlight the importance of diagnosis and treatment of hypothyroidism in infancy.

Method and results: A two month old female patient with a history of first degree parental consangunity admitted to hospital with failure to thrive. At initial examination her weight was 2990 gr. height was 53 cm and she was hypotonic. Laboratory evaluation revealed serum sodium concentration 108 mEq/l, potassium 5.3 mEq/l, chloride 71 mEq/l. She received saline solution, hydrocortisone and fludrocortisone with an initial diagnosis of adrenal failure. Additional evaluation was not remarkable with adrenal failure since ACTH was 18.8 pg/ml (10-70 pg/ml), 17-OH Progesteron, 7.7 ng/ml (1.7-17 ng/ml), cortisol, 14 mcg/dl (3-23 mcg/dl), DHEA-S: 35 mcg/dl (-45 mcg/dl) and aldosterone was 408 pg/ml(20-1300 pg/ml). Urinary sodium excretion was 27 mEq/l and serum osmolality was normal. Thyroid replacement therapy was initiated because her TSH and FT4 levels were 100 mIU/l and 0.47 ng/dl respectively. With the initiation of L thyroxin therapy and with the exclusion of adrenal failure fludrocortisone was tapered. An immediate decrease in serum Na levels was seen and fludrocortisone was restarted. Metabolic diseases that can because hyponatremia was excluded with normal lactic acid, pyruvic acid, tandem mass and quantitative urinary amino acid levels. She was noted to have increasing values of urea, creatinine and uric acid and intermitent metabolic acidosis on the second week of her hospitalization. She died with metabolic acidosis and septic shock on the 6th week of admission.

Conclusions: The patient was negative forRNR3C2, SCNN1B,SCNN1G and a heterozygous genetic variant in SCCN1A gene (pThr633Ala) was found. Glycolisation deficiency disorder, systinosis and membrane transport defects (Pendrin mutation) was thought in the differential diagnosis of these two siblings.

PAO-125
Intractable hypercalcemia following transplantation for osteopetrosis
Sung Yoon Cho; Sohn Young Bae; Jin Dong-Kyu
Samsung Medical Center, Pediatric, Seoul, Republic of Korea

Background: Autosomal recessive osteopetrosis is characterized by insufficient osteoclast activity resulting in defective bone resorption and marked increase in skeletal mass and density. Osteopetrosis results in generalized sclerotic bones and bone marrow failure. Allogeneic bone marrow transplantation(BMT) is the only treatment for cure, secondary to engraftment of donor-derived functioning osteoclasts resulting in remodeling of bone and establishment of normal hematopoesis. One of the complications following a successful BMT is hypercalcemia that is a unique complication in this group of patients.

Methods and results: We report a three-year-old girl with osteopetrosis who developed hypercalcemia following the successful bone marrow transplantation. These findings indicated an active donor-derived osteoclastic function and thus bone resorption following the successful donor engraftment in the patient. Her calcium level was 14.8 mg/dL at postBMT 10 days, therefore calcitomin (4 IU/kg sc every 12hr) as well as hyperhydration and furosemide were started. However, the calcium level increased to 16.8 mg/dl at post-BMT 13 days, and then intravenous pamidronate (15mg/BSA) and steroid (methylprednisolone 1mg/kg every 12hrs) was started. At that evening, she...
was very irritable with more increased calcium level of 18.2 mg/dL. Her status was considered malignant hypercalcemia, therefore we started continuous renal replacement therapy. After two days, the calcium level decreased to 13 mg/dL without any adverse events, and CRRT had been maintained for six days. At present (post-BMT 45 days), her calcium level below 11 mg/dL with weekly pamidronate, daily calcitonin and daily methylprednisolone with tapering dose.

Conclusions: In conclusion, hypercalcemia is common in patients with osteoporosis after BMT. If the conventional therapeutic strategies including isotonic saline, furosemide and calcitonin would not be successful, continuous renal replacement therapy should be considered seriously to prevent severe adverse events of hypercalcemia.

**PAO-126**

**Vitamin D status in pediatric patients with malignancy**

Dali Moden-Moses1; Ori Pinhas-Hamiel1; Vered Temam1; Dafna Munitz-Shenkar1; Toren Amos1
1The Edmond and Lily Safra Children’s Hospital, Pediatric Endocrinology, Ramat-Gan, Israel; 2The Edmond and Lily Safra Children’s Hospital, Pediatric Hemato-Oncology, Ramat-Gan, Israel; 3The Edmond and Lily Safra Children’s Hospital, Pediatric Hematology-Oncology and BMT, Ramat-Gan, Israel

**Background:** Multiple studies demonstrated an inverse association between vitamin D and its metabolites and cancer morbidity and mortality. Despite this impressive body of evidence, only a handful of studies estimated vitamin D status in pediatric patients with malignancy.

**Objective and hypotheses:** Our aim was to assess vitamin D status in a large cohort of pediatric cancer patients and survivors, and to define risk factors to vitamin D deficiency. We hypothesized that 25OHD levels will be low in this population, particularly among actively treated patients.

**Methods:** 25OHD levels were obtained in 154 consecutive patients (aged 12.1±5.9y, M=76) during their routine visits to the hemato-oncology department (mean time from diagnosis 4.4±3.9y). Patients or their parents were asked to answer a questionnaire regarding calcium intake and sun exposure habits.

**Results:** Average daily calcium intake was 742.1±415.5mg/day. Mean 25OHD levels were 28.9±34.7ng/ml. 106 patients (11.1%) were vitamin D deficient (<11ng/ml), and another 87 (80.3%) were vitamin D insufficient (11-32ng/ml). Only 12 patients (7.9%) were vitamin D sufficient. Younger age and the amount of sun exposure were associated with higher serum 25OHD levels (r=−0.24, p=0.003; r=0.21, p=0.008, respectively). No association was found with sun protection habits, calcium intake, disease type, gender, years since diagnosis, or undergoing stem cell transplantation.

**Conclusions:** The prevalence of vitamin D deficiency and insufficiency in pediatric hematopoietic patients is high, while daily calcium intake is significantly lower than the RDA. While these values may be similar to those of the general pediatric population in Israel, they are of particular concern in this patient population, which is at high risk for osteoporosis. Furthermore, given the current knowledge regarding the importance of vitamin D in the context of malignancy, maintaining an adequate vitamin D status may be important for recovery and prevention of recurrence of pediatric malignancy.

**PAO-128**

**Osteoporosis-pseudoglioma syndrome: clinical outcome after treatment with growth hormone and bisphosphonates**

Gloria Bueno1; Feliciano Ramos1; Jesus Fleta1; Inés Bueno1; Jesus Maria Garagorry1; Nizar Smaoui2; Jose Luis Olivares1
1Lozano Blesa University Clinical Hospital, Department of Pediatrics, Zaragoza, Spain; 2GeneDx, DNA Diagnostic Experts, Gaithersburg, United States

**Background:** Osteoporosis-Pseudoglioma Syndrome (OPPG, MIM 259770) is a very rare genetic autosomal recessive condition characterized by early blindness and bone fragility with fractures. The affected gene is called LRPS, located at the chromosomal region 11q13.4. Recently, the combined growth hormone (GH) and bisphosphonates treatment in OPPG patients was proposed.

**Objective:** To present the case and the clinical evolution of a 10-year-old Moroccan girl with OPPG, confirmed by the identification of a mutation in exon 11 of the LRPS gene (c.2490C>T), treated by growth hormone (GH) and intravenous bisphosphonates.

**Case report:** The patient is a 10-year-old Moroccan girl with OPPG, confirmed by the identification of a mutation in exon 11 of the LRPS gene (c.2490C>T), who was treated for one year with GH and intravenous bisphosphonates.

**Laboratory analyses included:**
- Calcium: 10.3 mg/dL, phosphatemia: 5 mg/dL, alkaline phosphatase: 221 U/L, PTH 43,4 pg/mL, 25(OH)D3: 28 ng/mL, osteocalcin: 17 ng/mL, all in normal ranges.
- Skeletal survey: Generalized osteopenia, thin long bones, flattened dorsal vertebrae, pectus carinatum and deformed chest. Epiphyses were normal. No anomalies were found in the skull. Bone densitometry (L1-L4): 0.378 g/cm2, all in normal ranges.

**Conclusion:** After 1 year of treatment, the intravenous pamidronate therapy was safe, bone mineralization increased (~2.5 SD for age) and fracture rate and pain decreased. Further follow-up is needed in order to confirm the long term efficacy of this treatment.
PAO-129

Evaluation of cardiovascular risk factors in children with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Nicola Improda; Lucia De Martino; Flavia Barbieri; Daniela Cioffi; Raffaella Di Mase; Mariacarolina Salerno
Federico II University, Department of Pediatrics, Naples, Italy

Background: Classical Congenital Adrenal Hyperplasia (CAH) may present some traits of the metabolic syndrome.
Objective: Aim of this study was to investigate cardiovascular and metabolic risk profiles in children and adolescents with classical CAH.
Subjects and methods: We compared 20 classical CAH patients (10 males and 10 females, age range 9-19 years) with 20 age- and sex-matched controls. Anthropometry, lipids, blood pressure, fasting glucose concentrations, serum insulin levels and insulin sensitivity were studied. Adiposity was expressed as BMI SDS. Waist Circumference (WC) and Waist-to-Hip Ratio (WHR) were used to evaluate visceral adiposity.
Results: BMI SDS was significantly higher in patients than controls (0.9±0.9 vs -0.13±1.53; p=0.008). Five patients (25%) and two controls (10%) had a BMI SDS of >2.0. WC, but not WHR, resulted significantly higher in patients than in controls (82.9±13.7 vs 72.77±13.6; p=0.001). No differences were found for lipid parameters and mean systolic and diastolic blood pressures between the two groups. Fasting insulin levels (12.0±7.6 vs 5.1±5.08; p=0.003) and HOMA index (2.1±3.4 vs 0.98±1.03; p=0.01) were significantly higher in CAH patients, compared to controls. A significant correlation was observed between WC and BMI SDS (r=0.78, P<0.0001), fasting insulin levels (r=0.4525, p=0.04) and HOMA (r=-0.45, p=0.04).
Conclusions: Children with classical CAH are at risk for increased BMI, obesity, hyperinsulinism and reduced insulin sensitivity. WC is an accurate predictor of these metabolic abnormalities and thus it should be monitored during follow-up in patients with classical CAH.

PAO-130

Successful switching from insulin to oral sulfonylureas in neonatal diabetes mellitus patients
Ngoc Can1; Chi Dung Vu1; Phuong Thao Bui1; Ngoc Khanh Nguyen1; Maria Craig2; Sian Ellard2; Hoan Nguyen1
1National Hospital of Pediatrics, Endocrinology, Metabolism and Genetics, Hanoi, Vietnam; 2St George Hospital and The Children's Hospital, Endocrinology, Westmead, Australia; 3Human Molecular Genetics, Peninsula Medical School, Department of Molecular Genetics, Exeter, United Kingdom

Background: Neonatal diabetes mellitus (NDM) may be defined as hyperglycemia diagnosed within the first 6 months of life and can result from mutations in the Kir6.2 or sulfonylurea receptor 1 (SUR1) subunits of the ATP-sensitive K+ channel. Transfer from insulin to oral sulfonylureas in patients with NDM due to Kir6.2 or SUR1 mutations is well described.
Objective and hypotheses: Determine gene mutation of KCNJ11 and ABC8 in NDM patients; assess the results of oral sulfonylurea therapy replacing insulin injection.
Methods: Case study: 5 patients suffer NDM at 45, 35, 47, 36, 44 days of age, respectively with ABC8 or KCNJ11 mutations are treated in National Hospital of Pediatrics, Hanoi, Vietnam.
Results: 2 patients has heterozygous for a missense mutation on KCNJ11: R201H (p.Arg201His) & R201C (p.Arg201Cys); 3 patients with ABC8 mutations: missense R1183W (p.Arg1147Trp), nonsense E747X and compound heterozygote for E747X & E128K. All 5 patients switched from insulin to sulfonylurea therapy at 5 years, 2.5years, 7 years, 5 years and 8 months of age, respectively. Before of switching, Hba1C levels were 9.9; 6; 6; 8; 3.5. 5.8 percent with insulin dose of 1.1; 0.5; 0.2; 0.5; 0.67 U/kg/d, respectively. After 15; 10; 5; 5 and 5 days, they successfully discontinued insulin, respectively. Hba1C levels are improved in 3 first patients to 6.3; 6.2; 6.1 percent after 12 weeks of treatment) other patients has received sulfonylureas for 5 days. Improved glycemic control was sustained at one year.
Conclusions: KCNJ11 & ABC8 mutations for NDM has been determined in Vietnam and treatment with sulfonylureas.

PAO-131

A child with concomitant precocious puberty secondary to factor V leiden mutation and type II diabetes mellitus
Ayla Guven; Fatma Dururan; Heves Kirmizibekmez; Nurcan Cebeci
Goztepe Educational and Research Hospital, Pediatric Endocrinology, Istanbul, Turkey

Background: In children, the prevalence of type 2 diabetes (T2D) is increasing worldwide. At diagnosis, most patients have a positive family history of T2D. Heterozygosity for Factor V Leiden mutation (FVLM) leads to a 3-fold increase in relative risk of venous thrombosis. The most common causes of precocious puberty are organic cranial lesion such as tumors, trauma, cerebral anomalies, anoxic encephalopathy, in males.
Case: An eight year-old-boy was presented with polyuria. He was diagnosed as cerebral venous thrombosis secondary to FVLM two years ago. The patient’s father also was diagnosed as T2D and FVLM. Due to cerebral stroke the patient was on artificial ventilation with BIPAP, has spastic paraplegia and no verbal response. His weight was 40 kg (97th p), height couldn’t measured because of spasticity. Testes volume was Tanner stage 2, pubic hair Tanner stage 3. Basal LH (2.8 IU/L), FSH (2.38 IU/L and testosterone (0.55 ng/ml) levels of the patient were found pubertal. The other hormonal evaluation was normal. He was diagnosed as central precocious puberty with basal hormonal overactivity. Cranial and pituitary Magnetic Resonans was revealed encephalomalacic changes secondary to cerebral thrombosis. We considered that his central precocious puberty was secondary to cerebral thrombosis and anoxic encephalopathy. His blood glucose was measured 350 mg/dl with ketone in urinary analysis and no acidoses, he was diagnosed as diabetes mellitus and treated with insulin. All antibodies for type 1 diabetes were negative. HbA1c was high for his age (%10.4). Because of high C-peptide (14.7 ng/ml) the patient was diagnosed as type 2 diabetes. He was discharged with metformin and basal insulin glargine treatment.
Conclusions: In this report we presented an eight-year-old boy with concomitant precocious puberty, T2D and positive family history for these diseases.
Isolated 17,20-lyase deficiency with testicular regression

Ayla Guven1; Heves Kirmizibekmez2; Fatma Dursun2; Berrin Gucu2; Hamit Okur3
1Goztepe Educational and Research Hospital, Pediatric Endocrinology, Istanbul, Turkey; 2Goztepe Educational and Research Hospital, Pathology, Istanbul, Turkey; 3Goztepe Educational and Research Hospital, Pediatric Surgery, Istanbul, Turkey

Background: The CYP17A1 gene encodes P450c17 and is expressed in adrenal and gonads. Mutations of this gene is the cause of combined 17-hydroxylase/17,20-lyase deficiency or in very rare cases isolated 17,20-lyase deficiency. Disturbance of sex steroid production leads to disorder of sex development in 46 XY individual and failure of pubertal development in 46 XX individual.

Case report: A 2 years old male patient referred as bilateral undescended testis. He has been investigated for disorders of sex development. Physical examination revealed bilateral non-palpable gonads and hypospadiac scrotum, penile size was 3.2 x 1.5 cm (lower limit for age). In baseline hormonal analysis; total testosterone and androstenedione levels were low, while FSH and LH were elevated. ACTH (250 µg) and hCG stimulation tests were performed in order to evaluate adrenal and gonadal steroidogenesis. There was not meaningful increase in testosterone, androstenedione. DHEAS was low (0.54 µg/dL; N: 5.57-15.94 µg/dL). Cortisol production was normal. Normal deoxycorticosterone level and absence of water retention, hypertension or hypokalemia dissuaded us from thought of 17-hydroxylase deficiency. The caryotype was 46 XY, testicles could not be detected by ultrasonography. In laparoscopic examination gonads could not be found, but some remnant structures had been excised. Histopathologic investigation of these remnants revealed immature testis tissue with focal dystrophic calcifications and significant hyalinization which adjust to testicular regression syndrome.

Conclusion: Isolated 17,20-lyase deficiency is a rare cause of deficiency in sex steroid production. Normal penile formation and absence of Müllerian structures are proofs of normal testicular functions in critical time (12th-14th gestational weeks). This patient who had been presented with two different clinical entities made us think either a coincidental condition or evoked testicular regression syndrome by impaired steroidogenesis.

Registry of congenital adrenal hyperplasia in Vietnam

Chinh Dong Vu1; Phuong Thao Bui2; Ngoc Khanh Nguyen3; Thich Nguyen Can1; Tho Hoan Nguyen3; Thanh Liem Nguyen3; Kate Armstrong1; Maria Craig2; Maria Coppola2; Mariacarolina Salerno1
1National Hospital of Pediatrics in Hanoi, Endocrinology, Metabolism and Genetics, Hanoi, Vietnam; 2National Hospital of Pediatrics in Hanoi, Surgery, Hanoi, Vietnam; 3CLAN, CLAN (Caring & Living As Neighbours), Sydney, Australia; 4The Children’s Hospital at Westmead, Endocrinology and Diabetes, Sydney, Australia; 5Royal Children’s Hospital, Endocrinology and Diabetes, Melbourne, Australia

Aims: The National Hospital of Pediatrics (NHP) in Hanoi is an 900 bed tertiary referral centre servicing approximately 40 million people from northern provinces of Vietnam. This audit was undertaken to analyze anecdotal reports of increasing patient numbers.

Methods: Retrospective review of all CAH patients registered at NHP from 1999-2010. Ethical clearance was granted by the NHP Directorate.

Results: At the start of 1999 there were 90 children with CAH managed at NHP. By December 2010 this increased to 551 (47% male and 53% female; 72% salt wasting CAH), representing a more than five fold increase over 11 years. Number of new cases doubled from 30 to 60 in 2009. Most children (72%) were diagnosed at less than 12 months of age (39% at less than 1 month of age); 70% of all children were younger than 10 years. Formal mortality figures were low (6 known deaths), although loss to follow-up unknown. There are data to suggest persisting mortality from undiagnosed CAH (evidenced by low ethnic minority group representation; few children from remote provinces; higher average income of CAH families; gender ratio shift; reports of sibling deaths).

Patient to paediatric endocrinologist (551:6) ratios at NHP are very high compared with higher income countries.

Conclusions: The caseload of CAH at NHP has increased since 1999 and additional capacity is needed for patient care given high patient to staff ratios. Introduction of NBS would enable more accurate estimation of CAH incidence, reduce infant mortality and minimize trauma to affected infants and their families.

Thrombophilia.

Horm Res 2011;76(suppl 2) Printed Abstracts Only

Bilateral adrenal hemorrhage in a neonate

Nicola Improda1; Manuela Cerbone1; Iolanda Di Donato1; Lucia De Martino1; Antonio Coppola1; Mariacarolina Salerno1
1Federico II University, Department of Pediatrics, Naples, Italy; 2Federico II University, Regional Reference Centre for Coagulation Disorders, Department of Clinical and Experimental Medicine, Naples, Italy

Background: Adrenal hemorrhage is a rare yet potentially life-threatening event that occurs both in traumatic and in a variety of nontraumatic conditions. The incidence of acute adrenal hemorrhage in infancy range from 0.2 to 3%. Only 5% to 15% of cases reported have bilateral hemorrhage. We report on a neonate with bilateral adrenal hemorrhage associated with thrombophilia.

Case report: On day 3 of life the child, a female, presented signs of neonatal sepsis. On day 7, an occasional abdominal ultrasound revealed bilateral adrenal hemorrhage. However, the adrenal function was still normal. On day 36, the child appeared pale and lethargic. Subsequent hormonal and biochemical assessment showed adrenal insufficiency and she, therefore, started therapy with Hydrocortisone and Fludrocortisone. Serial ultrasound evaluations showed a gradual decrease in size of the adrenal hemorrhage with calcifications in a gradual decrease in size of the adrenal hemorrhage with calcifications in a gradual decrease in size of the adrenal hemorrhage with calcifications in a gradual decrease in size of the adrenal hemorrhage with calcifications in a gradual decrease in size of the adrenal hemorrhage with calcifications in a gradual decrease in size of the adrenal hemorrhage with calcifications. The incidence of acute adrenal hemorrhage in infancy range from 0.2 to 3%. Only 5% to 15% of cases reported have bilateral hemorrhage. We report on a neonate with bilateral adrenal hemorrhage associated with thrombophilia.

Case report: On day 3 of life the child, a female, presented signs of neonatal sepsis. On day 7, an occasional abdominal ultrasound revealed bilateral adrenal hemorrhage. However, the adrenal function was still normal. On day 36, the child appeared pale and lethargic. Subsequent hormonal and biochemical assessment showed adrenal insufficiency and she, therefore, started therapy with Hydrocortisone and Fludrocortisone. Serial ultrasound evaluations showed a gradual decrease in size of the adrenal hemorrhage with calcifications involving the whole gland bilaterally by the third month of life. Investigations performed to evaluate the cause of adrenal hemorrhage showed heterozygous Factor V Leiden mutation inherited from her father, resulting in resistance to activated protein C, and homozygous MTHFR C677T polymorphism with no elevation of plasmatic homocysteine levels.

Discussion: The adrenal gland of the newborn is particularly vulnerable to hemorrhage. In this condition of vulnerability, it seems likely that sepsis and combined thromboembolic risk may have interact in causing bilateral adrenal hemorrhage. Moreover, accumulating evidences suggest that the association of multiple haemostatic defects increases the risk of thrombosis. Thus, thrombosis might be considered as a cause of neonatal adrenal hemorrhage and pro-thrombotic risk factors should be investigated in case of familiar history of thrombophilia.
Background: The aim of this study was to determine the frequency of acute and chronic complications of diabetes mellitus type 1 (DM1) at children 0-17 y.o. during the last 3 years based on the Ukraine Pediatric Diabetes Register (UPDR).

Methods: UPDR was established in 2004, it contains information about children with diabetes, 0-17 y.o.: their age, duration of DM1, frequency of acute complications (diabetic ketoacidosis (DKA2, DKA3), severe hypoglycemia (Hypo) and diabetic ketoacidosis (DKA1)), presence of chronic complications (diabetic cataract (DK), retinopathy (DR), nephropathy (DN), peripheral neuropathy (DNP), angioopathy of legs (DA), neuropathy (DNPA)), frequency of children without complications (CW), and type and dose of insulin, the level of HbA1c.

Results: Based on the UPDR the number of children 0-17 y.o. with DM1 in 2007 was 6650, in 2008 – 6762, in 2009 - 6974, therefore prevalence increased over 3 years by 4.7% (especially in group of children 0-6 y.o. by 15.7%).

Table 1. The frequency of acute complications (%) and HbA1c level (%).

<table>
<thead>
<tr>
<th>Years</th>
<th>DKA 2-3</th>
<th>Hypo</th>
<th>HbA1c</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>6.04</td>
<td>0.45</td>
<td>8.9±1.52</td>
</tr>
<tr>
<td>2008</td>
<td>9.23</td>
<td>0.43</td>
<td>8.8±1.45</td>
</tr>
<tr>
<td>2009</td>
<td>11.39</td>
<td>0.57</td>
<td>8.9±1.44</td>
</tr>
</tbody>
</table>

Table 2. The frequency of acute complications (%) in children with different age.

<table>
<thead>
<tr>
<th>Age</th>
<th>DKA 2-3</th>
<th>Hypo</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-5 y.o.</td>
<td>9.83</td>
<td>17.32</td>
</tr>
<tr>
<td>6-10 y.o.</td>
<td>5.32</td>
<td>9.24</td>
</tr>
<tr>
<td>11-14 y.o.</td>
<td>5.82</td>
<td>8.98</td>
</tr>
<tr>
<td>15-17 y.o.</td>
<td>5.94</td>
<td>7.90</td>
</tr>
<tr>
<td>Total</td>
<td>6.04</td>
<td>9.23</td>
</tr>
</tbody>
</table>

Table 3. The frequency of chronic complications (%).

<table>
<thead>
<tr>
<th>Years</th>
<th>DK</th>
<th>DR</th>
<th>DN</th>
<th>DA</th>
<th>DNP</th>
<th>DL</th>
<th>DH</th>
<th>DS</th>
<th>CW</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>0.94</td>
<td>7.56</td>
<td>10.69</td>
<td>15.42</td>
<td>18.67</td>
<td>3.01</td>
<td>7.59</td>
<td>11.49</td>
<td>51.29</td>
</tr>
<tr>
<td>2008</td>
<td>1.92</td>
<td>8.52</td>
<td>11.43</td>
<td>19.14</td>
<td>19.31</td>
<td>7.29</td>
<td>8.55</td>
<td>16.12</td>
<td>47.68</td>
</tr>
<tr>
<td>2009</td>
<td>2.01</td>
<td>8.92</td>
<td>12.95</td>
<td>19.04</td>
<td>20.46</td>
<td>8.26</td>
<td>8.30</td>
<td>14.75</td>
<td>51.55</td>
</tr>
</tbody>
</table>

Conclusions: The main reason of increasing the frequency of chronic diabetic complications in Ukraine for the last 3 years is the using of the unified methods of diagnostics.

PAO-138

Clinical presentation and its relationship with chromosomal abnormalities in Turner syndrome

Phuon Thao Bui; Thi Hoan Nguyen; Chi Dung Vu; Ngoc Khanh Nguyen; Thi Bich Ngoc Can; Thi Phuong Nguyen

1National Hospital of Pediatrics, Endocrinology-Genetics-Metabolism, Hanoi, Vietnam; 2Hanoi Medical University, Pediatrics, Hanoi, Vietnam

Background: Turner syndrome is a relatively common chromosomal disorder. The disease affects only females, causing hypogonadism and short stature. Early treatment can improve short stature and hypogonadism.

Objective and hypotheses: Describe chromosomal abnormalities, clinical characteristics and its relationship with chromosomal abnormalities in patients with Turner syndrome.

Methods: 116 patients with Turner syndrome diagnosed in National Hospital of Pediatrics, Hanoi. Methods: A crosssection study was used.

Results: Mean age on diagnosis was 12.2 ± 4.9 years. Monosomy 45, XO occupied 54.31% ; 45, X/46, XX was seen in 14.66% ; 27.59% had structural disorders of chromosome X. Short stature was found in all patients aged more than 15 years. Severity of short stature and percentage of patients with short stature went up with age. There was no difference in term of height between karyotype groups. In group aged ≥ 12 years, 95.2% of cases had hypogonadism. Other symptoms frequently seen were nail hypoplasia (77.4%), cubitus valgus (74.7%), broad chest (69.2%) Abnormalities in face and neck were epicanthic fold (55.6%), low posterior line (51.3%), excessive skin in the back of the neck/webbed neck (42.5%). In a group aged <1 year, lymphoedema of hands/feet, epicanthic fold, broad chest, cubitus valgus were found in 100%. Majority of symptoms, congenital defects of heart/kidney were seen more frequently in 45, X group.

Conclusions: Lymphoedema of hands/feet in infants, low growth velocity, delayed puberty, abnormalities in face and neck, and other symptoms should be checked to early diagnose and treat Turner syndrome. Patients with 45, X had more severe presentation compared to patients with 45, X/46, XX and structural abnormalities of X chromosome.

PAO-139

Changing trends in epidemiology of type 1 diabetes mellitus in children and adolescents in Cyprus

Elligeorgi Ellistathio1; Andreas Kyrakiou1; Tassos C Kyriakides2; Andria Savvidou1; Leonidas A Phylactou1; Vassos Neocleous1; Christos Shammas3; Nicos Skordis1

1Makarios III Hospital, Paediatric Endocrine Unit, Nicosia, Cyprus; 2Yale University, School of Medicine, Department of Epidemiology, New Haven, United States; 3The Cyprus Institute of Neurology and Genetics, Molecular Genetics, Function and Therapy, Nicosia, Cyprus

Background: The incidence of Type 1 diabetes mellitus (T1DM) has dramatically increased worldwide and it is estimated that it may reach the status of an epidemic in the 21st century.

Objective and hypotheses: To calculate the incidence of T1DM in Greek-Cypriot children aged less than 15 years between 1990 and 2009 and to examine any changes in the incidence between the two decades, to analyse gender differences in the age of onset and any seasonal variation at the manifestation of the disease.

Methods: All newly diagnosed cases of T1DM in children less than 15 year old were registered with the capture – recapture method from 1990 until 2009 and relevant information was obtained. The data were statistically processed in relation to the population data provided by the Department of Statistics and Research of the Ministry of Finance.

Results: The overall mean annual incidence of T1DM during this 20 year period is 12.46/100000. By using the Wilcoxon two-sample test the mean incidence rate in the second decade 2000-2009 was significantly increased when compared to the first one (14.4 vs 10.6/100000). There was an overall male predominance (M/F: 1.03) but not in the group who manifested T1DM at ages 10-15 years, where females prevail. The percentage of children who
A rare cause of primary ovarian failure in a 16 years old patient: 48,XXXX karyotype

Marie-Béatrice Saade; David Briand; Laurent Pasquier; Livie Chatelais; Marc de Kerdatet; Sylvie Nivot; Patrick Pladya
CHU Rennes, Paediatric department, Rennes, France

Background: 48,XXXX is a rare karyotype. Since first described in 1961, fewer than 60 patients have been described in literature as suffering from this condition. The main feature described is mental retardation. Some women have tall stature, as in other extra X chromosome karyotype (47,XXX, 47,XXXX). Only three patients have been reported so far with primary ovarian failure. Irregular or normal menses are more often described.

Case report: Our patient was first seen in the paediatric endocrine ward at 16 years old for primary amenorrhea. She had a mild mental retardation and attended a special school. She had hyperphagic excess and obesity, her parents also had obesity. Her pubertal status was A2P2S1 with important adipomasty giving a “false” stage 3 breast development. She had a tall stature (183 cm) above her target height (168.5cm) and had little finger insertion anomaly. Her bone age was 15 years as determined by the Greulich and Pyle method. Blood analysis showed high levels of gonadotrophins: luteinizing hormone: 25.6 mIU/ml and follicle-stimulating hormone: 33.6 mIU/ml and low level of estradiol 10 pg/ml, consistent with primary ovarian failure. Neither pelvic ultrasound nor MRI showed any ovaries. She had prepubertal uterus. She had chromosome analysis regarding to the amnorrhoea associated with the mental retardation and it showed a 48,XXXX karyotype. Estrogen therapy was started to develop sexual secondary characters, close epiphyseal growth plates and prevent osteoporosis.

Conclusion: Theses features add data on height and ovarian function in 48,XXXX women. Mental retardation is often described in women with 48,XXXX but tall stature and primary ovarian failure are described in a few cases. This patient had obesity which is not, to our knowledge, described in literature. Not only small patients (Turner syndrome) but also tall women with primary amenorhhea should benefit from chromosome analysis.

PAO-140
Comparison of injection dose force between three growth hormone injection pens: NordiFlex®, FlexPro® and GoQuick®
Anne-Marie Kangelgaard1; Marianne Fye Hansen; Niels Aage Hansen

Background: A reduced injection force potentially makes it easier for patients to administer their injected medication.

Objective and hypotheses: This report compares dose force and dose accuracy of three growth hormone injection devices: Norditropin® NordiFlex® (NF), Norditropin® FlexPro® (FP) (both Novo Nordisk A/S, Denmark) and Genotropin® GoQuick® (GQ) (Pfizer Inc, NY, USA).

Methods: Mean of maximum dose force was determined for a 1.5 mg dose at speeds of 4, 6 and 8 mm/s for NF and GQ pens and the dose activation force was measured for FP in 25 pens of each type. Dose accuracy was assessed at 0.1, 0.75 and 1.5 mg doses (60 measurements at each level) in 30 pens of each type. All pens were fitted with a Novofine 32 G x 6 mm needle. Testing was done at 20°C, 45% relative humidity. Dose force was measured with a tensile testing machine in compression mode (within specifications Lloyd, LRX plus (ID: 24K-04-115) and transducer (measuring cell) of max 100 N (ID: 24K-04-082). Dose accuracy was assessed using an analytical balance (ID: M7813) and METDose data system (ID: LP38188).

Results: Estimated relative dose force (N/N) for FP was significantly lower than for GQ (3.6, 4.4, 5.2; p<0.0001) and NF (2.5, 2.9, 3.5; p<0.0001) at all speeds (4, 6, 8 mm/s). Dose force for NF was reduced compared with GQ (1.4, 1.5, 1.5; p<0.0001). Dose accuracy at 0.10, 0.75 and 1.50 mg doses was 97, 99 and 99% for FP, 100, 95 and 97% for GQ, and 101, 99 and 99% for NF. Dose precision (CV, %) was 2.5, 0.8 and 0.8 for FP, 11.1, 2.6 and 1.6 for GQ and 3.8, 0.7 and 0.7 for NF.

Conclusions: Dose force was significantly lower for FP and NF than for GQ. Dose accuracy was not dissimilar between devices but dosing precision was improved with FP and NF vs. GQ.

PAO-143
Virilization of a toddler girl by paternal use of testosterone cream
Sophie Stoppa-Vaucher1; Timothy Hirter1; Franziska Phan-Hug1; Claire-Lise Fawer2; Michael Hauschild1
1University of Lausanne, Pediatric Endocrinology and Diabetology Unit, Lausanne, Switzerland; 2University of Lausanne, Pediatrics, Lausanne, Switzerland

Background: A 15-month-old healthy female was referred because of rapid growth of dark pubic hair and a high testosterone (T) level (9 nmol/L, normal value (N) < 0.45).

Objective and hypotheses: Demonstrate the cause of the patient’s virilization.

Methods: Clinical and laboratory work up as well as imaging studies were performed to exclude the main causes of an androgen excess.

Results: Past medical history and review of systems were unremarkable. Family history revealed a 4-year-old brother and unrelated parents, all in good health. Weight (11 kg, 0.78 SDS), height (78.1 cm, + 0.4 SDS) were normocygorganism was considered and a surgical procedure was proposed. However, facing the slow size increase of the pituitary lesion an option for a regular follow-up was taken with laboratory and image control. Nowadays she is 16 years-old, bone age is 18yr and puberty is complete with regular menses. Laboratory determinations regarding pituitary function remain normal except for the IGF-1 (consistently around +5.4SDS). MRI performed when she was 15 years-old showed an enlarged pituitary gland (1.2x1.1x0.8cm) with small suprasellar extension. Final height was 1.58m (-0.7SDS), below middle parental height.

Conclusions: After 10 years of follow up we believe that the lack of IGF negative feedback due to a partial IGF-insensitivity could explain the high concentrations of GH and IGF-I with normal height and the pituitary image. Height velocity analysis was misleading by puberty during the investigation.
mal, no growth acceleration was observed. Tanner stage II pubic hair and an enlarged clitoris (12 mm) were found. She had no palpable breast tissue or posterior labial fusion, axillary hair, or acne. Pelvic ultrasound showed prepubertal uterus but no adrenal or ovarian mass were visualized. Adrenal hyperandrogenism was ruled out based on normal values of 17-OHDP (0.7 nmol/L; N<3), Androstenedione (<0.5nmol/L; N 0.38 ± 0.20) and DHEAS (<0.5 µmol/L, N 0.06 ± 0.04). Prolactine, thyroid function test and tumoral markers (β-hCG (< 2 U/L, N<5), αFP (5.5 KU/l; N<10)) were normal. Her father, a former elite athlete, reported that he was using a T-cream (T 10% in PCCA Lipoderm-Base®) for muscle problems the last 2-3 months. Four weeks after the father had ceased the treatment, T level decreased to 1.7 nmol/L. The child’s clinical virilization signs regressed. We observed no sign of attenuated androgen exposure in her medical history of virilized children.

Conclusions: We describe a virilized toddler girl with isolated high T level due to transfdermal intoxication. The differential diagnosis of virilization in childhood includes both endogenous and exogenous causes. Increased utilization of easily available cutaneous androgen applications should prompt clinicians to inquire about exogenous androgen exposure in the medical history of virilized children.

PAO-144
Silent corticotrope adenoma – report of two cases

Liliana Maria Mejía1; Ernest Senz2; William Zubía3
1Clinica Valle del Lili, Centro de Endocrinología, Universidad Libre Fundación Clínica Infantil Club Noel, Valle Del Cauca, Cali, Colombia; 2Clinica Valle del Lili, Valle Del Cauca, Cali, Colombia; 3Centro de Endocrinología, Valle Del Cauca, Cali, Colombia

Background: Some Pituitary adenomas exhibit immunoreactivity to hypothalamic hormones but because of the absence of clinical syndromes. They are known as silent adenomas. In 1979 Hassouny and collaborators describe the silent pituitary adenomas. In reference to corticotrope adenomas 43% are silent because they produced a biologically inactive hormone. They can be large and have a tendency to invade and recur.

Objective and hypotheses: We describe two cases of silent corticotrope adenomas in children.

Methods and results: CASE1: Nine years old boy presented with frontal-paretal headaches , loss of vision , no hypertension , no obesity or evidence of Cushing syndrome Laboratory: 8 am cortisol 4.2 µg/dL ,TSH 2·μU/mL prolactin 25.9 ng/ml MRI revealed Intrasmall mass of 3·7x3.2x3.4 mm .Treatment surgery Pathology revealed a ACTH producing adenoma Pituitary K167 3%.Tumor recurred 6 months later .ACTH 15 pg/ml, cortisol 12µg/dl , similar results pathology but K167 15%. Case 2 A fourteen years old girl had a cranepharyngioma removed a year before .She presented with headaches visual loss and obesity , acantosis nigricans , no hypertension and no clinical manifestation of Cushing’s syndrome .A solid suprasellar mass of 15x19mm MRI .Surgical pathology revealed an ACTH producing Adenoma Pituitary K167 1% .Post surgery ACTH 13.4 µg/ml cortisol 7µg/dl prolactina 20·4ng/ml

Results: Silent corticotrope adenoma are not associated with a clinical picture of hormone excess but they can cause pituitary damage and they have a tendency to recur .Clinical diagnostic is difficult.

PAO-146
Late development of celiac disease in type 1 diabetes mellitus

Gioiu Maitrin1; Stefano Zucchini; Mirella Scipione; Angela Rizzillo; Silvana Sallardi; Alessandro Cicognani
S.Orsola-Malpighi Hospital, Pediatrics, Bologna, Italy

Background: Patients with type 1 diabetes mellitus (T1DM) are at a high risk for developing autoimmune diseases such as coeliac disease (CD). Although CD mainly occurs at T1DM onset, it can also develop in the following years, but in our experience never after 6 years from T1DM onset (Salardi et al, J Pediatr Gastroenterol Nutr 2008). There is no consensus as to the duration of follow-up for autoimmune diseases in T1DM. We report a case of a male who developed CD 15 years after the diagnosis of T1DM.

Case report: A 19 yr-old male diagnosed with T1DM at 4 years of age. HLA phenotype was DR 3, 4 and DQ 2, 3. His siblings were also tested for autoimmune diseases and the older sister developed CD and few years after autoimmune thyroiditis. Lab examinations for associated autoimmune diseases were performed annually. 13 years after T1DM onset Hashimoto’s thyroiditis was diagnosed, not leading to clinical hypothyroidism. Unexpectedly, after 15 years from T1DM onset, he showed a marked positivity for CD autoantibodies (anti-transglutaminase autoantibodies 128 u/ml, normal value <10). During the previous year he was completely asymptomatic: he did not refer gastrointestinal symptoms or an increased frequency of hypoglycaemic episodes. There were no biochemical signs of CD (ferropenic anaemia, hypertransaminasemia, hypocalcaemia). Antibody positivity was also confirmed in another laboratory. Bowel biopsy showed a total villous atrophy. Conclusions: The development of CD so far from diabetes onset (>15 years) has never been described before to our knowledge and the literature reports a follow up period never longer than 10 years. We conclude that screening for autoimmune disease should be annually performed in T1DM patients possibly lifelong, even in the absence of clinical symptoms, especially in those with a strong family history of autoimmune disease.

PAO-147
A case of congenital hypothyroidism with Hirschsprung’s disease: an unusual association

K.D Mod1; Madan Mohan Rao2; Sunil Kumar Kota
1Medwin Hospitals, Endocrinology, Hyderabad, India; 2HOPE Children’s hospitals, Paediatrics, Hyderabad, India

Background: Hirschsprung’s disease (HD) as well as congenital hypothyroidism can present with functional intestinal obstruction and abdominal distension in neonate. Both the diseases are considered as differential diagnosis, rather than as coexistence. We report one such interesting case with unusual coexistence of these 2 conditions.

Objective and hypotheses: Thyroid hormone is necessary for neuronal migration and lamination during brain development. Although hypothyroidism impairs colonic motility resulting in pseudo-obstruction the effects of hypothyroidism on neuronal migration through bowel have not been adequately studied.

Methods: A 21 days baby girl, product of consanguineous marriage presented with a tendency to recur. Clinial diagnostic is difficult.
with vomiting and abdominal distension. Weight was 2.5 kg and length 48 cm. On examination, there was facial puffiness, open posterior fontanelles, dry skin, cold peripheries and prominent abdominal veins with visible peristalsis. There was no maternal history of hypothyroidism. Patient was subjected to various investigations.

Results: Routine hemogram, liver & kidney function tests were within normal limits. Plain abdominal radiographs revealed gas filled bowel loops with barium enema showing dilated proximal colon, empty rectum, delayed emptying time with funnel like transition zone between proximal dilated & distal constricted bowel (Image 1). TSH was >150 µU/mL. Thyroid scintigraphy revealed athyrosis, confirming congenital hypothyroidism due to athyrosis. Biopsy following cisternotomy revealed aganglionic segment, confirming the diagnosis of Hirschsprung’s disease. Baby was discharged with oral levothyroxine treatment.

Conclusions: With the present case, we propose that thyroid hormones may have a role in the development of HD. Further studies are needed to establish this.

PAO-148

Metabolic syndrome in obese Ukrainian schoolchildren: prevalence and risk factors

Ihor Hrytsyuk
Western Ukrainian Specialized Children’s Medical Centre, Paediatrics, Lviv, Ukraine

Background: Obesity in children and adolescents is currently on a rise in Ukraine, posing challenges to personal health and state health care system.

Objectives: To assess prevalence of metabolic syndrome (MS) among obese children and adolescents residing in Lviv, Ukraine, and risk factors leading to its development.

Methods: Obese children and adolescents were selected during annual (2009) medical check-up in 10 city schools. These were referred for further investigations. The major components of MS (abdominal obesity, hypertension, dyslipidemia, and glucose intolerance) were evaluated in a cross-sectional study. Potential risk factors for developing MS (weight at birth, parental obesity, degree of obesity, age, sex) were assessed in a multivariate logistic regression analysis.

Results: The nutritional status of 8523 school students aged 11 to 18 years showed that the prevalence of obesity (BMI >95%) is 9.1% (n = 776, boys = 381, girls = 395). The prevalence of MS among obese children reaches 14.3% (n = 111, boys = 62, girls = 49). The prevalence of MS tends to increase with increasing of BMI class (3.1% in class I, 6.2% in class II and 18.2% in class III). In a multivariate analysis more advanced age (OR = 4.08, CI = 3.13 –6.24), BMI (OR = 2.71, CI = 1.34 –4.75) and parental obesity (OR = 2.11, CI = 1.07 –4.14) were found to be the most significant risk factors for having MS in obese children and adolescents.

Conclusions: Although lower than in neighbouring countries, the prevalence of MS in Ukrainian schoolchildren is growing, which warrants preventive measures. The older the obese child, the higher are chances for MS. The most important preventable risk factors are degree of obesity (BMI) and parental obesity.

PAO-149

Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia and its association with mineral homeostasis and duration of inpatient stay

Musab Elmantaser; David Young; Brenda Gibson; S. Faisal Ahmed
Bone and Endocrine Research Group, Department of Child Health, Glasgow, United Kingdom; University of Strathclyde, Department of Statistics and Modelling Science, Glasgow, United Kingdom; University of Glasgow, Department of Haematology, Royal Hospital for Sick Children, Glasgow, United Kingdom; Bone and Endocrine Research Group, Department of Child Health, Royal Hospital for Sick Children, Glasgow, United Kingdom

Background: Reduced activity, older age and abnormal bone mineral status are considered as important determinants of poor bone health in children with acute lymphoblastic leukaemia (ALL).

Aim: To investigate the influence of activity, age and mineral status over the first 12 months of chemotherapy on subsequent SM.

Patients and methods: The medical records of 56 children presenting with ALL between 2003 and 2007 and treated on UKALL 2003 were reviewed for the number of in-patient days over the first 12 months of chemotherapy as a surrogate marker of inactivity and lack of well-being. Data for serum Ca, Alb, Mg and Pho were also collected over this period. SM was defined as any episode of musculoskeletal pain (MSP) or fractures.

Results: The median duration of in-patient days in the first 12 months of treatment in children with no SM was 58 days(40,100) whereas the median number of in-patient days during the first 12 months in those children with any SM, MSP only or fractures was 83 days(54,131), 81 days(52,119) and 91 days(59,158), respectively(p<0.001). Children with SM and fractures particularly had lower levels of serum Ca, Mg and Pho compared to those without SM over the first 12 months of chemotherapy. There was a higher risk of SM in those who were diagnosed after the age of 8 years(p=0.001,OR=16.95%,CI:3.80). Multiple regression analysis showed that the incidence of SM only had a significant independent association with age at diagnosis (p=0.001) and the number of inpatient days (p=0.03) over the first 12 months (r=23). All children who were diagnosed after the age of 8 years with an inpatient stay of greater than 75 days in the first 12 months of the chemotherapy (n,14) children had some form of SM (OR=64).

Conclusion: The incidence of SM in children receiving chemotherapy for ALL is associated with a higher likelihood of being older and having longer periods of in-patient stay. The close link between age and changes in bone mineral status may be one explanation for the increased bone morbidity in ALL children.

PAO-150

Trends of body mass index in children with craniopharyngioma from the west of Scotland

Muhammad Jaffar Khan; Khadija Humayunn; Malcolm Donaldson; S. Faisal Ahmed; M Gufar Shaikhi
1University of Glasgow, Human Nutrition, Glasgow, United Kingdom; 2Aga Khan University, Department of Pediatrics and Child Health, Karachi, Pakistan; 3Royal Hospital for Sick Children, Paediatric Endocrinology, Glasgow, United Kingdom

Background: Hypothalamic obesity is one of the major causes of reduced quality of life in survivors of childhood craniopharyngioma, predisposing the patient to a wide variety of complications, including cardiovascular disease.

Objectives and hypothesis: The aim of this study was to examine the trends of change in body mass index (BMI) in childhood onset craniopharyngioma patients over 5 years. The hypothesis being all children with a craniopharyngioma gain weight irrespective of their BMI at presentation.

Methods: This was a retrospective study of 23 children with a diagnosis of craniopharyngioma presenting to the West of Scotland regional endocrine unit over a 5 year period. Data on height, weight, gender and age was collected. BMI SDS for each patient was subsequently calculated and analysed over the first 5 years of follow-up. The close link between age and changes in bone mineral status over the first 5 years of follow-up was assessed.

Results: At presentation, (M: F 11:12) 47.5% (n=11) patients were obese, with 52.5% (n=12) non-obese patients. BMI increased further in 7 of the
obese patients. There was a rise in mean BMI SDS in the first year after di-
agnosis, followed by a fall in BMI over the 5 year period in both groups; how-
ever the obese group at presentation remained obese. In the non-obese
group only 10 had an increase in BMI SDS from presentation, with 8 patients
becoming obese during the 5 years.

**Conclusions:** Craniosynostosis patients who are obese at presentation con-
tinue to gain weight and remain obese. This probably reflects a greater degree of
hypothalamic damage in these individuals.

### PAO-151

**Pseudotumor cerebri and diabetes insipidus. Association or coincidence?**

**Gabriela Pozzo; Giuseppe Cannella; Chiara Maria Damia; Gisella Garbetta; Maria Piera Fierarello; Alessandra Musco; Berardo di Natale; Giovanna Weber; Giuseppe Chiumello**

Vita Salute San Raffaele University, Pediatric Endocrine Unit, Milano, Italy

**Background:** Pseudotumor cerebri (PTC) is characterized by intracranial
hypertension in the absence of clinical, laboratory or radiological evidence of
space occupying lesion. It can occur in the pediatric population with an
increasing incidence among adolescents, especially in obese females. Idio-
pathic PTC can be associated with anterior pituitary deficiency but there is
no evidence in literature of association with central diabetes insipidus (CDI).

**Objective and hypotheses:** We report a case of PTC and concomitant CDI.

**Methods:** 13-year-old obese female (BMI 2.64 SD) presented progressive
headache, important visual impairment followed by complete blindness, sixth
cranial nerve palsy, bilateral papilloedema, right hemicraniopharyn-
gia with no ketones, HbA1c level 7.5%, negative anti GAD antibodies and
ICA antibodies. Treatment: diet and a dose of 0.5 IU/kg/day of insulin for 2
months, followed by the diet only, while keeping glucose values between 85-
112 mg% and HbA1c level decreased to 6.5%.

**Case 2:** the 12-year-old sister was hospitalized after two months without clini-
cal signs of diabetes, but with the ambulatory blood glucose levels between
112-138 mg%, HbA1c level 6%, OGTT with fasting blood glucose 124 mg% and
2-h postprandial blood glucose 174 mg%, negative anti GAD antibodies and
ICA antibodies. Personal history: first child, with normal evolution of the
pregnancy, gestational age at birth 36 weeks, birth weight 2600g, Apgar score
9, breastfed for four months, psychomotor and weight development according
to child development stages. Clinical examination: weight 35 kg, length 143
cm, BMI 17.5 kg/m2. It was established a diet that maintained a good glyc-
emic control, after 3 months HbA1c was 6.5%.

**Conclusions:** The main goal of treatment in these cases of MODY diabetes
was to maintain blood glucose levels as close to normal reducing the risk of
complications. An early diagnosis of the disease is very important for family
screening and also for therapy and prognosis.

### PAO-153

**Long-term (five-year) height outcome in children treated with Norditropin®
(AnsewR) Program®, a US-based registry, has collected long term efficacy and
safety information on patients treated with Norditropin® (somatropin
tDNA origin, Novo Nordisk A/S) at the discretion of participating physicians.

**Objective and hypotheses:** To assess the long-term (5 years) height standard
deviation score (HSDS) and ΔHSDS by age, gender, and pubertal status in
children treated with GH.

**Methods:** Treatment-naïve pediatric patients with isolated/idio-pathic GH
deficiency (GHD; n=4454), multiple pituitary hormone deficiency (MPHD;
n=387), small for gestational age (SGA; n=461), idiopathic short stature (ISS;
n=758), and Turner syndrome (TS; n=435) were analyzed.

**Results:** Mean ages (yrs) were generally younger in patients with
MPHD (7.4), SGA (8.5), and TS (8.6) than with GHD (10.8) and ISS (11.2).

**Background:** The American Norditropin Studies: Web-enabled Research
(ANSWER) Program®, a US-based registry, has collected long term efficacy and
safety information on patients treated with Norditropin® (somatropin
tDNA origin, Novo Nordisk A/S) at the discretion of participating physicians.

**Objective and hypotheses:** To assess the long-term (5 years) height standard
deviation score (HSDS) and ΔHSDS by age, gender, and pubertal status in
children treated with GH.

**Methods:** Treatment-naïve pediatric patients with isolated/idio-pathic GH
deficiency (GHD; n=4454), multiple pituitary hormone deficiency (MPHD;
n=387), small for gestational age (SGA; n=461), idiopathic short stature (ISS;
n=758), and Turner syndrome (TS; n=435) were analyzed.

**Results:** Mean ages (yrs) were generally younger in patients with
MPHD (7.4), SGA (8.5), and TS (8.6) than with GHD (10.8) and ISS (11.2).

**Lowest peak GH levels were observed in patients with MPHD (3.1 mg/mL)
and GHD (5.3 mg/mL). In the overall population, HSDS increased from -2.2
at baseline to -1.1 at Y3 and 0.9 at Y5, with GHD, MPHD, and SGA showing
better growth response. Boys had significantly greater ΔHSDS than girls after
3 years or longer treatment duration (p<0.001). When stratified by baseline
age, younger patients showed greater ΔHSDS than older patients for both

genders (Table). In addition, children with GHD who remained pre-puberal
after 5 years of treatment had the greatest ΔHSDS (2.02±1.14) as compared
to patients who were already pubertal at treatment start (1.42±0.69) or who
transitioned into puberty during the study (1.58±0.68).

**Conclusions:** These results show that boys generally have greater height
gain than girls after long-term treatment. A better growth response is observed in
younger and pre-puberal children, emphasizing the importance of starting
GH treatment at a young age and pre-puberal status.

**Table.** Mean (SD) ΔHSDS over 5 years by Age and Gender.

<table>
<thead>
<tr>
<th>Age (yrs)</th>
<th>All MAles</th>
<th>Males &lt; 11 yrs</th>
<th>Males &gt; 11 yrs</th>
<th>Female all</th>
<th>Females &lt; 16 yrs</th>
<th>Females &gt; 16 yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 yrs</td>
<td>0.53 (0.49)</td>
<td>0.73 (0.57)</td>
<td>0.39 (0.35)</td>
<td>1659 (0.55)</td>
<td>0.70 (0.55)</td>
<td>0.29 (0.40)</td>
</tr>
<tr>
<td>&gt; 11 yrs</td>
<td>0.96 (0.65)</td>
<td>1.16 (0.71)</td>
<td>1.00 (0.55)</td>
<td>1142 (0.70)</td>
<td>1.12 (0.73)</td>
<td>0.78 (0.61)</td>
</tr>
<tr>
<td>Y2</td>
<td>1.27 (0.77)</td>
<td>1.39 (0.83)</td>
<td>1.13 (0.66)</td>
<td>733 (0.84)</td>
<td>1.26 (0.86)</td>
<td>0.78 (0.78)</td>
</tr>
<tr>
<td>Y3</td>
<td>1.47 (0.83)</td>
<td>1.55 (0.89)</td>
<td>1.35 (0.68)</td>
<td>411 (0.89)</td>
<td>1.35 (0.92)</td>
<td>0.81 (0.87)</td>
</tr>
<tr>
<td>Y4</td>
<td>1.65 (0.91)</td>
<td>1.70 (0.97)</td>
<td>1.52 (0.92)</td>
<td>194 (0.95)</td>
<td>1.41 (0.99)</td>
<td>1.38 (0.70)</td>
</tr>
<tr>
<td>Y5</td>
<td>1.70 (0.99)</td>
<td>1.52 (0.95)</td>
<td>1.50 (0.98)</td>
<td>184 (1.04)</td>
<td>1.39 (1.07)</td>
<td>1.30 (0.96)</td>
</tr>
</tbody>
</table>

50th Annual Meeting of the ESPER.

Horm Res 2011;76(suppl 2) 305
PAO-154
Role of prophylactic medical examination for early diagnosis of endocrine disorders
Alexey Resnenko1; Lelia Namazova-Baranova2
1Scientific Center of Children’s Health, Diagnostic, Moscow, Russian Federation; 2Scientific Center of Children’s Health, Head, Moscow, Russian Federation

Background: Considerable increasement of endocrine disorders in pediatric population within last years was observed. Routine children and adolescent check up does not include examination by endocrinologist.

Objective and hypotheses: To estimate rate of endocrine disorders in pediatric population we explored 911 Moscow schoolers.

Methods: All children were splitted into groups by sex (sex ratio was 54% boys to 46% girls), age (junior school - from 6 to 11 years, middle school from 11 to 14 years, senior school- from 14 to 17 years). Physical examination, anthropometric measuring, and thyroid ultrasound were performed. On the base of measurements BMI, height velocity and standard deviation score of mesurements were estimated.

Results: 12% of children had signs of endocrine disorders. Leading position belongs to overweight and obesity (61% of revealed endocrinological disorders). 25% of children with endocrinological disorders had thyroid gland enlargement. 9% had growth abnormalities (7% cases of short stature and 2% cases of high stature), abnormalities of sexual development were revealed in 5%. 9% of children with detected endocrine disorders had two of more diagnoses. Our data shows that overweight and obesity more common for middle and senior school groups and had no significant differences between sexes (sex ratio for overweight and obesity was 51% boys to 49% girls). Thyroid abnormalities predominate at the age of 11-17 years and more common for female population (sex ratio was 13% boys to 87% girls). Most children with growth abnormalities revealed at age 7-14 years, and sex ratio was 82% boys to 18% girls. 5% of boys and 95% of girls with endocrine disorders had sexual development abnormalities with predominance at the age of 11-17 years.

Conclusions: Results of our study show importance of endocrine function assessment in school-age children on a regular basis. This tactics helps to reveal possible endocrine disorders at early stages and form groups of children with high risk of endocrine disorders for prophylactic medical examination.

PAO-155
Rett syndrome associated with thyroid hypothyroidism – a synergic association for neurological disturbances: case report
Otilia Marginean1; Ioan Simea2; Tamara Marcovic1; Daniela Chiru2
1Pediclinic Pediatric University of Medicine and Pharmacy Timisoara, Endocrinology, Timisoara, Romania; 2Pediclinic Pediatric University of Medicine and Pharmacy Timisoara, Gastroenterology, Timisoara, Romania

Background: Rett syndrome is a neurodevelopmental disorder that characterized by normal early growth and development followed by a slowing of development, loss of purposeful use of the hands, distinctive hand movements, slowed brain and head growth, problems with walking, seizures, and intellectual disability.

Case presentation: CA 4 years 3 month old girl admitted in our department in September 2010 for developmental regression, loss of purposeful hand movements. On admission the examination of the child have weight 19kg, height 98.5 cm (age weight 104.9SDS -1.70 according to Prader criteria), dry rough pale skin, coarse, dry hair, hair loss, constipation, small feet and hands and severe neurologic problems; blood samples show normal BC, liver function, low FT3 , elevated TSH (73.5mU/ml), Low IGF1(23.5ng/ml) according to the age; small thyroid volume 1 ml (more then -2SD). We add to the treatment L thyroxine. The evaluation after 2 month show mild improved movements but her communications with family was improved.

Conclusions: 1. Rett syndrome is a rare genetic disease. 2. Brain damage can be induced by hyothyroidism and Rett syndrome.

PAO-156
Central hypothyroidism secondary to maternal hyperthyroidism
Pilar Sevilla Ramos1; Maria Alia2; Esther Cid2; Nerea Lopez Andres3; Jose Maria Jimenez-Bustos4
Hospital Universitario Guadalajara, Paediatric Endocrinology, Guadalajara, Spain

Background: Neonatal central hypothyroidism is very rare in paediatric patients. We present the case of a breast-fed baby developing central hypothyroidism when aged 2 months old, secondary to maternal Graves’ disease detected after birth.

Results: PA: Pregnancy monitored. Caesarean at 34 weeks due to premature breakdown of membranes, APGAR 9/10. WAB: 2.570 g (P 75-90); LAB: 45 cm (P 50-75). FH: Father healthy, height 170 cm. Mother healthy, height 165 cm. Evolution during neonatal period: Admission at birth due to early asymptomatichypoglycaemia birth. Metabolopathy screening for low TSH, with TSH of 0.03 mU/L and T4L of 1.84 ng/dl detected. Presents TA 90/43-78/40, FC 157-130 bpm during the first 5 days of life. Irritability and diarrhoea observed. Mother: TSH undetectable, T4L 2.82 mg/dl, antithyroglobulin Ab 45, antiperoxidase Ab 75, TSI Ab 13 (N=10). Follow-up at surgery: 15-day follow-up: Weight: 2.570 kg (P3), Length: 46 cm (P3), macroglossia. TSH 0.02 mU/L, T4L 1.31 ng/dl, T3 1.05 ng/dl, antimicrosomal Ab 71 (N 0-5.6) 2.5 month follow-up: Weight: 4.250 (P3), Length: 53.

Conclusions: In maternal Graves’ disease the transplacental transfer of Ac TSI affects the development of the hypothalamic-pituitary-adrenal axis (HPA). Rarely, exposure to high levels of intratrheine thyroid hormones in Graves’ disease can halt the hypothalamic-pituitary-adrenal axis, leading to a hypothroidism in the fetus that continues for a variable period of time among newborns.

PAO-157
Congenital chloride diarrhea with congenital hypothyroidism in two siblings: case report
Erdal Adal1; Atilla Ersen2; Hasan Onal3; Sezen Ugan1; Tugba Kontbay1; Ahmet Aydir1
1Ministry of Health Bakirkoy Maternity and Children Education Hospital, Pediatric Endocrinology, Istanbul, Turkey; 2Kasimpasa Military Hospital, Pediatrics, Istanbul, Turkey; 3Ministry of Health Bakirkoy Maternity and Children Education Hospital, Pediatrics, Istanbul, Turkey; 4Istanbul University, Cerrahpasa Medical Faculty, Division of Metabolic Diseases, Istanbul, Turkey

Background: Congenital chloride diarrhea (CCD) is a rare autosomal recessively inherited disorder causing watery stool and dehydration characterized by impairment of Cl-/HCO3 exchange.

Objective: Infrequency of CCD makes diagnostics difficult and CCD companying with congenital hypothyroidism has never been reported so far.

Population: A 7-year-old male who was followed with the diagnosis of congenital hypothyroidism, Bartter syndrome and idiopathic chronic diarrhea in different medical centers and treated with L-thyroxine and indomethacin, admitted our unit with electrolyte abnormalities and mental retardation. His medical history was notable for prolonged jaundice and congenital hypothyroidism in neonatal period. L-thyroxine was started but euthyroidism status was hardly supplied with alterations of thyroid hormones. Additionally, dehydration and metabolic alkalosis were recognized in his second months of age with the history of intrauterine polyhydramniosis; he was diagnosed as Bartter syndrome and indomethacin treatment was started. But all the medications until now could not heal the problems of watery diarrhea, abdominal distention and electrolyte abnormalities. Additionally, we recognized that this family had a 3-month-old sibling and he was followed up with the initial diagnoses of congenital hypothyroidism and Bartter syndrome.

Results: We figured out CCD in our investigation of these two siblings that...
feecal Cl-level was over 90 mEq/L. Indomethacin was stopped and Cl-supplementation was started. Watery diarrhea was recovered and L-thyroxine treatment was optimized to supply euthyroidism.

**Conclusion:** These two cases are worthy of particular attention in the literature because of the first reported cases of CCD companying with congenital hypothyroidism. One point in this regard is that mutations in the SLC26A4 gene have been associated with CCD and surprisingly similar gene mutation of SLC26A4 is also seen in Pendred syndrome (Hereditary hearing loss with thyroid abnormalities). We have investigated for genetic mutations in our patients.

**Background:** Whilst X chromosome structural aberrations in female patients are most frequently characterized by a short stature and Turner’s phenotype, only several patients with strikingly different phenotype have been reported so far.

**Objective and hypotheses:** To describe clinical and genetic findings in a girl with a rare structural X chromosome rearrangement.

**Methods:** Physical examination, biochemical analysis, cytogenetic studies, imaging methods, neurological and psychological investigation were performed.

**Results:** The patient was referred at the age of 13 years because of obesity (BMI 26.3 kg/m2, +2.53 SD), only initial pubic hair (Tanner P2), breast enlargement was caused by fatty tissue. No psychomotor delay or mental retardation were mentioned, however she had to attend a special school. Basal gonadotropin levels were normal. IGFI levels and thyroid function were normal. Chromosomal aberration - an isochromosome i(Xp). The result was confirmed by FISH analysis 46, X, i(X) (p10), ish (STS++, DXZ+, SRY-). Bone age corresponded to calendar age. Ultrasound visualized a hypoplastic uterus, ovaries were not visible. MRI of central nervous system demonstrated slight cortical atrophy.

**Conclusions:** We describe a girl with tall stature, obesity, mild mental retardation, gonadal dysgenesis and a rare structural rearrangement of X chromosome. Tall stature can be explained by a triple gene dosage of SHOX (short stature homeobox containing gene) in PAR1 (short arm pseudoautosomal region) together with estrogen deficiency. Oral estrogen replacement therapy was initiated to accelerate puberty and promote epiphyseal fusion, unfortunately the therapeutic effect was diminished due to non-compliance.

**PAO-159**

17-years old girl with autoimmune polyendocrine syndrome type 2 – how to obtain the best metabolic control of diabetes

**Daniel Witkowski**

The Children's Memorial Health Institute, Department of Endocrinology and Diabetology, Warsaw, Poland

**Background:** The association between Addison’s disease (AD) and type 1 diabetes (T1DM) is well recognised. The prevalence of T1DM in patients with autoimmune polyendocrine syndrome type 2 (APS-2) ranges above 50%.

**Objective and hypotheses:** We report the case of 17 years old girl with primary adrenal insufficiency recognised at age of 11 and AITD who developed T1DM after 6 years. The immunological status has been observed for several years before clinical diabetes onset.

**Method and result:** The results are presented in the table:

<table>
<thead>
<tr>
<th>Date</th>
<th>4.11.2004</th>
<th>6.03.2009</th>
<th>2.12.2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c</td>
<td>5.00%</td>
<td>5.40%</td>
<td>9.30</td>
</tr>
<tr>
<td>anti GAD /U/mL/ N: &lt;0.9</td>
<td>0.56</td>
<td>2.11</td>
<td>1.18</td>
</tr>
<tr>
<td>anti IAA /U/mL/ N: &lt;0.75</td>
<td>&lt;0.2</td>
<td>&lt;0.7</td>
<td>&lt;0.7</td>
</tr>
<tr>
<td>anti TG-AB /U/mL/ N:30-70</td>
<td>75.9</td>
<td>183</td>
<td>1.48</td>
</tr>
<tr>
<td>anti TPO-AB /U/mL/ N:30-50</td>
<td>277.9</td>
<td>1660</td>
<td>139.17</td>
</tr>
<tr>
<td>TSH-H-AB /U/L/ N:&lt;9.0</td>
<td>5.5</td>
<td>5.33</td>
<td></td>
</tr>
<tr>
<td>p-ANA</td>
<td>1:280(+), 1:640(+)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

It is well known that glucocorticoid replacement therapy in patients with primary adrenal insufficiency and T1DM may lead to quite often and significant changes in insulin requirement and insulin sensitivity. That is why the multiple pen injection regimen was replaced by continuous subcutaneous insulin infusion (CSII) after one month since the diabetes onset. There are several options of “smart” pumps like: 1) temporary basal change, 2) additional basal rate i.e., „for disease”, 3) automatically calculate meal or correction boluses, 4) continuous glucose monitoring devices with real-time display which can participate in improving and maintain good metabolic control in such patients.

**Conclusions:** 1. In the immunological course of diabetes, there was no increase of autoantibodies against β cell, in particular, anti-IA2 just before clinical manifestation of diabetes 2. The patient with APS requires observation for clinical signs of diabetes and glucose monitoring by the determination of HbA1c at least once/twice a year 3. Type 1 diabetes treatment make沉esment using personal insulin pump allows to obtain good metabolic control of diabetes in spite of insulin requirements changes consequently steroid replacement therapy 4. Insulin pump treatment will improve the quality of life in patient with APS type 2.

**PAO-160**

Abstract withdrawn.

**PAO-161**

The evaluation of body composition and metabolic parameters in girls with central precocious puberty receiving GnRH agonist therapy

**Dogus Vural**; Huseyin Demirbilek; Didem Aydogdu; Nazli Gonc; Ayfer Alkalasalp; Alez Ozon; Nurgun Kandermir

Hacettepe University, Pediatric Endocrinology, Ankara, Turkey; Hacettepe University, Pediatrics, Ankara, Turkey

**Background:** The changes in body composition and metabolic parameters in girls with central precocious puberty during GnRHa therapy is still under debate. Objective: To evaluate the changes in BMI and metabolic parameters in girls with central precocious puberty during GnRHa therapy.

**Population and methods:** Thirty-nine girls (mean age 9.13±0.73 years) with central precocious puberty treated with GnRHs were enrolled in the study. BMI-SDS, lipid profile, serum leptin, adipsonecin and HbA1c levels were evaluated and standard OGTT was done at the beginning, sixth and twelth month of therapy.

**Results:** At diagnosis; mean BMI-SDS was 1.13±0.83. Four girls (10,2%) were obese (BMI>95%). None of the patients had impaired glucose tolerance, 8 girls (20%) had insulin resistance. Dyslipidemia was observed in 35,9% (14/39) of patients. At the sixth month, 5 cases (12,8%) had insulin resistance, 2 of whom developed impaired glucose tolerance. BMI-SDS did not change significantly in six month period (p=0.96). No changes in frequency of dyslipidemia (35.9%) was observed at sixth month of therapy. No statistically significant difference was found in serum leptin, adiponecin, HbA1c values between baseline and sixth month of therapy. (p values 0.141, 0.433, 0.443 respectively)

**Conclusion:** At the beginning of therapy one fifth of girls with central precocious puberty had impaired glucose metabolism. However BMI-SDS, lipid and carbohydrate metabolism parameters did not show significant change during six months period. The results of twelth month evaluation will shed light on the long term changes in patients with central precocious puberty under GnRHa therapy.
PAO-162

Re-evaluation of metabolic parameters of obese children after 5-7 years

Gulay Demirdag*; Sibel Tulgar Kinik; Ayse Canan Yazici

*Baskent University, Pediatrics, Ankara, Turkey; †Baskent University, Pediatric Endocrinology, Ankara, Turkey; ‡Baskent University, Biostatistics, Ankara, Turkey

Background: Obesity beginning in the childhood continues to adulthood and becomes more complicated.

Objective and hypotheses: In this study we aimed to re-evaluate obese children with respect to obesity status and metabolic parameters after 5-7 years from the first admission.

Methods: 100 cases who admitted to our clinic for exogen obesity were called again. 40 of them were male. Their relative BMI was calculated, serum levels of lipids, glucose, insulin, free T4, TSH were studied. There was significant. The cases were divided into 4 group according to metabolic disorders in the first visit.

Group 1: only dislipidemia (HDL<40 mg/dL, triglyceride>150 mg/dL, LDL>130 mg/dL)

Group 2: only insulin resistance (HOMA>3)

Group 3: dyslipidemia and insulin resistance

Group 4: norm

Results: At the last evaluation, rel BMI decreased significantly in group 1 and 2 compared to first visit (p=0.006 and 0.034 respectively). The percentage of cases whom metabolic parameters improved to normal limits were 56% in groups 1,2,4 and 18% in the group 3.

Conclusion: Loosing weight is easier in children whom have only dyslipidemia or only insulin resistance than children who have both of them. Having that metabolic disorders together makes the metabolic improvement harder. So, prevention of early stages of obesity and metabolic disorders plays important role in adulthood life quality.

PAO-164

Autoantibody positivity and clinical characteristics of childhood diabetes

Jiyun Park; Jong Seok Oh; In Chang Seong; Jeesuk Yu

Dankook University Hospital, Department of Pediatrics, Cheonan, Republic of Korea

Background: Most childhood diabetes was usually thought as type 1 diabetes (T1DM), but there is a tendency of increasing type 2 diabetes (T2DM) and sometimes, it might not be easy to determine the type of diabetes. It’s important to know the type of diabetes and it’s very useful to choose the best treatment modality.

Objective and hypotheses: In this study, we searched the clinical and laboratory characteristics of the patients with childhood diabetes to compare those according to the type of diabetes.

Methods: We retrospectively reviewed the medical records of the patients who was diagnosed as diabetes and followed at the department of Pediatrics, Dankook University Hospital to find the clinical and laboratory characteristics.

Results: Total 43 patients were enrolled in this study. The patients were grouped as T1DM (n=29), T2DM (n=10) and unclassified (n=4), according to the clinical characteristics and laboratory findings. There was a little female predominance (M:F 1.1:1.5). Autoantibody positivity was high in T1DM, implying it as the very valuable marker in T1DM. T1DM had an earlier onset age, as expected. In 55%, diabetic ketoacidosis (DKA) was the presenting symptom in T1DM, but no DKA in T2DM as an initial symptom. Initial and F U/HOa1c did not show statistically significant differences between the group. Initial serum c-peptide or insulin levels were lower in T1DM. Obesity was not the major portion in childhood T2DM but BMI was higher in T2DM. In T2DM, oral hypoglycaemic agents with or without insulin were chosen as a treatment. During follow up, adolescence, especially in girls, was thought as a very vulnerable period to manage the diabetes requiring more intensive emotional support including family cooperation.

Conclusions: In this study, we can confirm that the autoantibody test is very valuable to diagnose specific type of diabetes and to determine the diverse treatment modality. And female adolescence was thought as a vulnerable period to manage the diabetes requiring more intensive emotional support including family cooperation.
Horm Res 2011;76(suppl 2)  309

PAO-166

Patient with congenital hypothyroidism, adrenal insufficiency, and SRY deletion: a case report

Shamita Trivedi; Carla Minutti; Carolyn Jones

Loyola University Medical Center, Pediatrics, Maywood, United States

Background: SRY deletion is a rare genetic condition which can cause androgen insensitivity syndrome and ambiguous genitalia. Congenital hypothyroidism and adrenal insufficiency together with an SRY mutation are rare.

Objective and hypotheses: To determine whether congenital hypothyroidism and adrenal insufficiency have been reported in a patient with an SRY deletion. There may be a condition where congenital hypothyroidism, adrenal insufficiency, and SRY deletion occur together.

Methods: Literature search.

Results: This patient was born via in vitro fertilization at 37 weeks gestation to an Indian mother. Physical exam revealed jaundice, a broad nasal bridge, ambiguous genitalia with well rugated empty scrotum/labia, micropenis, no hypospadias, and bilateral undescended testicles. Karyotype was 46, XY and FISH analysis showed deletion for part of the SRY region that is usually caused by a copying error during spermatogenesis. LH and FSH levels were elevated, while DHEA-S, DHT, and testosterone levels were low at 0.4mg/ml, 1.1ng/dl, and 115ng/dl respectively. As beta-hCG stimulation test yielded no increase in testosterone, the patient was diagnosed with hypergonadotropic hypogonadism. Intramuscular injections of testosterone enanthate 25mg/month for 3 months were started with monitoring of pubic growth to follow. As his TSH level was high (19.5uu/ml) and free T4 level was low (1.3ng/dl), the patient was diagnosed with hypothyroidism. After starting levothyroxine, TSH and FT4 levels normalized. At two months of age, the patient developed hyperpigmentation. He subsequently failed an ACTH stimulation test and was therefore diagnosed with adrenal insufficiency.

Conclusions: To our knowledge this patient is a novel presentation of congenital hypothyroidism and adrenal insufficiency occurring with an SRY deletion in an in vitro baby.

PAO-167

Response to rhIGF-1 therapy in patients with primary IGF-1 deficiency

Oksana Lazareva; Shelia Perez; Julianna Predescu; Shahid Malik; Svetlana Ten; Amit Bhanoo

State University of New York, Downstate, Pediatric Endocrinology, Brooklyn, NY, United States

Background: Patients with growth hormone insensitivity or Laron syndrome are a heterogeneous group of children with a variety of clinical phenotypes and variable severity of short stature. A relatively high prevalence of IGF-1 deficiency has been reported in ISS patients without classical Laron syndrome features.

Objective and hypotheses: To study the response to rhIGF-1 therapy in short children with Primary IGFD.

Methods: 21 children with short stature, who passed GHRH (1 mg/kg IV) stimulation test (GH peak>15ng/ml) were included in the study. They were treated with Increlex® 0.24 mg/kg/day. Height velocity (HV) and Height (Ht) SDS were measured after 6 months of therapy.

Results: Patient's characteristics: age 9.84±2.5 SD years, Ht -2.49 ± 0.36 SDS were measured after 6 months of therapy.

GH after GHRH was 48.9±24.1 SD ng/ml. HV after 6 months of Increlex® therapy was 10.3 ± 3.9 cm/yr. There were only 3 patients in this group whose HV was less than 5 cm/yr on Increlex® therapy. The mean change in Ht SDS was +0.35±0.33 SD after 6 months of Increlex® therapy.

Conclusions: This pilot data revealed that the rhIGF-1 therapy has good efficacy in less severe Primary IGFD. The average HV after 6 months of therapy is similar to the data on severe Primary IGFD (Ht<-3SDS, IGF-1<-3SDS) patients treated with rhIGF-1.

PAO-168

Hot nodule harboring a papillary microcarcinoma in a girl from an iodine sufficient area

Ana Tenegi1; Horacio M. Solariz2; Javier Farias3; Horacio Bignon3; Paula Morano3; Patricia Papendieck4

1Sanatorio Güemes, Endocrinologia Pediátrica, Buenos Aires, Argentina; 2Sanatorio Güemes, Departamento de Patología, Buenos Aires, Argentina; 3Sanatorio Güemes, Endocrinología, Buenos Aires, Argentina; 4Hospital de Niños Ricardo Gutierrez, Departamento de Cirugía, Buenos Aires, Argentina; 2Sanatorio Güemes, Clínica Pediátrica, Buenos Aires, Argentina; 3Hospital de Niños Ricardo Gutierrez, División de Endocrinología, Buenos Aires, Argentina

Background: Hot nodules on radionuclide imaging of thyroid are generally benign but there are reported some cases of hot nodules associated with thyroid cancer with only a few cases in pediatric age. However a relative high incidence in children’s was reported in iodine deficiency area after introduction of iodine supplementation.

Objective and hypotheses: To report a case of thyroid cancer associated with a hot nodule in a pediatric patient from an iodine sufficient area.

Methods: 3 years old girl consulted for a one week evolution tumor in her neck, her aunt had thyroid cancer. On physical examination an approximately 2 cm mobile nodule on thyroid topography was palpated. Thyroid ultrasonography showed a cystic nodule of 19 x 14 x 13 mm with heterogeneous parathyroid mass of irregular limits in the right lobe. The rest of the gland was normal.99mTc thyroid scan showed a focal increase of the thyroid with an area of high Tc uptake in the nodule topography corresponding to a hyperfunctioning nodule with normal uptake in the rest of the gland. Thyroid function tests showed T4: 9.24 ug/dl (6-14) free T4: 1.44 ng/dl (0.8-2.2) T3: 178 ng/dl (80-220) TSH 4.42 mU/ml(0.27-4.2)Calcitonin and thyroid antibodies were negative. Fine needle aspiration biopsy (FNAB) showed: molarophages with hemosiderin and erythrocytocytes without follicular cells. Because the presence of the risk factor, irregular limits in polyloid mass and no conclusive FNAB a right hemithyroidectomy was performed.

Results: Histologic section revealed a nodular hyperplasia with lymphocytic thyroiditis. A papillary microcarcinoma of 0.25 mm was detected.

Conclusions: Hot nodules in iodine sufficient areas could be associated with malignant disease in pediatric populations too. We recommend the systematic practice of FNAB in pediatric patients with hot nodules especially if suspicious ultrasonography characters or familial history of thyroid cancer are present. The concomitance of an inflammatory process with cancer was previously reported but others studies too.

PAO-169

45,X male with ambiguous genitalia: a case report

Senay Savas Erdove1; Bulent Hacihamdioglu; Merih Berbenoglu; Zeynep Siklar; Timur Tuncali; Gulnur Gollu; Sadiye Ekinen; Gonul Ocal1

1Ankara University School of Medicine, Department of Pediatrics, Division of Pediatric Endocrinology, Ankara, Turkey; 2Ankara University School of Medicine, Department of Medical Genetics, Ankara, Turkey; 3Ankara University School of Medicine, Department of Pediatric Surgery, Ankara, Turkey

Background: A 45,X karyotype usually result in a female phenotype, with clinical symptoms of Turner syndrome. Rarely, the nonmosaic 45,X chromosomal constitution is associated with maleness. Maleness is usually caused by a reciprocal of the SRY gene on an autosome. These cases generally have
paO-170

The difficulties of investigating and treating an endocrine patient in resource limited countries

Edra Sima Masaia1; Kandi Catherine Muze1; Muharriani National Hospital, Paediatric and Child Health, Dar es Salaam, Tanzania

Introduction: Adrenal masses (AMs) are often discovered incidentally and are then termed adrenal incidentalomas (AIs). They are often discovered after an imaging procedure is performed that is unrelated to the adrenal gland. Less commonly, AMs are discovered as part of the clinical workup for suspected adrenal disease (eg, Cushing syndrome). However it took us more than three months and we are not yet at the final diagnosis.

Case presentation: A 3 years old child presented with overweight. Was born prematurely, Birth weight 2.4kg and a mild birth asphyxia, current weight 310 kgm, height 92.8 cm (+2.5 SD), upper segment 60 cm, lower segment 32.48 cm, span 85 cm. The electrocardiogram revealed low voltage QRS complexes. The girl was born on 14.9.2006, is a first infant born to non-consanguineous parents. She was delivered by caesarean section with birth weight 2.000 kgm, height 40 cm, OFC 41 cm at full term, the second baby is 3 years and is unaffected. Our patient presented with short stature and large head at birth. Examination on 16.2.2011. The child is active, cheerful with average intelligence. Paternal height 180 cm, maternal height 163 cm. The bone age is 5.6 years. Low set ears, skull is large with prominent forehead, flat nasal bridge, small chest compared to abdomen, medial arm and forearm creases are prominent.

Molecular testing: Fibroblast growth factor receptor-3 (FGFR3) mutation: G1138A and G1138C mutations.

Discussion: On September 2008 he was given growth hormone (GH) 0.09 u/kg/day to maintain an appropriate height velocity.

Result: One mutation G 1138 A is detected consistent with achondroplasia. Discussion: On September 2008 he was given growth hormone (GH) 0.09 u/kg/day, patient height was 78 cm. (<2SD), GH dose increased to 0.12 u/kg/day. On February height is 92.8 cm. ~2.5 SD, height velocity 6.048 cm/year.

Conclusion: Patients with achondroplasia with G 1138 A mutation may benefit from GH at a dose range from 0.09 kgm/day to 0.12 kgm/day to maintain an appropriate height velocity.

PAO-172

Achondroplasia in a girl with G 1138 A mutation, response to growth hormone therapy, two and half years follow up

Sameh Tawfik; Mona Altea; Heba Hassan; Solal Mohamed

Maadi, Pediatrics, Cairo, Egypt; Cairo University, Pediatrics, Cairo, Egypt; Ain Shams, Pediatrics, Cairo, Egypt; Ain Shams, Genetics, Cairo, Egypt

Background: Achondroplasia is the most common form of skeletal dysplasia in man, has autosomal dominant inheritance and causes extreme short stature. More than 90% of patients with achondroplasia have a G to A transversion or G to C transversion at position 1138 of the fibroblast growth factor receptor-3 (FGFR3) gene.

Objective: To evaluate the response to growth hormone of Egyptian patient with achondroplasia.

Methods: A prospective follow up study of a girl with achondroplasia.

Case presentation: The girl was born on 14.9.2006, a first infant born to non-consanguineous parents. She was delivered by caesarean section with birth weight 2.000 kgm, height 40 cm, OFC 41 cm at full term, the second baby is 3 years and is unaffected. Our patient presented with short stature and large head at birth. Examination on 16.2.2011. The child is active, cheerful with average intelligence. Paternal height 180 cm, maternal height 163 cm, patient height 92.8 cm (<2SD), upper segment 60 cm, lower segment 32.48 cm, span 85 cm, weight 18.9 kgm, OFC 55 cm. Bone age is 5.6 years. Low set ears, skull is large with prominent forehead, flat nasal bridge, small chest compared to abdomen, medial arm and forearm creases are prominent.

Molecular testing: Fibroblast growth factor receptor-3 (FGFR3) mutation: G1138A and G1138C mutations.


Result: One mutation G 1138 A is detected consistent with achondroplasia. Discussion: On September 2008 he was given growth hormone (GH) 0.09 u/kg/day, patient height was 78 cm. (<2SD), GH dose increased to 0.12 u/kg/day. On February height is 92.8 cm. ~2.5 SD, height velocity 6.048 cm/year.

Conclusion: Patients with achondroplasia with G 1138 A mutation may benefit from GH at a dose range from 0.09 kgm/day to 0.12 kgm/day to maintain an appropriate height velocity.
weight was 3,348g (75-90 percentile). Family history was unremarkable. He showed poor weight gain from the age of 4-month-old. He had severe-dehydrated. He had neither genital pigmental nor abnormalities of the external genitalia. Blood examination showed hypoponatremia(117mEq/L), hyperkalemia(5.7mEq/L) and metabolic acidosis. Cloudy urine obtained by catheterization yielded Escherichia coli. Renal ultrasonography revealed left hydroureter and hydrourerter. Endocrine test results showed high levels of aldosterone (22900pg/mL) and plasma renin activity (88ng/mL/hr). We gave him a diagnosis of TPHA caused by urinary tract malformation and urinary tract infection. Serum sodium and potassium levels normalized after 24 hours of intravenous fluids and antibiotic therapy. On the fifth hospital day, he became irritable again and was made a diagnosis of right posterior cerebral infarction by head CT scan. We treated him with aspirin and free radical scavenger immediately. He underwent left ureteroplasty at 1-year. Now, he have normal development at the age of 1-year-4-month.

Precise conclusions: Hyperaldosteronism causes endothelial dysfunction and impairs vascular reactivity. Predominant causes of this patient’s infarction were infection and severe-dehydration. Remaining cause might be involved in vascular damage from hyperaldosteronism because the action of aldosterone was not defective except in renal tubular tissue in patients with TPHA.

---

### PAO-174

#### The efficacy of gonadotropin-releasing analogues in children with central precocious puberty

**Anna Bolmasova, Maria Kareva, Elizaveta Onova, Valentina Peterkova**

**Endocrinological Research Center, Institute of Pediatric Endocrinology, Moscow, Russian Federation**

**Background:** GnRH analogues have been used for treatment of precocious puberty for almost 30 years. However, it is still discussed whether this treatment significantly improve adult height (AH) and how it can impact body mass.

**Objective and hypotheses:** To evaluate the efficacy of GnRH analogues regarding final height and weight of children with central precocious puberty (CPP).

**Methods:** Total number of 50 patients was evaluated in this retrospective single-centre study. Group 1 included 33 patients (26 females, 7 males). All of them had been treated with triptorelin 100mg/kg/28 days during 3.5 yrs (0.9-7.8 yrs). The median age at the start of treatment was 5.2 (2.0-8.0 yrs). This group was subdivided for Group 1A - 19 patients with still opened epiphysis and Group 1B - 14 patients who have already reached adult height. Group2 included 17 CPP patients (14 females, 3 males) that have never received any treatment. Predicted adult height (PAH) was calculated according to the Bayley and Pinneau tables. Target Height (TH) was evaluated as midparental height adjusted for sex (+/- 6.5).

**Results:** GnRHa treatment significantly improved PAH in Group 1a. AH in Group 1B was significantly higher to untreated Group 2 (p =0.0002). However, TH still was not reached in Group 1. BMI-SD was similar before and after the treatment (Table 1).

<table>
<thead>
<tr>
<th>Groups</th>
<th>Group 1A</th>
<th>Group 1B</th>
<th>Group 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAH (cm) before treatment (1)</td>
<td>156.9</td>
<td>157.0</td>
<td>155.0</td>
</tr>
<tr>
<td>PAH (cm) after treatment (2)</td>
<td>159.8</td>
<td>157.0</td>
<td>156.0</td>
</tr>
<tr>
<td>BMI SDS before treatment (3)</td>
<td>0.92</td>
<td>1.21</td>
<td>1.38</td>
</tr>
<tr>
<td>BMI SDS after treatment (4)</td>
<td>0.92</td>
<td>1.21</td>
<td>1.38</td>
</tr>
<tr>
<td>Target height (TH) (cm)</td>
<td>164.7</td>
<td>166.5</td>
<td>163.0</td>
</tr>
<tr>
<td>Adult height (AH) (cm)</td>
<td>156.0</td>
<td>146.2</td>
<td></td>
</tr>
<tr>
<td>p (TH-AH)</td>
<td>0.003</td>
<td>0.0001</td>
<td></td>
</tr>
</tbody>
</table>

**Conclusions:** In our study GnRHa treatment did not allow reaching TH but significantly improved AH and did not influence body mass in patients with CPP. Our results correspond to majority of similar studies reported by others.

---

### PAO-175

#### Physical activity and sedentary behaviours among obese prepubertal children

**Syonja Galcheva, Violeta Iotova, Mina Lateva, Yoto Yotov**

**1Varna Medical University, Department of Pediatrics, Varna, Bulgaria; 2Varna Medical University, Department of Internal Medicine, Varna, Bulgaria**

**Background:** Physical inactivity is implicated in the development of childhood obesity.

**Objective and hypotheses:** To investigate the relationships of physical activity (PA) and sedentary behaviours (television (TV) viewing and computer use) with the presence of abdominal obesity in healthy prepubertal children.

**Methods:** A case-control study of 168 healthy prepubertal children (75 males; mean age 8.1±1.2 years) was conducted. Body weight, height and waist circumference (WC) were measured; BMI was calculated. Children were divided into three groups according to the WC percentiles for Bulgarian children as a measure of central obesity (“normal-WC”, 31.5%; “children at risk”, 27.4% and “abnormally obese”, 41.1%). A structured parental interview was used to obtain data about children’s physical and sedentary behaviours.

**Results:** No significant difference was found in the frequency and duration of PA among the WC categories in both boys and girls (p>0.05). More than 58% of the parents reported the presence of a seasonal difference in children’s activity with higher mean PA levels during the spring and summer months. This seasonal behaviour was significantly more frequent among the abdominally obese children compared to the normal-WC group (68.1% vs. 47.1%, p=0.04). Children spent an average of 2.7±1.2 h/d watching TV and 0.9±1.0 h/d in using computers. Although insignificantly, the abdominally obese children spent more hours a day in front of the TV sets and computers compared to their normal-WC counterparts (2.8±1.3 vs. 2.6±1.0 and 0.9±1.0 vs. 0.6±0.9 h, respectively, p>0.05). Boys from all WC-groups used computers more often than girls (1.1±1.0 vs. 0.7±0.9 h/d, p<0.05).

**Conclusions:** Physical inactivity may be associated with the excess accumulation of abdominal fat mass in prepubertal children, which warrants further investigations.

---

### PAO-176

#### Retrospective study of 215 patients admitted in a pediatric intensive care unit for diabetic ketoacidosis between 1998 and 2008

**Frederique Tixier, Aline Guevart, Cecilia Heng Yong, Jean Claude Berthier, Philippe Klee, Frederic Valla, Marc Nicolino**

**1Hôpital Femme Mère Enfant, Division of Pediatric Endocrinology, Lyon Bron, France; 2Hôpital Femme Mère Enfant, Pediatric Intensive Care Unit, Lyon Bron, France**

**Methods:** This retrospective study presents data collected in one center on 215 type 1 diabetic patients admitted in the pediatric intensive care unit (PICU) between 1998 and 2008 for diabetic ketoacidosis (DKA). All patients were treated on the basis of a single standardized protocol.

**Results:** Among 270 episodes of DKA, 2 populations were distinguished: 1) patients in whom type 1 diabetes was revealed by DKA and 2) known type 1 diabetic patients admitted for compensation of their pre-existent disease. DKA in new type 1 diabetic patients represented 53% of all episodes of DKA and predominantly concerned young patients (58% below 10 years), males (56%), patients with polyuria and polydipsia with a mean duration of 20 days, and patients with a weight loss of a mean of 12.5%. Secondary DKA in known patients represented 47% of all episodes of DKA and predominantly concerned adolescents (90% above 10 years), females (56%) and patients with psychosocial risk factors (61%). 62% of all patients admitted inadequate self-management. In this group, 11 patients were admitted to the PICU between 3 and 12 times and represented 48% of all episodes of DKA. We did not find any significant difference in DKA severity between both above-mentioned populations. All 4 encountered complications during DKA correction (cardiovascular failure, hypoglycemia, cerebral edema and hypokalemia) had a favorable outcome in our study.

**Conclusions:** In order to limit the incidence of DKA and its complications, it is necessary to reduce the delay between the onset of type 1 diabetic symptoms and the time of diagnosis by providing better education to health care providers and to the general population.
We suggest to diffuse treatment guidelines to healthcare providers to limit iatrogenic risks, to educate patients on management of situations at risk for DKA and to intensify the follow up of patients at risk of relapse.

**PAO-177**

**Follow-up of girls with complete androgen insensitivity syndrome (CAIS) and gonads in situ during and after puberty – two case reports**

**Ulla Doehnert1; Lutz Wunsch2; Ralf Werner1; Olaf Hort1**

1University of Luebeck, Department of Pediatrics and Adolescent Medicine, Luebeck, Germany; 2University of Luebeck, Department of Pediatric Surgery, Luebeck, Germany

**Background:** In recent publications the prevalence of germ cell tumors in CAIS has been estimated <1% until puberty. Leaving the gonads in situ will allow endogenous hormone production and spontaneous puberty. However there is no data on the tumor prevalence in CAIS after puberty.

**Patients and methods:** In two sisters with a 46,XY karyotype we identified a M749V mutation in exon 5 of the androgen receptor gene. According to the family’s request the gonads remained in situ. The girls were first seen in our clinics at the age of 13.6 and 11.3 years. Follow-up visits every six months included clinical assessment of growth and puberty, gonadal ultrasound, hormone profiles (LH, FSH, SHBG, testosterone and estradiol) and tumor markers (HCG and AFP).

**Results:** Both girls showed a CAIS phenotype with normal female external genitalia and absence of Mullerian duct remnants. At the age of 15.8 years the older sister had normal breast development without growth of pubic hair. Hormone profiles showed elevated LH levels and FSH, testosterone, estradiol and SHBG levels within the adult male reference ranges. Gonadal ultrasounds and tumor markers revealed no pathology. The younger girl had not shown any signs of puberty at the age of 12.7 years, but stimulated gonadotropins and testosterone levels were detected with prepubertal estradiol and SHBG levels. Ultrasonic scans displayed unsuspicious testes in the inguinal canals.

**Conclusions:** The two sisters are undergoing spontaneous puberty, at which they profit from their specific endogenous hormone production. A follow-up protocol has been designed for early diagnosis of malignancy. However further studies are necessary to evaluate the safety of such protocols and establish criteria for intervention.

**PAO-179**

**Secondary transient pseudohypoaldosteronism – a report of two cases**

**Agnieszka Rudzka-Kocjan; Elzioba Moszycnska; Mieczyslaw Szalecki**

Children’s Memorial Health Institute, Department of Endocrinology and Diabetology, Warsaw, Poland

**Background:** Secondary pseudohypoaldosteronism (PHA) is a syndrome with a state of renal tubular unresponsiveness to aldosterone and is manifested by hyponatremia, hyperkalemia and metabolic acidosis. Major contributing factors are urinary tract infections, urinary tract malformations.

**Objective:** A report of two cases of transient PHA in infants, including one unusual case where PHA occurred in the course of diarrhea due to Crohn disease.

1. A 2-months-age boy admitted to hospital with diarrhea and weight loss. Clinical and laboratory findings revealed dehydration, hyponatremia at 118 mmol/l, hyperkalemia at 7.05 mmol/l, metabolic acidosis (bicarbonate 15.7 mmol/l). Urinary tract infection was excluded. Renal sonography was normal. Congenital adrenal hyperplasia (CAH) was excluded. Pathologically high aldosterone in plasma, plasma renin activity (PRA) and elevated levels of corticosteron metabolites, THAldo (128.3; range: 4.3-12.3, 18-OXO-THF and 18-OHF in urinary steroid profile confirmed PHA. Oral supplementation of high dose sodium was applied. Secretive diarrhea was diagnosed. Colonoscopy was typical for Crohn disease. Treatment with high dose glucocortico-steroids and 5-ASA was applied. Sodium supplementation was withdrawn.

2. A 1-month-age boy admitted to hospital with dehydration and failure to thrive. Laboratory findings revealed hyponatremia at 114 mmol/l, hyperkalemia at 9.48 mmol/l, metabolic acidosis (bicarbonate 15.0 mmol/l), elevated levels of urea and creatinine, positive urine culture. Urosepsis was diagnosed. Laboratory tests confirmed PHA. Oral supplementation of sodium was applied. Obstructive uropathy was diagnosed and urological therapy applied. Salt supplementation was discontinued after about 5 months. Both electrolytes and PRA, aldosterone levels remain within range.

**Conclusions:** PHA should be suspected in cases of severe hyponatremia, hyperkalemia and weight loss in infants. Secondary PHA is usually associated with urological problems, however it one presented patient PHA occured in the course of secretive diarrhea.

**PAO-180**

**Invasive pituitary adenoma secreting growth hormone, TSH, prolactin and α-subunit in a 12-year-old girl**

**Elzioba Moszycnska; Agnieszka Lecka-Ambrozik; Mieczyslaw Szalecki**

The Children’s Memorial Health Institute, Department of Endocrinology and Diabetology, Warsaw, Poland

**Background:** Prolactinoma is the most common secreting pituitary adenoma, growth hormone (GH) secreting adenomas are less common and thyrrotropinoma only constituting 1% of all pituitary adenomas.

**Objective:** 12-year-old girl first presented with headaches and worsening of vision of a left eye that lasted for 4 months. Clinical symptoms included: overgrowth, signs of acromegaly, hyperthyroidism and galactorrhea. Ophtalmological examination revealed signs of raised intracranial pressure. Hormonal tests showed: high GH levels with lack of inhibition in an oral glucose tolerance test, high IGF-1, both free thyroid hormones and TSH levels were high with no reaction after TRH administration and very high concentration of prolactin (PRL) and α-subunit.

Head MRI revealed a sellar invasive tumour, size 80x55x50 mm, penetrating to interior jugular arteries and optic nerves. A stereotacic biopsy was performed, with tumour hemorrhage complication. Histopathological and immunohistochemical examinations confirmed the diagnosis of invasive pi-
Constitutionally developed hyperkalemia. She was born at 33rd gestational week, weight started at 4th month. She had severe hyponatremia (Na: 108 mmol/L) 6 month female patient was hospitalized for vomiting and lose in

Introduction: Lipoid congenital adrenal hyperplasia is an autosomal recessive disease due to deficiency of StAR protein that transports cholesterol into the mitochondria for adrenal steroid synthesis. StAR is also essential for gonadal steroidogenesis and is encoded by a gene on chromosome 8p11.2.

Case: 6 month female patient was hospitalized for vomiting and lose in weight started at 4th month. She had severe hyponatremia (Na: 108 mmol/L) and dehydration. She has been referred for persistent hyponatremia and subsequently developed hyperkalemia. She was born at 33rd gestational week, birth weight was 1750 gr. Parents were second degree related, infant death or sexual development disorder was not described in family history. Physical inspections revealed paleness, vital findings were normal. Dehydration or hyperpigmentation was not present. Height: 58 cm (10-25p), weight: 4 kg (< 3p), external genitalia seemed normal female and systemic examination findings were normal. Na: 130 mEq/L, K: 6.4 mEq/L, Glucose: 82 mg/dl, baseline ACTH was high, DHEA-S was normal. In classical ACTH stimulation test, mineralocorticoid, glucocorticoid and androgen precursors had not been increased. Significant hyperplasia of both adrenal glands observed in magnetic resonance imaging. Carotype was 46 XY, t(4;9)(p16.6;p13.3) and a paternal translocation was determined.

Laparoscopic investigation showed intra-abdominal located testes, any Mullerian structure was not found. There was no increase in testosterone after three days of stimulation with hCG 1500 UI/dose and gonadectomy was performed. She is still receiving hydrocortisone (14mg/m2/day) and fludrocortisone (0.1 mg/day) treatments.

Result: StAR protein deficiency is the most severe and rare form of steroid biosynthesis disorders. Mineralocorticoids, glucocorticoids and androgens can not be synthesized and ACTH level is high. Normal DHEA levels helps for differentiating from 3 beta-hydroxysteroid dehydrogenase deficiency. Carotype analysis and advanced investigations if needed should be performed.

Conclusions: Although the adrenal tumours are the most common cause of hypercortisolaemia, on the basis of the results of hormonal tests, a neurosurgical procedure in case of hypercortisolaemia and normal imaging examinations.

50th Annual Meeting of the ESPE

Horm Res 2011;76(suppl 2) 313
PAO-184

Different skeletal maturation patterns in patients with constitutional delay of growth (CDG) and growth hormone deficiency (GHD)

Sandra Barth; Stefan A. Wudy
Justus Liebig University, Division of Paediatric Endocrinology and Diabetology, Center of Child and Adolescent Medicine, Giessen, Germany

Background: The determination of bone age is one of the most important criteria to diagnose and work clinically with short stature.

Objective and hypotheses: The study aimed to identify disparities in the level of phalangeal bone (PH), metacarpal bone (MC) carpal bone (CP) and radius/ulna (RU) - development in patients with CDG or GHD.

Methods: Left hand radiographs of patients with CDG (bone age retardation > 1 yr; no organic diseases; family history of delayed growth and puberty) were compared with those of untreated GHD patients (maximum stimulated GH peak <5µg/l). In each patient PH, MC, RU, - and CP-bone age were calculated by the method of Greulich/Pyle.

Results: In the CDG cohort (13 males, 2 females, mean age 10.2 yr) bone age was retarded on average by 2.0 years. Differences in the developmental stages of PH, MC, CP and RU bone were identified as shown in table 1. Likewise, the CDG group (14 males, 2 females, mean age 5.7 yr) showed delayed bone maturation as revealed in table 1. In GHD patients primarily carpal bone development was delayed, whereas in CDG patients the maturity of metacarpal bones was primarily delayed.

Conclusions: The pattern of bone maturation as assessed by left hand radiographs is different between patients with CDG and GHD. We suggest that the extreme delay in carpal bone maturation could be used as a marker for GHD in the assessment of short stature.

<table>
<thead>
<tr>
<th></th>
<th>Chronicage</th>
<th>PH Mean</th>
<th>MC Mean</th>
<th>CP Mean</th>
<th>RU Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>in yr</td>
<td>in yr</td>
<td>in yr</td>
<td>in yr</td>
<td>in yr</td>
</tr>
<tr>
<td>Patients with CDG</td>
<td>10.2</td>
<td>8.1 (21%)</td>
<td>7.4 (27%)</td>
<td>8.2 (20%)</td>
<td>8.5 (17%)</td>
</tr>
<tr>
<td>Patients with GHD</td>
<td>5.7</td>
<td>4.8 (16%)</td>
<td>4.4 (23%)</td>
<td>3.5 (39%)</td>
<td>4.0 (29%)</td>
</tr>
</tbody>
</table>

PAO-185

Abstract withdrawn.

PAO-186

Transsexualism in an African setting; case report

Olumide Jarrett1; Oluyomi Esan2; Omolola Ayoola2
1University College Hospital, Paediatrics, Ibadan, Nigeria; 2University College Hospital, Psychiatry, Ibadan, Nigeria; 3Royal Manchester Children’s Hospital, Endocrine Science Research Group, Manchester, United Kingdom

Background: Transsexualism is the condition in which a person with apparently normal somatic sexual differentiation of one gender is convinced that he or she is actually a member of the opposite gender. It is associated with an irresistible urge to be and live in that gender hormonally, anatomically and psychosocially. The patient has persistent discomfort with his or her sex and a sense of inappropriateness in the gender role of that sex. It occurs in all societies and cultures however it is a rare occurrence in Africa.

Objective: We describe a case of Male-to-Female Transsexual who presented at the paediatric endocrine clinic of the University College Hospital.

Case report: EA is a 27 year old male who presented with the desire for sex reassignment surgery. He has already stated wearing female clothes, cosmetics and jewellery. He also changed his name to a female one and moved to another town. Physical examination revealed an individual with Tanner stage I for breast and a well developed normal male external genitalia with a solitary right testis. Hormonal profile revealed normal testosterone (31.2nmol/l, normal values 15 – 40nmol/l) and low estradiol levels (0.3nmol/l). He is awaiting laparoscopy and other investigations which have largely been delayed as a result of lack of funds to pay for them. He is being co-managed with the Psychiatry and Surgical teams.

Conclusions: Transsexualism is a rare condition and it is often marginalized even in developed economy. This report exposes the socio-cultural and religious influences associated with management. The dilemma it causes to the immediate family and relatives which has not been highlighted in previous reports is also described. The financial implication of management in this part of the world could also be frustrating to the individual. To our knowledge, this is the first case reported in Nigeria.

PAO-187

An unusual presentation in an adolescent with parathyroid adenoma: tendinitis

Selim Kurtoglu1; Leyla Akın1; Salih Özgöçmen1; Mustafa Kendirci1; Nilfan Solmaz2; Sena Oncu2
1Erciyes University Faculty of Medicine, Pediatric Endocrinology, Kayseri, Turkey; 2Erciyes University Faculty of Medicine, Physical Therapy and Rehabilitation, Kayseri, Turkey; 3Erciyes University Faculty of Medicine, Pediatrics, Kayseri, Turkey

Background: Primary hyperparathyroidism (PHPT) in children and adolescents is a rare condition. PHPT is usually sporadic and caused by parathyroid adenoma. Patients may present with bone pain, proximal myopathy, bony deformities, fractures, renal calculi, neck swelling or acute pancreatitis.

Case: We describe an unusual presentation for PHPT in a 15-year-old male patient. He presented with difficulty in walking due to swelling of the ankles bilaterally. Ultrasoundography revealed intratendinous calcific nodules in both achilles tendons. Serum biochemistry showed hypercalcemia and hypophosphatemia. Serum parathormone level was found high (512 pg/ml N:4.5-36).

Parathyroid scanning suggested parathyroid adenoma. Parathyroidectomy was performed and the diagnosis of parathyroid adenoma was confirmed histopathologically. The family history was negative for multiple endocrine neoplasim syndrome. The intervention was followed by normalization of phosphocalcific profile and improvement of signs and symptoms of the patient.

Conclusion: We suggest that hyperparathyroidism should be kept in mind in the differential diagnosis of tendinopathies.

PAO-188

Trend in body height distribution and short stature prevalence among children and adolescents aged from 6 to 18 years in two districts of Shanghai

Mingying Zhang1; Feihong Luo2; Shuxian Shen1; Hong Xia1; Yuechen Tu1; Fengxia Guo1; Tingting Huang1; Djing Zhi2; Zhuohui Zhao3; Rong Ye1; Ruqiang Cheng1; Xiaojing Li1
1Children’s Hospital, Fudan University, Department of Endocrinology and Metabolism, Shanghai, China; 2Public Health Bureau, Minhang District, Shanghai, China; 3Center for Disease Control and Prevention, Minhang District, Shanghai, China

Background: It is unclear how is the trend of height distribution and short stature prevalence change among children and adolescents in Shanghai.

Objective: The aim of this survey was to establish baseline data on the trend in body height distribution and short stature prevalence among children and adolescents in Shanghai.

Methods: We selected two districts in Shanghai in 2003, randomly, one in urban area and the other in suburb area. All students in the primary schools, junior and senior high schools of the two districts were screened in 2003 and 2008. The main variables we studied were the subjects’ height, age and sex. We analysed the body height distribution and the prevalence of short stature.

Results: (1) Body heights were significantly higher in boys than that in girls. (2) Compared with data in 2003, the mean height of 2008 was higher. (3) In the past 5 years, the overall increments were 0.09-4.03cm (Urban male), 0.57-(2) Compared with data in 2003, the mean height of 2008 was higher. (3) In the past 5 years, the overall increments were 0.09-4.03cm (Urban male), 0.57-2.55m (Rural male), 0.42-3.76cm (Urban female) and 0.04-1.81cm (Rural female) for stature. (4) The prevalence of short stature was significantly higher in urban district than in suburb area (2003:X2 = 139.73, p<0.01; 2008:X2
-186.73, p<0.01) and also was significantly higher in male than in female (2003: X² = 21.36, p<0.01; 2008: X² = 8.77, p<0.01). (5) The overall prevalence of short stature in all children and adolescents (6-18 years) decreased significantly from 3.74% to 2.22% between 2003 and 2008 (X² = 315.46, p<0.01).

Conclusions: The distribution of height among children and adolescents aged from 6 to 18 years old in the two districts showed significantly increase between the two sexes from the year 2003 to 2008. The prevalence of short stature has decreased during the last past 5 years in the two districts of Shanghai.

**PAO-189**

**LEOPARD syndrome: clinical characteristics and molecular study**

Claudia Heredia1; Lidia Castro-Felipo2; Emilia Balboa2; Jesus Barreiro2; Paloma Cabañas1; Isabel Martínez2; Francisco Barros1; Manuel Pombó1

1Hospital de Santiago de Compostela, Universidad de Santiago de Compostela, Unidad de Endocrinología Pediátrica, Crecimiento y Adolescencia, Santiago de Compostela, Spain; 2Fundación Publica Galega de Medicina Xenomórfa, Ciberer, Medicina Molecular, Santiago de Compostela, Spain; 3Hospital de Santiago de Compostela, Cardiología Pediátrica, Santiago de Compostela, Spain

Background: LEOPARD syndrome (LS) is an autosomal dominant disorder and features overlap closely with those observed in Noonan syndrome (NS). PTPN11, BRAF and RAF1 are genes known to be associated with LS. The characteristics are including lentigines and cardiac defects.

Methods: Three patients were diagnosed with LS and required the presence of lentigines as the main feature features outlined by Storey et al. We made a mutational analysis. Cyclic sequencing was performed after PCR amplification of all the encode regions and the exon/intron boundaries of PTPN11.

Results: There were two female (2.5 years and 7.3 years) and one male patient (13.4 years). Phenotypically, the two girls are typical facies of NS; in all patients we observed low-set ears, high palatal arch and epicanthal folds; in two patients we found pterigium colli and ocular hypertelorism. Cardiac anomalies were detected in two patients: hypertrophic cardiomyopathy (HCM) and two patients with ECG anomalies (left axis deviation and left anterior hemiblock). In all patients, reveals the presence of multiples lentigines appeared during childhood; one girl has conductive deafness, actually is solved. The three patients had short stature below -2SDS and twice with normal growth velocity for age. One patient had mild mental retardation (IQ75-86) and other patient delayed psychomotor development. Mutational analysis: We found three different mutations in the PTPN11 gene: G464A, T468M and Y279C. These mutations have been reported in the literature associated with LS. The mother of the boy also had the same mutation as his son and once girl the mutation occurred de novo.

Conclusions: LS is a rare genetic disorder, the major features are lentigines, cardiac defects as HMC, hypertelorism, short stature and variable degree of neurological disability. All patients need close follow-up by pediatricians and might require early intervention, moreover the molecular analysis enables us to confirm the diagnosis and make genetic counseling diagnosis more accurate.

**PAO-190**

**Disorders of sex development -DSD-(46,XX ovotestis) in 3 children of Africa**

Amaya Rodriguez1; Amaia Vela1; Gema Grau Bolado1; Francisco Oliver2; Jose Luis Blanco2; Luis Castaño3

1Cruceros Hospital, Pediatric Endocrinology, Barakaldo, Spain; 2Cruceros Hospital, Pediatric Urology, Barakaldo, Spain; 3Cruces Hospital, Research Department, CIBERER, Barakaldo, Spain

Background: The ovotestis DSD (OMIM # 235600) is characterized by histological presence of testicular and ovarian tissue in the gonads of the same individual. Karyotype is usually 46 XX (60-100%), SRY negative. The most common form of presentation is ambiguous genitalia at birth. Biopsy of gonad around its longitudinal axis is mandatory to avoid misdiagnosis of mixed forms. Frequency of DSD in Africa is high in some series (51% in South Africa vs 8% in Brazil).

Population: We report 3 cases of ovotestis DSD from Mauritania, raised as males. They have different degrees of penile curvature and micropenis, proximal hipoplasias, bifid scrotum and unilateral or bilateral cryptorchidism. In 2 of them a gonad was palpable. No uterus was found. 17OH-progesterone and DHEA-S were in the normal range. Karyotype 46 XX, SRY gene negative. Gonadal biopsy was performed in cases 1 and 3. In case 2, macroscopic diagnosis of bilateral ovotestis was made (Table 1).

<table>
<thead>
<tr>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>6.5</td>
<td>3.9</td>
</tr>
<tr>
<td>Palpable gonad</td>
<td>Right</td>
<td>Left</td>
</tr>
<tr>
<td>Right gonad</td>
<td>Ovotestis</td>
<td>Ovotestis</td>
</tr>
<tr>
<td>Left gonad</td>
<td>Ovary</td>
<td>Ovotestis</td>
</tr>
</tbody>
</table>

Penile curvature correction was performed with penoscrotal transposition and testis / ovotestis orchidopexy, with removal of ovary and internal female genitalia at (Case 1). Subsequently, stage-two urethroplasty was performed. In Case 2, treatment of micropenis with testosterone ointment 2% was carried out with good response.

Conclusions: The diagnosis of ovotestis DSD should be considered in children of African origin with ambiguous genitalia. The most common presentation is the ovotestis (44-64%). They are usually reassigned male because they have already been raised as males in their origin country.
PAO-192

Generalised arterial calcification of infancy - a novel mutation of the ENPP-1 gene
Vishal Mehta1; Sanjay Gupta1; Rupal Patel1; David Horton1; Eamonn Sheridan1; Frank D1
1Hull Royal Infirmary, Paediatrics, Hull, United Kingdom; 2St James' university hospital, Department of Clinical Genetics, Leeds, United Kingdom; 3Munster University Children's Hospital, Paediatrics, Munster, Germany

Background: Generalised Arterial Calcification of Infancy (GACI) is a severe autosomal recessive disorder characterized by calcification and stenosis of large and medium sized arteries. Although many affected children die in early infancy approximately 34% children would be expected to survive beyond infancy. Inactivating mutations of the Ectonucleotide Pyrophosphatase/Phosphodiesterase -1 (ENPP-1) gene have been implicated in many cases of GACI and more recently, in causation of hypophosphataemic rickets.

Case report: A female baby was born of on-consanguineous Caucasian parents, at 29 weeks of gestation with evidence of GACI on antenatal scans. She died within 24 hours of birth secondary of congestive cardiac failure. Her female sibling was born at 31 weeks of gestation and was diagnosed antenatally to have complex congenital heart disease including hypoplastic left ventricle, double outlet right ventricle, arterial-pulmonary window and idopathic arterial calcification. A postnatal scan confirmed these findings. Due to very poor prognosis of this condition, after extensive discussion with parents and paediatric cardiologist it was decided not to actively treat her cardiac condition. Molecular analysis of the ENPP1 gene showed two novel nonsense mutations on Exon1 (c. DelGC 190/191, p. A64A fsX11) and Exon21 (c. 2230 A>G, p. N744X). At two and half years of age she started showing evidence of phosphaturia and hypophosphataemia.

Discussion: Within last 20 years, anecdotal GACI cases of survival beyond infancy with spontaneous regression of calcification have been reported. The factors which lead to survival beyond infancy are poorly understood but hypophosphataemia and treatment with bisphosphonates was associated with survival in a large retrospective study. The presence of a novel mutation in our case is unlikely to explain the association with complex CHD but this is the first reported case of such association. In our case, the long term outcome and survival could be affected by pulmonary hypertension, despite bisphosphonate treatment.

PAO-193

Gonadal function in patients with classic galactosemia
Miva Orquidea Bai1; Sara Monti; Ilaria Bettocchi; Federico Baronio; Alessandra Castic; Alessandro Cicognani
University of Bologna, S. Orsola-Malpighi Hospital, Department of Pediatrics, Bologna, Italy

Background: Classic galactosemia is an inherited inborn error of the major galactose assimilation pathway, caused by galoctose 1-phosphate uridyltransferase (GALT) deficiency, with an incidence of 1:30,000 newborns. Many GALT mutations have been described, with different clinical consequences. In the neonatal period, after ingestion of milk containing galactose, newborns present a severe clinical situation with jaundice, hepatosplenomegaly and hepatocellular damage, vomiting, hypoglycemia, renal tubular disease and hypotonia. Therapy is represented by a galactose-restricted diet which, unfortunately, does not prevent long-term complications, particularly cognitive and motor abnormalities and primary ovarian failure (POF). The pathogenesis of galactose-induced ovarian toxicity remains unclear but probably involves galactose itself and its metabolites such as galactitol.

Objective and hypotheses: The aim of the study is to evaluate pubertal development in classical galactosemia.

Method: We report data of our patients (2 couples of brothers) identified by neonatal screening.

Results: The table shows our results, 5 patients with classic galactosemia, genotypically characterized, present a cognitive and gonadal behavior in accordance with literature. Indeed, patients 1A and 1B, 2A and 2B show a more severe phenotype although an early diagnosis and therapy and a good dietary compliance; patient 3 has a normal phenotype and is a compound heterozygous for a known mutation linked to a severe phenotype and a mutation not present in literature. Moreover she is carrier of Los Angeles variant, Duarte 1, associated with an increased activity of enzyme GALT.

Conclusions: Since it is a rare disease, the number of patients is low, so that further investigations are needed with larger series and long-term follow-up.

PAO-194

Pattern of inheritance and analysis of clinical and cerebral MRI features of familial cases of central precocious puberty
Mariana Blasci1; Laura Losa1; Vania Giunta1; Francesca Marabotto1; Gabriele Ruff1; Luisa Strocchio1; Arianna Zorili1; Orsetta Zuffardi2
1University of Pavia, Department of Pediatrics - IRCCS Fondazione Policlinico San Matteo, Pavia, Italy; 2University of Pavia, Department of Human Genetics, Pavia, Italy

Background: Many clinical observations show that central precocious puberty (CPP) may be in some cases familial. However, the scientific support to this assumption remains sparse up to now.

Objective and hypotheses: The aim of the present study was to define a pattern of inheritance of familial CPP, and to identify possible clinical differences between familial (FPP) and sporadic (SPP) forms of CPP.

Methods: We studied 110 patients affected by CPP (104 F; 6 M). The family tree of each patient was analysed and all information regarding the age of puberty and of menarche, and the presence of CPP among first and second degree relatives was collected.

Results: Forty-one cases (37.3%; 40 F; 1 M) met the criteria for FPP and the remaining 69 cases (62.7%; 64 F, 5 M) were SPP. The FPP showed a pattern of inheritance that was autosomal dominant in 24 (58.5%) cases, autosomal dominant with incomplete sex-dependent penetrance in 16 (39%) girls and autosomal recessive in only 1 (2.5%) case. The age at onset and the age at diagnosis of CPP did not differ between FPP and SPP, the girls with FPP showed a higher BMI-SDS than girls with SPP (2.77 ± 2.28 SD vs 1.72 ± 1.71SD; P=0.0402) and a greater bone age acceleration (2.12yrs ± 1.28 SD vs 1.56yrs ± 1.32 SD; P=0.0275). MRI showed CNS anomalies in 14/69 (20%) children with SPP and in 7/41 (17%) children with FPP.

Conclusions: A familial origin was found in 1/3 of cases with CPP. Girls with FPP have a higher BMI and bone age maturation than those with SPP. CNS abnormalities were found either in SPP either in FPP and do not allow to exclude the need of performing cerebral MRI in FPP. The high prevalence of FPP suggests a careful inquiry regarding precocious puberty in young siblings and first-degree cousins of a child diagnosed with CPP.
Effectiveness of gonadotropin-releasing hormone analogue treatment in children with central precocious puberty with respect to bone age acceleration before the therapy

Irena Bobeff1; Diana Bobeff2; Joanna Smyczynska3; Barbara Pniewska-Slark1; Maciej Hilczer3; Andrzej Lewinski1

1Polish Mother’s Memorial Hospital - Research Institute, Department of Endocrinology and Metabolic Diseases, Lodz, Poland; 2Medical University of Lodz, Medical Faculty, Lodz, Poland; 3Medical University of Lodz, Department of Pediatric Endocrinology, Lodz, Poland

Background: Central precocious puberty (CPP) is defined as the onset of puberty in girls and boys before the age of 8 and 9 respectively. It has a higher incidence in girls. Bone age is almost always advanced. The treatment of choice is long term depot gonadotropin-releasing hormone analogue (GnRHa). The goal of mentioned therapy is to inhibit pubertal development and improve the height prognosis.

Objective and hypotheses: The aim of this research was to evaluate the influence of GnRHa therapy in children with CPP on the height prognosis depending on pretreatment bone age.

Methods: The group of 62 patients with diagnosed CPP was enrolled in the study: 48 girls and 14 boys. Patients were treated with GnRH analogues depot – triptorelin 3.75 mg. For all the patients, the following pre- and post treatment parameters have been calculated and expressed as SDS: height, predicted adult height (PAH), bone age/chronological age (BA/CA) and bone age/height age (BA/HA). Patients were divided in two groups. Group A comprised those children who began their treatment with BA or slightly advanced in relation with CA and HA. Group B gathered those patients whose BA was definitely advanced with respect to CA and HA.

Results: Height prognosis improvement was observed in group B (in children whose BA before treatment was definitely advanced with respect to CA and HA). There was no height prognosis improvement noticed in the group A (which was characterized by consistent or only slightly elevated BA). The results are presented in the Table 1 for BA/CA and in the Table 2 for BA/HA.

### Table 1. BA/CA advanced vs normal

<table>
<thead>
<tr>
<th>Age before GnRHa [years]</th>
<th>Advanced</th>
<th>Normal</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.4±2.2</td>
<td>9.3±1.7</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>hSDS before GnRHa</td>
<td>1.84±1.14</td>
<td>0.87±1.22</td>
<td>0.007</td>
</tr>
<tr>
<td>PAH SDS before GnRHa</td>
<td>-0.95±1.35</td>
<td>0.14±1.18</td>
<td>0.005</td>
</tr>
<tr>
<td>Therapy duration [years]</td>
<td>3.7±2.2</td>
<td>2.8±1.90</td>
<td>0.066</td>
</tr>
<tr>
<td>hSDS after GnRHa</td>
<td>1.02±1.34</td>
<td>0.48±1.21</td>
<td>0.156</td>
</tr>
<tr>
<td>PAH SDS after GnRHa</td>
<td>-0.42±1.15</td>
<td>-0.31±1.23</td>
<td>0.806</td>
</tr>
<tr>
<td>ΔPAH SDS</td>
<td>0.53±0.99</td>
<td>-0.44±0.86</td>
<td>0.001</td>
</tr>
</tbody>
</table>

### Table 2. BA/HA advanced vs normal

<table>
<thead>
<tr>
<th>Age before GnRHa [years]</th>
<th>Advanced</th>
<th>Normal</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.8±2.5</td>
<td>8.7±1.6</td>
<td>0.265</td>
<td></td>
</tr>
<tr>
<td>hSDS before GnRHa</td>
<td>0.97±1.15</td>
<td>2.03±1.16</td>
<td>0.001</td>
</tr>
<tr>
<td>PAH SDS before GnRHa</td>
<td>-1.40±0.93</td>
<td>0.60±0.97</td>
<td>0.001</td>
</tr>
<tr>
<td>Therapy duration [years]</td>
<td>3.7±2.3</td>
<td>2.8±1.7</td>
<td>0.094</td>
</tr>
<tr>
<td>hSDS after GnRHa</td>
<td>0.32±1.17</td>
<td>1.41±1.23</td>
<td>0.001</td>
</tr>
<tr>
<td>PAH SDS after GnRHa</td>
<td>-0.96±0.93</td>
<td>0.31±1.05</td>
<td>0.001</td>
</tr>
<tr>
<td>ΔPAH SDS</td>
<td>0.42±0.94</td>
<td>-0.28±1.05</td>
<td>0.032</td>
</tr>
</tbody>
</table>

Conclusions: The therapy with GnRHa proved to be effective in improving height prognosis only in children with advanced BA.

Autoimmune thyroiditis and phenylketonuria: a new association

Giovanni Cersello1; Marina Caserta2; Cinzia Castanae; Angela Mortillaro2; Silvano Bertelloni3; Maria Cristina Maggio4

1University of Palermo, University Department, Palermo, Italy; 2ARNAS Civico, IV Maggioro, Palermo, Italy; 3University of Pisa, Pediatric Endocrinology, Division of Paediatrics, Department of Reproductive Medicine and Paediatrics, Pisa, Italy; 4University of Palermo, University Department “Materno-Infantile”, Palermo, Italy

Background: Phenylketonuria (PKT) is an inherited metabolic disorder characterised by an absence or deficiency of the enzyme phenylalanine hydroxylase. The neonatal screening and the early treatment, with a low-phenylalanine diet, prevent developmental delay and support normal growth.

Objective and hypotheses: There is no evidence of endocrine disorders or of autoimmune diseases associated with PKT.

Method: We describe two cases of unrelated girls affected by PKT with a clinical presentation of thyroid disease.

Results: G.A. 14 years, born SGA showed a poor growth from the first years. GH treatment was purposed but never started for the poor familial compliance. Stature: 133,5 cm (<-4SDS); weight: 29 kg; bone age: 13 years, pubertal stage: PH2B2; eutrophic; 46XX. She had menarche at 13,9 years. She presents goitre with a palpable “Delphic” node. Thyroid scan evidences an enlarged thyroid with a pattern of thyroiditis; TSH: 1.2; FT3: 7.4; FT4: 0.95; anti-TG and anti-TPO antibodies in the normal range; glycaemia, IGF-1, celiac disease markers: negative.

S.C. 10,7 years, presented hyperglycaemia with positive ICA, IAA, anti-GAD, treated with a4-doses insulin schedule. She underwent an endocrinological investigation for the evidence of a goitre. She has myxedema, mild anaemia, goitre with a nodular consistence. Stature is 139 cm; weight:34 kg; pubertal stage: PH2B2-3. Hormonal tests evidence: TSH: 199; FT3: 3,19; FT4: 0.35; anti-TG and anti-TPO antibodies: 277 and 1260 respectively; celiac....
Two cases report of Turner syndrome associated with metabolic syndrome

Ying Zhang; Ruizin Cheng; Xiangquan Lin; Xiaohong Yang
Fuzhou Children's Hospital of Fujian, Department of Endocrinology, Fuzhou, China

Background: Turner syndrome (TS) occurs in approximately one in 2500 female births and is characterized by short stature and sex hormone deficiency. However, it is becoming increasingly evident that patients with TS are also susceptible to a range of disorders.

Methods: We present two patients with metabolic syndrome (MS).

Results:
Case 1: A 13.3ys female patient, karyotype was 45,X/46,X,+mar. height 127.3cm (< -4.95SD), weight 32.7kg, shield thorax, several pigtails on her face, no puberty signs. Elevation of hepatic enzymes (ALT 60 U/L), AST 101 U/L, fasting blood glucose, insulin, HbA1C, GH peak of GH stimulating test, LH, FSH, TPO and Tg antibodies are presented in Table 1. T3, T4, TSH were normal, BA: 10y, Ultra-sound: small uterus and ovaries were not detected, fatty Liver, MRI: pituitary gland dysplasia, partial empty sella turcica. She also suffered epilepsy since 6 months-old. Diagnosis: TS, MS, adiposis, diabetes mellitus (DM), hyperlipidemia, growth hormone deficiency (GHD), hashimoto thyroiditis, epilepsy. Case 2: A 16.5ys female patient, karyotype was 45,XO. height 134cm (< -4.76SD), weight 40.5kg, short neck, micrognathia, shield thorax, cubitus valgus, no puberty signs. Elevation of hepatic enzymes (ALT:170 U/L, AST:101 U/L), TG: 5.42 mmol/L, CHOL: 6.12 mmol/L, HDL: 1.06 mmol/L, fasting blood glucose, insulin, HbA1C, GH peak of GH stimulating test, LH, FSH, TPO and Tg antibodies are presented in Table 1. T3, T4, TSH were normal, BA: 10y, Ultrasound: small uterus and ovaries could not be detected, fatty Liver; Saddle area MRI showed normal. Diagnosis: TS, MS, adiposis, DM, hyperlipidemia, GHD.

Conclusions: It appears that fcell dysfunction or insufficiency response to glucose is intrinsic to TS and is at the core of the high risk for DM, excess weight and an abnormal lipid profile, in particular excess triglyceride levels, worsened insulin sensitivity. So to detect and interfere with these disorders earlier are significant for TS patients.

First results from the screening for congenital adrenal hyperplasia in Bulgaria

Antoaneta Kostova; Iva Sloveva; Radoslava Emilova
University Pediatric Hospital, Screening and functional endocrine diagnosis, Sofia, Bulgaria

Background: Congenital adrenal hyperplasia (CAH) is difficult to diagnose and potentially life-threatening in the neonatal period.

Objective and hypotheses: The objective of the present study is to analyze the first results from the novel Bulgarian neonatal screening (NS) for CAH for the period April 2010 - March 2011.

Methods: The level of 17-OH-Progesterone (17-OHP) in dried blood spot was assessed in all Bulgarian newborns (n=74 133). Until the end of 2010 we used only the cut-off value of 30 nmol/l for full-term infants at age 3-5 days. We began to apply the ISNS referent values since the beginning of 2011.

Results: An increased levels of 17-OHP were found in 637 cases (recall rate 0.85%). On a second assessment the results were confirmed in 410 cases (recall rate 0.55%). Most of the babies were preterm. Only 52 of them (12.6 %) had birth weight ≥ 2500 g. and 47 (11.5 %) were born after the 36 week of gestation. The diagnosis classic CAH was confirmed in 7 children. Estimated prevalence for the country - 9.4 100 000. The treatment was started at average age 15.6 ± 8.3days). Three of the children with CAH were preterm (birth weight < 2500 g and gestational age < 36 gestational week).

Conclusions: The first data on CAH (classical forms) prevalence for the Bulgarian population obtained by NS do not differ significantly from the published for other countries. The results show the importance of NS for the early diagnosis and initiation of treatment. Constant improvement of the existing screening logistic is possible during expansion of the screening programs.
PAO-201

The medium and short-term effects of sinusoidal and vertical vibratory training on the musculoskeletal and endocrine system in healthy men
Musab Elmantaser; Martin McMillan; Sheila Khanna; Karen Smith; S. Faisal Ahmed
1University of Glasgow, Department of Child Health, Royal Hospital for Sick Children, Glasgow, United Kingdom; 2Royal Infirmary, Clinical Biochemistry, Glasgow, United Kingdom

Introduction: The underlying mechanisms that explain the beneficial effect of whole body vibration (WBV) on bone health are unclear.

Aim: To compare the immediate and medium term effects of WBV using the Galileo platform (sinusoidal WBV’s WBV) and the Juvent1000 platform (v-WBV) on muscle function, endocrine status and markers of bone turnover.

Material and method: 10 healthy men (36yrs±2.4) randomized into two groups; the first group stood on the sWBV and the second group stood on vWBV 3times/wk/2months. The measurements were performed at five timepoints(T) over 4 months. T0 (1 month pre-WBV), T1 (the first day of exercise), T2 (1/month WBV), T3 (2/month WBV) and T4 (1/month post-WBV). T1, T2 and T3 consisted of four sampling times 60 mins before WBV and 5-30-60mins post WBV. Each participant had anthropometry, assessment of body composition by Tanita and assessment of muscle function by mechanography and grip strength force and measurement of serum markers of bone turnover, glucose, IGF-1, cortisol.

Results: There were no significant changes in anthropometry, body composition or muscle function in the two groups at the end of the study period. The change in creatine kinase following exercise was similar in both groups. Both vibratory platforms were associated with an immediate decrease in cortisol following the exercise, but there was no difference in the decrement between the two devices. In the medium term, sWBV was associated with a reduction in median serum cortisol from 333nmol/l(247,442) to 269 nmol/l (192,322),(p,0.04) whereas there were no significant changes in the vWBV group. Serum CTX, a marker of bone resorption fell significantly after 2months in the sWBV group from a median of 0.42ng/ml(0.30,87) to 0.29ng/ml(0.20,4.0),(p,0.03).

Conclusion: WBV is associated with a fall in endogenous cortisol and a reduction in bone resorption particularly in those subjects who were exposed to sinusoidal vibration. Longer-term comparative studies are required to further investigate the effect on bone.

PAO-202

An interesting case of delayed puberty associated with neurofibromatosis type 1 and hamartoma
Fiorella Galluzzi; Perla Scalini; Maria Luisa Vettrano; Cristina Manoni; Salvatore Seminara
University of Florence, Department of Sciences for Woman and Child’s Health, Florence, Italy

Background: Neurofibromatosis type 1 (NF1) is one of the most common neurogenetic disorder. Complications are quite variable however the most frequent are optic pathway tumors (glioma), short stature and precocious puberty.

Objective and hypotheses: Herein we report an infant who diagnosed CHI, due to a novel homozygote mutation (Q392H) in ABBC8 gene. The patient had very severe brain damage, despite early diagnosis and appropriate management.

Patient: A two-day-old baby boy was referred to our center due to resistance to hypoglycemia. His parents were first degree relatives. At the admission, his hypoglycemia was detected and glucose infusion was started and elevated to 15 mg/kg/min. During hypoglycemia (glucose: 5 mg/dL) blood ketone was negative, ammonia level was normal, insulin:400 uL/mL, c-peptide:2.65 ng/mL. Blood glucose levels were elevated more than 30 mg/dl with IV glucose. He was diagnosed as CHI. Diazoxide, somatostatin were started and later nifedipine and uncooked corn starch were added to the therapy. The doses of the diazoxide, somatostatin and nifedipine were increased to maximum doses along with diet. There were no significant changes in anthropometry, body composi­tion or muscle function in the two groups at the end of the study period. The change in creatine kinase following exercise was similar in both groups. Both vibratory platforms were associated with an immediate decrease in cortisol following the exercise, but there was no difference in the decrement between the two devices. In the medium term, sWBV was associated with a reduction in median serum cortisol from 333nmol/l(247,442) to 269 nmol/l (192,322),(p,0.04) whereas there were no significant changes in the vWBV group. Serum CTX, a marker of bone resorption fell significantly after 2months in the sWBV group from a median of 0.42ng/ml(0.30,87) to 0.29ng/ml(0.20,4.0),(p,0.03).

Conclusion: WBV is associated with a fall in endogenous cortisol and a reduction in bone resorption particularly in those subjects who were exposed to sinusoidal vibration. Longer-term comparative studies are required to further investigate the effect on bone.

PAO-203

A novel mutation of abcc8 gene in congenital hyperinsulinism
Nurser Muratoglu Sahin; Sibel Tulgar Kinkic; Abdullah Kurt; Deniz Anuk insa; Ayse Ecevit; Andrew Hattersley; Baske1 University, Pediatric Endocrinology, Ankara, Turkey; Baskent University, Neonatology, Ankara, Turkey; 2Peninsula Medical School, University of Exeter, Institute of Biomedical and Clinical Science, Exeter, United Kingdom

Background: Congenital hyperinsulinism (CHI) is a heterogeneous disease characterized by disregulation of insulin secretion resulting life-threatening hypoglycemia. Mutations of SUR1 gene (ABBC8) are responsible for 50-60% of CHI.

Objective and hypotheses: Herein we reported an infant who diagnosed CHI, due to a novel homozygote mutation (Q392H) in ABBC8 gene. The patient had very severe brain damage, despite early diagnosis and appropriate management.

Patient: A two-day-old baby boy was referred to our center due to resistance to hypoglycemia. His parents were first degree relatives. At the admission, his hypoglycemia was detected and glucose infusion was started and elevated to 15 mg/kg/min. During hypoglycemia (glucose: 5 mg/dL) blood ketone was negative, ammonia level was normal, insulin:400 uL/mL, c-peptide:2.65 ng/mL. Blood glucose levels were elevated more than 30 mg/dl with IV glucose. He was diagnosed as CHI. Diazoxide, somatostatin were started and later nifedipine and uncooked corn starch were added to the therapy. The doses of the diazoxide, somatostatin and nifedipine were increased to maximum doses along with diet. There were no significant changes in anthropometry, body composition or muscle function in the two groups at the end of the study period. The change in creatine kinase following exercise was similar in both groups. Both vibratory platforms were associated with an immediate decrease in cortisol following the exercise, but there was no difference in the decrement between the two devices. In the medium term, sWBV was associated with a reduction in median serum cortisol from 333nmol/l(247,442) to 269 nmol/l (192,322),(p,0.04) whereas there were no significant changes in the vWBV group. Serum CTX, a marker of bone resorption fell significantly after 2months in the sWBV group from a median of 0.42ng/ml(0.30,87) to 0.29ng/ml(0.20,4.0),(p,0.03).

Conclusion: WBV is associated with a fall in endogenous cortisol and a reduction in bone resorption particularly in those subjects who were exposed to sinusoidal vibration. Longer-term comparative studies are required to further investigate the effect on bone.

PAO-204

Hypercalciuria and renal function and in children affected by osteogenesis imperfecta
Francesco Doggi; Elena Monti; Grazia Morandi; Evelina Maines; Milena Brugnara; Paolo Cavarzer; Rossella Gaudino; Antoniazzi Franco
1Pediatric Clinic, Department of Life and Reproduction Sciences, Verona, Italy; 2Pediatric Clinic, Department of Life and Reproduction, Verona, Italy

Background: Osteogenesis Imperfecta (OI) is an heterogeneous group of inherited disorders of connective tissue characterized by bone fragility, reduced bone mass, laxity of ligaments, blue sclera and different levels of low stature. Hypercalciuria is a condition characterized by an increased urinary calcium without hypercalcemia. It is characterized by an urinary calcium excretion >4mg/kg/die or urinary Ca/Cr ratio >0,21. The relation between hypercalciuria and OI had been already analyzed in several studies.

Objective: The aim of this study is to observe the incidence of hypercalciuria...
among patients affected by OI and the possible correlation with the severity of the underneath condition. We also want to verify the presence of any kidney damage related with the increased urinary calcium or with the ongoing treatment with bisphosphonates.

**Methods:** We have recruited 36 patients, followed at our clinic, treated with bisphosphonates. We collected, in a period of 3 months (T0-T1), auxological, clinical and laboratory parameters. All patients performed an abdominal ultrasound.

**Results:** Through urinary Ca/Cr ratio we have identified 11 hypercalcicuric patients in T0, 15 in T1. We didn’t found any alterations in kidney function both in biochemical and in imaging data. But estimating the urinary calcium in mg/kg/die in T1, we’ve also observed that hypercalcicuric patients were only 6.

**Conclusion:** We haven’t found correlation between hypercalcicuria and severity of OI. Urinary Ca/Cr ratio is not specific enough to detect hypercalcicuria in our patients, maybe because of low creatinine levels as a consequence of OI. It is important, in these children, to integrate Calcium and Vitamin D. Hypercalcicuria and the treatment with bisphosphonates do not cause any significant kidney alteration. The next studies with DXA are going to make a better evaluation of the influence of hypercalcicuria on bones of patients affected by OI.

**PAO-205**

**Myxedematous coma due to secondary hypothyroidism with panhypopituitarism**

*Nesrin Karabul; Seyfullah Gökce; Andreas Herzog; Michael Beck*

**Introduction:** Craniofaringiomas (CP) are rare brain tumors in children. The tumor itself or its subsequent surgical treatment causes the most common multiple hormone deficiency and replacement is frequently necessary. Myxedema coma (MC) is a rare, but often fatal endocrine emergency. The majority of cases occur in primary hypothyroidism but in central origin is extremely rare. We report the case of a patient with panhypopituitarism due to a craniopharyngioma surgery, who developed myxedema coma due to pituitary hypothyroidism.

**Case:** A 12-year-old girl with loss of consciousness was admitted to a nearby hospital. She was transferred to our hospital for further hormonal evaluation and treatment. Her medical history was learned that she took multiple hormone replacement for two years because of CP had been operated, but took no medicine for the last three weeks. On physical examination; she was unconscious, hypotensive, bradycardic and hypothermic. Oxygen saturation was 75% without administration of supplemental oxygen. She had pretibial, non-pitting edema.

Peripheral blood tests detected decrease in hemoglobin, serum sodium, potassium, calcium levels. All of the pituitary hormone levels was demonstrated as decreased. A thyroid function test reported undetectable levels of both fT3(0.67ng/dL), fT4<0.67pg/mL), TSH(0.002 IU/mL). Magnetic resonance imaging of the pituitary gland revealed an empty sella. We initiated replacement of electrolytes and erythrocyte then adrenocortical hormone replacement therapy, followed by oral administration of levothyroxine at an initial dose of 600 mcg. As a result, the patient’s awareness level gradually improved. Following this, dosages were reduced. Our final diagnosis for the patient was MC due to central hypothyroidism together with panhypopituitarism. She was 75% without administration of supplemental oxygen. She had pretibial, non-pitting edema.

**Conclusion:** We suggested that panhypopituitarism together with stress could rapidly cause MC in children. The reason of this case presentation is that MC is a rare case of secondary hypothyroidism with panhypopituitarism.

**PAO-207**

**Menstrual cycle in adolescence and its relationship with parameters of metabolic syndrome**

*Isabel Bouzagl; Claudia Braga; Lenora Leard; Maria Cristina Kuschnir; Daniela Rodeiro*

**Background:** Clinical evaluation of adolescents should include an assessment of the menstrual cycle (MC), with emphasis on changes in the pattern of the cycle that can represent the first sign of a systemic and evolutive disease as the metabolic syndrome (MS), whose clinical manifestation can occur only in adulthood.

**Objective and hypotheses:** The evaluation of changes in the pattern of CM may be the opportunity for early diagnosis and initiation of preventive and effective actions.

**Objective:** Evaluate the menstrual cycle in adolescence and its relationship with parameters of MS.

**Methods:** Observational, comparative and transversal-cut study with 59 female adolescents aged between 12 and 19 and presence of at least one of factors: Overweight/Obesity. All of adolescents underwent a clinical evaluation with anthropometric and laboratorial data, composed of Fasting Glucose, Total Cholesterol, HDL-Cholesterol, Triglycerides, Oral Glucose Tolerance Test (Glucose 120) and Fasting insulin and Insulin post OGTT (insulin 120), Follicle- Stimulating-Hormone (FSH), Luteinizing Hormone (LH), Total Testosterone (TT), Androstenedione. Two groups were created. G-1 adolescents with irregular cycles, and G-2 with regular cycles.

**Results:** 59 adolescents evaluated, 36 formed G-1, and 23 formed G-2. In statistical analysis it was observed: G-1 presented: Waist/Height (p<0.009), Waist (p=0.026), Fasting Insulin (p=0.009), Glucose 120 (p=0.002), insulin 120 (p=0.0001), HOMA-IR (p=0.0008), Triglycerides (p=0.013), MS (p=0.001) and POS (p=0.0001) greater and QUICK (p=0.008), G/I (p=0.002) HDL (p=0,001) lower than G-2. 90% of G-1 presented irregularity since menarche Logistic regression analysis observed insulin 120 >75 (p=0.010) were significant to predict irregular cycle.

**Conclusions:** We believe that greater knowledge about the correlation between changes in menstrual cycle in adolescents and variables related to metabolic risk in this age group is very useful for an early screening that will enable the prevention of MS and related diseases.
Effect of urtica dioica leaves distillate on blood glucose of patients with type 1 diabetes

Maryam Razzagh-Azar; Hossein Zaree Aghmashnadi

Tehran University of Medical Sciences, H. Aliashgar Hospital, Tehran, Islamic Republic of Iran

Background: Urtica dioica is an edible plant that is traditionally used for its different effects including lowering of blood glucose.

Objective and hypotheses: The aim of this study was to determine the glucose lowering effect of urtica dioica in patients with type 1 diabetes mellitus (T1DM).

Methods: This phase one study is registered as the number “IRCT2010081745851NL” and has ethical approval. It was done on 24 patients with T1DM aged 12 ± 2 years and duration of diabetes was more than 1 year. They had no chronic complication of diabetes or concomitant disorder. Distillate of urtica dioica leaves was prepared in the laboratory. Patients were divided into 8 groups of 3 subjects and were studied in 6 days. In the first 3 days, they did not receive the solution but in the second 3 days, they drank urtica distillate in the morning once daily while they were on usual insulin therapy. The carbohydrate counting of their foods was equal on these two periods. Their blood glucose was monitored by continuous glucose monitoring system (Medtronic USA) every 5 minutes in these 6 days. Total daily blood glucose and insulin compared by paired T test on these two periods (SPSS 12). The first group received 30 ml/M2 of the solution and the other groups received 15 ml/M2 more than the previous one up to 150 ml/M2.

Results: Mean blood glucose in the second period and on day 6 were 201 ± 48.6 mg/dL and 194.75 ± 55 respectively that were significantly lower than first period (218 ± 50) (P<0.017, and 0.014 respectively). The total dose of insulin did not change during these periods.

Conclusions: Urtica dioica leaves have a substance with blood glucose lowering effect in T1DM.

Coagulation-factor deficiencies and abnormal bleeding in Noonan's syndrome

Gabriella Gamb$; Francesca Marabotto$; Laura Losa$; Gabriele Rufii$; Luisa Strocchi$; Arianna Zoroli$; Mariangela Cisternino$

1University of Pavia, Department of Internal Medicine - IRCCS Fondazione Polinico San Matteo, Pavia, Italy; 3University of Pavia, Department of Pediatrics - IRCCS Fondazione Polinico San Matteo, Pavia, Italy

Background: Noonan syndrome (NS) is a congenital autosomal disorder, characterized by dysmorphic facies, congenital heart defects, short stature and other anomalies including coagulation abnormalities not fully studied so far.

Objective and hypotheses: The aim of this study was to evaluate phenotype-specific features, gene mutations and coagulation parameters in a cohort of NS patients.

Method: We studied 19 NS patients (10 M, 9 F), 12 probands and 7 first degree relatives, we found in 7/19 a mutation of PTPN11, in 8 of SOS1 and in 1 case of SOS1/RAF1, the remaining 3 cases were mutation-negative.

Results: A positive history for abnormal bleeding was found in 9 patients (47%), a prolonged PTT in 5 cases (26%), coagulation factors deficiency in 9 patients (47%) and abnormal platelet aggregation in 8 cases (44%). The coagulation abnormalities were found both in CAPT patients with a history of abnormal bleeding and in 6 cases (60%) without clinical evidence of bleeding disorders. The coagulation abnormalities were reported both in patients with or without a mutation and were not correlated with a mutation of a specific gene. Important differences in haemostatic status were found between probands and their relatives: the former showed coagulation abnormalities in the majority of the cases while the latter showed a history of bleeding diathesis, but normal laboratory hematological findings. The coagulation abnormalities were more frequent in patients with heart defects; however, a history of bleeding diathesis was detected in patients without cardiopathy.

Conclusions: A high frequency of coagulation abnormalities was found in NS. These abnormalities do not seem to be related with the patients' genotype. The heart defects should not to be the only cause of the haemostatic disorders. The bleeding disorders, as well as the other phenotype NS features, tend to decrease with age. Our advice is to screen patients with NS for bleeding diathesis to avoid bleedings and post-operative complications.
Methods: moglobin concentration or erythrocyte count at prepubertal age when androgenization begins. We hypothesized that PA could affect blood hematocrit. Androgens are known to enhance erythropoiesis.

Results: We studied 8 patients aged 22.1 years (15-33). Their BMI was 20.5 kg/m², and their body fat percentage was 26.4% (20.4%-33%). Mean age at menarche was 13.2 years (11-15). They had menstrual cycles every 28.3 days (21-35), lasting 5.1 days (1-7). Oligo/anovulation was found in 2 cases (number 5 and 6). We detected asthma and impaired lung function (FEV1 <80%) in 3 cases (number 3, 5 and 6). One case presented CF-related diabetes (number 5 and 6). We detected impaired fasting glucose in 3 cases (number 4, 6 and 7) with HOMA index (A4)/(A1). DHEA-S, SHBG and free androgen index (FAI). Results are expressed by mean values and ranges.

Conclusions: Children with PA had higher blood erythrocyte count than their prepubertal controls [mean 4.7 (95% confidence interval 4.7-4.8) vs. 4.6 (4.5-4.7) E121; P=0.01]. The difference in erythrocyte count remained significant after adjustment for age and sex (P=0.04). There was also a small but significant difference in the mean blood hemoglobin concentration between the PA and control children [130 (128-132) vs. 128 (126-130) g/L; P=0.03]. No differences between the groups were found in the mean corpuscular hemoglobin, corpuscular volume or blood leucocyte count. In the entire study population, erythrocyte count was positively correlated with DHEAS, IGF-I and BMI SD score, and hemoglobin concentration with DHEAS, IGF-I and height SD score.

Conclusions: Relatively small increases in androgen concentrations due to androgenization may have a positive effect on erythropoiesis at prepubertal age.

Background: A lower reproductive capacity in women with cystic fibrosis (CF) has been associated with delayed puberty and amenorrhea.

Objective and hypotheses: To evaluate ovarian function in women with CF, regarding their clinical and nutritional status.

Methods: Cross-sectional study in women (3 years post-menarche) with CF controlled in our hospital. Data of menarche and menstrual cycles were collected by telephone survey. Anthropometric and spirometric data were obtained by medical history review. Blood samples were taken 3-5 days post-menstruation and after 21 days. The biochemical and hormonal parameters measured were glucose, insulin, HOMA, HbA1c, follicular estradiol (E), FSH, LH, luteal progesterone (P), total testosterone (T), androstenedione (A4), DHEA-S, SHBG and free androgen index (FAI). Results are expressed by mean values and ranges.

Results: We studied 8 patients aged 22.1 years (15-33). Their BMI was 20.5 (18.3-23.6) and their body fat percentage was 26.4% (20.4%-33%). Mean age at menarche was 13.2 years (11-15). They had menstrual cycles every 28.3 days (21-35), lasting 5.1 days (1-7). Oligo/anovulation was found in 2 cases (number 5 and 6). We detected asthma impaired lung function (FEV1 <80%) in 3 cases (number 3, 5 and 6). One case presented CF-related diabetes (number 5 and 6). We detected impaired fasting glucose in 3 cases (number 4, 6 and 7) with HOMA index (A4)/(A1). DHEA-S, SHBG and free androgen index (FAI). Results are expressed by mean values and ranges.

Conclusions: None had delayed puberty. We detected normal ovarian function (number 6) and impaired fasting glucose in 3 cases (number 4, 6 and 7) with HOMA index (A4)/(A1). DHEA-S, SHBG and free androgen index (FAI). Results are expressed by mean values and ranges.

Conclusions: Relatively small increases in androgen concentrations due to androgenization may have a positive effect on erythropoiesis at prepubertal age.

Background: In our outpatient department we evaluated 1218 oral glucose tolerance tests (oGTT) for impaired glucose tolerance (IGT), impaired fasting glucose (IFG), insulin resistance syndrome (IRSy) and Type 2 Diabetes (T2D).

Objective and hypotheses: The indication for oGTT was obesity (n=1052), small for gestational age (SGA) (n=36), SHOX- Gen deficiency/ Ullrich Turner Syndrome (UTS) (n=55) and Prader Willi Syndrome (n=25) before or during growth hormone therapy, as well as IRS at follow up (n=39) and risk factors for disturbance of the glucose homeostasis (n=48).

Methods: All subjects underwent in our ambulance a two hour oGTT (1,75g glucose per kilogram bodyweight, maximum 75g). Following parameters were measured/collected: fasting-, 1- and 2 hour glucose and –insulin, HbA1c, height, weight, body mass index.

Results: The older the children the percentage of impaired fasting glucose and impaired glucose tolerance were rising up from about 12% to 35%. We detected Type 2 Diabetes in children between eight to ten years in one percent, between 10-13 years in three cases and in group older than 13 years of age in 2.1 percent. All patients were obese. The percentage of insulinresistance defined as a fasting insulin greater than 15mU /L and/or a peak insulin greater than 150mU /L (S. Ten. J.Clin. Endocrinol. Metab. 2004/9:2526-2539) was as higher as older the patient evaluated. The HOMA IR >2,5 climbed up from 28% in the younger prepubertal group to 80% in the older subjects. The highest risk factor to develop impaired glucose tolerance, insulin resistance and Type 2 Diabetes was obesity in pubertal children.

Conclusion: In obese children change in lifestyle has to begin before onset of puberty. Performance of OGTT is important to detected insulin resistance as major risk factor to develop Type 2 Diabetes. Insulin und glucose results of non obese children differ from obese children.

Background: Premature adrenarche (PA) refers to earlier than normal increase in adrenocortical androgen production, mainly DHEA and DHEAS, in mid-childhood. Adrenal DHEA and DHEAS are androgen precursors that are converted to more potent androgen receptor agonists in peripheral tissues. Androgens are known to enhance erythropoiesis.

Objective and hypotheses: We hypothesized that PA could affect blood hemoglobin concentration or erythrocyte count at prepubertal age when androgen production in gonads is low.

Methods: We examined 64 prepubertal children with PA (clinical signs of androgenization and serum DHEAS ≥1 μmol/L; 54 girls and 10 boys), and 62 age- and sex matched controls (52 girls, 10 boys) without clinical or biochemical signs of adrenarche. All subjects were clinically examined, and analyzed for serum steroid concentrations and blood count. Mann-Whitney test was used to compare the differences between the study groups along with Univariate linear model. Pearson correlation test was used for analyzing correlations.

Results: Children with PA had higher blood erythrocyte count than their prepubertal controls [mean 4.7 (95% confidence interval 4.7-4.8) vs. 4.6 (4.5-4.7) E121; P=0.01]. The difference in erythrocyte count remained significant after adjustment for age and sex (P=0.04). There was also a small but significant difference in the mean blood hemoglobin concentration between the PA and control children [130 (128-132) vs. 128 (126-130) g/L; P=0.03]. No differences between the groups were found in the mean corpuscular hemoglobin, corpuscular volume or blood leucocyte count. In the entire study population, erythrocyte count was positively correlated with DHEAS, IGF-I and BMI SD score, and hemoglobin concentration with DHEAS, IGF-I and height SD score.

Conclusions: Relatively small increases in androgen concentrations due to adrenarche may have a positive effect on erythropoiesis at prepubertal age.
at the Centre for the prevention, treatment and rehabilitation of obesity in children in the period from 27/07/2008 to 03/10/2010. Hospitalisation lasted 21 days.

**Results:** After the multidisciplinary treatment, the average reduction in body mass (p < 0.05) in all adolescents was 5.92 ± 2.71 kg. During the 21-day hospitalisation, the average BMI was reduced by -2.12 ± 0.31 in all examinees, the BMI z-score was considerably lower in all examinees upon release and it was (p < 0.05) 0.26 ± 0.08. % of fat was considerably lower (p < 0.05) in all examinees -1.65 ± 0.23, the waist circumference was reduced by -7.85 ± 3.01. Hypertension was observed in 28% of adolescents. Two factors of metabolic syndrome were present in 27.6%, and metabolic syndrome was present in 18.3% of the examinees. The disorder in sugar transport was observed in 8.9% of the examinees.

**Conclusions:** The effects of the ‘Cigotica’ programme are very encouraging and they show that the multidisciplinary approach directed towards the reduction in energetic intake, education, change of lifestyle and habits related to nutrition and physical activity, leads to a considerable reduction in body mass, improvement in blood pressure laboratory analyses, aerobic capacities and self-confidence in obese adolescents.

**PAO-216**

**Prevalence of cryptorchism, retractile testis and orchiopexy in children**

Shakhrizada Sultanova

Endocrinology, Paediatric-endocrinology, Tashkent, Uzbekistan

**Background:** Cryptorchism represents the most common congenital defect of the male urogenital system. It may be an important cause for male infertility. Very variable figures on the incidence of cryptorchism have been described in different type of studies.

**Objective:** The aim of the present study was to establish the prevalence of the abnormality in Uzbekistan population living in the Tashkent city and Tashkent region.

**Patients/methods:** In total there were surveyed 3417 children and adolescents at the age from 3-14 years. The testis determination was carried out by palpation method.

**Results:** As a whole, the frequency of cryptorchism was 1.2% for boys between 3 years and 14 years. The frequency of pathology was 2.5% for those of foreign sources.

**Conclusions:** The prevalence of cryptorchism differs significantly from the prevalence reported fifteen years ago. It is showed prevalence of cryptorchism, on Uzbek population correlates with those of foreign sources.

**PAO-217**

**Cushing syndrome due to adrenocortical carcinoma in an infant**

Emine Dilek1; Veyssel Oz2; Didem Bezen3; Mustafa Inan2;
Fulya Ozuyan4; Filiz Tutunculer1

1Trakya University School of Medicine, Pediatric Endocrinology, Edirne, Turkey; 2Trakya University School of Medicine, Department of Pediatrics, Edirne, Turkey; 3Trakya University School of Medicine, Department of Pathology, Edirne, Turkey

**Background:** Adrenocortical tumours are the most common cause of endogenous Cushing syndrome in infancy and early childhood. We present an infant with Cushing syndrome due to adrenocortical carcinoma.

**Case:** A 15 month-old female child was referred to the hospital with a history of progressively increasing weight gain, appetite, terminal hair growth on the face and palmar plethora. She had no cliteromegaly. Serum of oral intake and topical application of steroids. Physical examination revealed weight of 9 kg (25p), length of 69.5 cm (3-10p), blood pressure 80/40 mmHg, cushingoid features with moon face and facial plethora. Rest of the physical examination was unremarkable. She had no cliteromegaly. Serum androstenedione [0.9ng/ml (0.8-5)], total testosterone [<0.1ng/dl (0.1-1.3)] were normal. Abdominal ultrasound showed 30x40 mm intra-abdominal mass arising from the left adrenal gland. Magnetic resonance imaging also detected a solid mass sized 40x45 mm in the left adrenal gland. She was operated on left adrenalectomy under perioperative glucocorticoid coverage. Histopathological examination confirmed adrenocortical carcinoma. She was discharged 20 days after surgery on hydrocortisone 4 mg/day. She is doing well on hydrocortisone and has not shown any sign of disease recurrence during follow up.

**Conclusions:** Although Cushing syndrome is rarely seen in infants, the paediatricians should take it into consideration in cases presenting with rapidly weight gain and decreasing growth rate in infancy.

**PAO-218**

**Do children with growth hormone deficiency diagnosed on the strength of one growth hormone stimulation test grow better than patients diagnosed on the strength of two stimulation tests on GH replacement therapy?**

Suneela Nayak, Al Ng; Swati Upadrashta; Urmli Das;
Poonam Dharmanaj, Joanne Blair, Mohammed Didi
Alder Hey Childrens Hospital, Paediatric Endocrinology, Liverpool, United Kingdom

**Background:** A recent consensus statement recommends the use of two growth hormone (GH) stimulation tests for the diagnosis of GH Deficiency (GHD) in childhood. Some clinicians have used a single GH stimulation test because of the high frequency of distress that such tests cause children and the lack of a strong evidence base to the recommendation, while others have followed the recommendation.

**Objective:** To compare the change in height (Ht) Standard deviation score during the first year of GH treatment in subjects diagnosed with Idiopathic Isolated GHD (IGHD) following one GH stimulation test (GHST) to those diagnosed following two GHSTs.

**Methods:** A retrospective case note review of all patients diagnosed with IIGHD diagnosed on the strength of one and two GH stimulation tests on GH replacement therapy.

**Results:** 19 patients were studied. Results are summarised in table 1. Data presented as median(range). Table 1. Ht SDS at diagnosis and ΔHt SDS for patients at the three time points during treatment with GH.

<table>
<thead>
<tr>
<th></th>
<th>Group 1 [n=12]</th>
<th>Group 2 [n=7]</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ht SDS at diagnosis</td>
<td>-2.7 (-0.9 to -4.5)</td>
<td>-2.5 (-1.9 to -3.5)</td>
<td>Not significant</td>
</tr>
<tr>
<td>ΔHt SDS 3-8 months</td>
<td>0.2 (0.1 to 0.4)</td>
<td>0.5 (0.3 to 0.8)</td>
<td>0.02</td>
</tr>
<tr>
<td>ΔHt SDS 9-15 months</td>
<td>0.3 (-0.1 to 0.8)</td>
<td>0.3 (0.1 to 0.8)</td>
<td>Not significant</td>
</tr>
</tbody>
</table>

**Conclusions:** Patients with IIGHD diagnosed on the strength of one and two GHST show no difference in the growth response in the first year when on optimal GH replacement therapy.

**PAO-219**

**Prevalence of metabolic syndrome (IDF 2007 criteria) in obese children and adolescents**

Didem Bezen1; Emine Dilek2; Filiz Tutunculer; Necdet Suf1

1Trakya University School of Medicine, Pediatric Endocrinology, Edirne, Turkey; 2Trakya University School of Medicine, Biostatistics, Edirne, Turkey

**Background:** Metabolic syndrome (MS) frequency is increased in proportion to the increasing prevalence of obesity in children and adolescents.

**Objective and hypotheses:** This retrospective study was performed to de-
When cardiovascular risk factors are considered, the increase in the MS level was significantly lower in the MS group when compared to the non-MS group.

**Results:**
The overall prevalence of MS in our study was 38% with no intersubject difference. Mean age was 12.7±1.62 years. Eighty-nine percent (n=176) of the patients were pubertal and MS was more often in this group. The prevalence of high systolic BP was 30%, high diastolic BP 25%, hyperglycemia 20%, low HDL-C 48.5%. Impaired glucose metabolism was identified in 17.6% of patients; 21 of them having impaired fasting glucose (IFG) and 14 of them having impaired glucose tolerance (IGT). There was no silent type 2 diabetes. Hepatic steatosis prevalence was 44%. All of the anthropometric measurements and BP levels were found higher in the MS group than those in the non MS group as expected. When we analyzed the cardiovascular risk factors; fasting blood glucose levels, insulin resistance, levels of total cholesterol, prevalence of IGT, hyperinsulinemia were significantly higher but HDL level was significantly lower in MS group when compared to non-MS group. LDL-C levels were found to be similar between two groups.

**Conclusions:**
MS prevalence at diagnosis is high (38%) in obese children. When cardiovascular risk factors are considered, the increase in the MS frequency gets more important for the future of children.

**PAO-220**

**Central precocious puberty unresponsive to LHRH analogue treatment in a patient with chromosomal anomaly and cerebropathia**

**Alessandra di Lascio**1; Silvia Laura Carla Meroni2; Elena Grechi3; Gianni Russo1; Maria Pia Guarneri1; Stefano D’Amigo1; Giuseppe Chiumento3

1San Raffaele Scientific Institute, Department of Pediatrics, Milan, Italy; 2C. Besta Neurologic Scientific Institute, Department of Neurology, Milan, Italy; 3C. Besta Neurologic Scientific Institute, Department of Neurology, Milan, Italy

**Background:** The treatment of central precocious puberty (CPP) is based on LHRH analogue (LHRH-a) with a good hormonal inhibition.

**Objective and hypotheses:** Our aim is to describe the case of a child with chromosomal alteration, cerebropathia and CPP, who does not respond to the treatment with LHRH-a.

**Population:** The child, born at 38 gestational weeks, showed hypospadias, microphalpy and some dysmorphic notes. He presented a neuropsychic developmental delay and seizures, so at the age of 2 years he started antiepileptic treatment. The karyotype was 46XY, the array CGH showed [del(1)(q41)] and [del(7)(q36.1q36.3)]. At 6 months of age he developed pubic hair and then penile and testes (4 mL) size and gynecomastia. The hormonal investigations (1 years 7 months) showed the activation of hypotalamus-pituitary-gonadal axis (LH peak 18.3 mIU/mL, testosterone 1.94 ng/mL), normal adrenal function and advancement of the bone age, suggestive for CPP. The NMR did not demonstrate anomaly of the brain and the hypotalamic-pituitary region. He started treatment with LHRH-a.

**Results:** The treatment with LHRH-a did not permit an adequate inhibition of the hypotalamus-pituitary-gonadal axis and it also caused an advancement of the pubertal development (basal LH 4.3 mIU/mL, testosterone 6.27 ng/mL, in presence of a good compliance). At 2 years and 2 months the treatment with LHRH-a was stopped and the treatment with luteolozio and cyproterone acetate was started.

**Conclusions:** In our patient the treatment with LHRH-a failed to induce hormonal inhibition. To our knowledge, similar cases are not reported. The possible causes of this failure are unclear: the genetic alteration, the potential alteration of pharmacokinetic of LHRH-a and the cerebropathia may be involved. Investigations to assess the reliability of these assumptions are in progress.

**PAO-222**

**A rare cause of precocious puberty: β-hCG secreting tumor**

Silvia Laura Carla Meroni1; Alessandra di Lascio2; Matilde Ferrario3; Gianni Russo1; Maura Massimino1; Giuseppe Chiumento3

1San Raffaele Scientific Institute, Department of Pediatrics, Milan, Italy; 2Sant’Anna Hospital, Department of Pediatrics, Como, Italy; 3National Scientific Tumor Institute, Department of Pediatrics, Milan, Italy

**Background:** Beta human chorionic gonadotropin (β-hCG) secreting tumors are a recognized cause of precocious puberty (PP), almost exclusively in boys. These tumours may occur in gonads, liver, retroperitoneum and mediastinum or within the central nervous system (CNS).

**Objective and hypotheses:** We present one case of PP due to β-hCG secreting tumour, whose site was difficult to determine.

**Population:** The boy came to our attention at age 6 years. Neurological examination was normal. Physical examination showed scrotal hair, enlarged penile and testes (4 mL) size and gynecomastia. Hormonal test revealed suppressed levels of gonadotropins at LHRH test (FSH peak 0.6 mIU/mL, LH peak 0.5 mIU/mL), increased testosterone (3.47 ng/mL), normal adrenal function, prolactin and α-fetoprotein and slightly higher β-hCG (6.8 U/L; nv 0-5 U/L).

**Results:** Hormonal picture was compatible with gonadotropin-independent PP due to β-hCG secreting tumour. To determine its site testicular and abdominal ultrasound, thoracic CT, abdominal and CNS NMR were performed. These studies didn’t reveal any suspicious lesion, with the exception of a cyst-like aspect of pineal gland. A lumbar puncture was performed and revealed slightly higher β-hCG (11.3 U/L).

The abnormal cerebrospinal fluid (CSF)/serum ratio of β-hCG was consistent with a CNS germ cell tumour. Although the tumour was not clearly identified, he underwent four courses of multi-agent chemotherapy (bleomycin, etoposide and cisplatin) and ventricular radiotherapy. β-hCG and testosterone values fell to within the normal range after the first course, indicating significant regression of the tumour. Nowadays the clinical and hormonal picture is stable.
Background: Neonatal thyrotoxicosis (NT) caused by maternal Graves disease is a rare disorder. In the newborn, characteristic signs and symptoms include tachycardia, irritability, poor weight gain, and prominent eyes. Rarely, infants with NT present with thrombocytopenia, jaundice and hepatosplenomegaly. We report a infant with hemorrhagic diathesis and conjugated hyperbilirubinemia, who was diagnosed with NT due to maternal Graves disease.

Case: One month-old male infant was admitted to our hospital for further evaluation of a bleeding after vaccination. He was born vaginally at 38 gestational weeks to a 23 year-old primagravida mother, with a birth weight of 2550g. It was learned that his mother had Graves disease for 2 years and did not take propylthiouracil regularly during pregnancy. Physical examination revealed weight of 3100g (1p), height of 51 cm (3p), head circumference of 34 cm (<3p, -2,2SD), prominent eyes and 2x2cm hemaoma at left inguinal region. The other physical findings were unremarkable. Laboratory studies showed normal hematological and coagulation parameters but mildly elevat-ed transaminases (ALT 74U/L, AST 55U/L) and conjugated bilirubin (3.8 mg/ dl) levels. Blood and urine culture were negative as were titers for toxoplasmosis, rubella, CMV, herpes, hepatitis B and C. Metabolic screening tests were negative. Thyroid function tests revealed that the infant was suffering from NT [free T4 2.5 mg/dl (0.63-2.3), free T3 4.9 pg/ml (1.8-4.2), TSH 0.17 mIU/ml (0.4-4.6) and TSR-Ab 54U/l (0-9)]. We decided to follow up him without treatment, because he had only biochemical thyrotoxicosis but not clinical.

After 2 months, his conjugated hyperbilirubinemia level resolved as well as thyroid hormone levels returned to the normal range. We suggest that as infants born from mothers with Graves may develop different clinical signs, they should be followed up carefully and closely after birth.

Conclusions: We retrospectively compared growth data of girls with CPP (n= 14, mean age was 8,4 yrs (4.5 - 14 yrs); mean initial height was -3,18 SD below normal and 0,12 SD when compared to other girls with Turner syndrome of the same age; the mean period of treatment was 3,26 yrs (1-7 yrs) and the mean dosage was 0,327 mg/kg/week (0,27-0,42); growth velocity per year of treatment averaged at 7,02 cm and growth velocity per year of bone development of both serum and CSF levels of β-hCG may be useful. β-hCG value was also considered an additional parameter for the diagnosis of CAH before hormonal biochemical confirmation. Therapy was promptly started, preventing hydro-electrolytical imbalances. Clinical, hormonal and instrumental parameters monitoring, along with psychological parents support allowed to early manage this case successfully and to create the premises for a good future therapeutic alliance.
median treatment period 2.4 years) and ISS (n=7, median treatment period 1.7 years) as well as data of boys with ISS (n=8, median treatment period 1.8 years) and SGA (n=5; median treatment period 3.0 years) before, during and after treatment. Girls born SGA (n=7, median treatment period 1.9 years) had an additional treatment with growth hormone. Near final height or adult height was reached by n=8 patients.

**Results:** Girls with CPP (n=4), treated with GnRHa, showed an improvement of their near final height or adult height in median by 6.2 cm. In girls born SGA (n=2), treated with GnRHa and growth hormone, the final height improved by median 8.9 cm. One boy with ISS, treated with letrozole, had an improvement of adult height by only 1.9 cm. However, one boy born SGA, showed an improvement of adult height by 15 cm according to Bayley-Pinneau. A transient decrease of bone density, as measured by the DEXA method, was observed. A patient questionnaire revealed no other relevant side effects due to the treatment with both Letrozole and GnRHa. Fig 1+2 show the reached gain of height.

**Conclusions:** Both medications seem to be able to improve the PAH. However, a small number of patients failed to improve the prospective adult height. In some patients, the adult height was reached and was higher than calculated before. Therefore, the therapy should be continuously supervised by a pediatric endocrinologist. Prospective controlled trials are necessary in future to confirm the results.

**PAO-227**

**The one year catamnecis in children from mothers after combine treatment of thyroid cancer**

**Júlia Davydova**¹, **Tatyana Kurilina**²

¹Institution of Pediatrics, Obstetrics & Gynecology, Extragenital pathology & perinatal rehabilitation, Kiev, Ukraine; ²Institution of Pediatrics, Obstetrics & Gynecology, Neonatology, Kiev, Ukraine

**Background:** The frequency of the thyroid cancer in Ukraine is 36:100000 per year and in twice more in women with the tendency to growth.

**Objective and hypotheses:** The protocol of the combine treatment include different variation of the extended thyroidectomy (in 2nd trimester), radioiodine therapy, suppressive therapy by thyroxin (2,3 mg/kg).

**Method:** Complex observation in neonatal period and one year follow-up performed in 30 infants from mothers after combine treatment of thyroid cancer.

**Results:** The most frequent compication of gestation period were threat of abortion, discoordination of the delivery, distress of the fetus, postpartum hemorrhage. Optimal development of the placental complex due to using of gestagens in the treatment complex of threat of abortion decreased morbidity of children during first month of life. In neonatal period 60 % of newborns received treatment of prolonged jaundice, 34 % - severe allergic reactions, 18 % - hypoxic-ischemic encephalopathy. Most every newborns had vegetative disorders (abnormality of microcirculation, regurgitation, breach of cardiac rhythm on the electrocardiogram, heightened disposition to sweating). The data of one year catamnecis in 3, 6, 9, 12 months show direct close correlation between frequency of neurological pathology, allergic reaction, vegetative dysfunction and exhaustiveness of the postoperative hypothyroidism compensation, peculiarities of medication of threat abortion. The physiotherapy of perinatal encephalopathy must have been made out in 36 % of infants 3-6 months of life. Common conditions for all children from mothers after combine treatment of thyroid cancer are high frequency of rachitic, acute respiratory infections, disorders of feeding and decreasing of frequency & duration of breast-feeding.

**Conclusions:** All this peculiarities make it possible to include children from mothers after combine treatment of thyroid cancer in high risk group for creation prophylactic-treatment arrangements for them.

**PAO-228**

**New onset type 1 diabetes in the pediatric population of a second level hospital: 12 years’ review and evaluation of recent treatment and connection between hospitals**

**Ana Laura Fitas**¹, **David Lito**², **Patrícia Ferreira**², **Rosa Pina**², **Florbela Cunha**²

¹Hospital de Dona Estefânia, Hospital de Reynaldo dos Santos, Pediatrics, Lisboa, Portugal; ²Hospital de Dona Estefânia, Pediatrics, Vila Franca de Xira, Portugal; Hospital de Dona Estefânia, Endocrinology, Lisboa, Portugal

**Background:** In the pediatric department of a Lisbon area’s second level hospital, new onset diabetes is managed in coordination with the tertiary hospital’s endocrinology team.

**Objective:** To characterize the children with new onset type 1 diabetes (1999-2011). To describe treatment procedures (2009-10) in order to evaluate the compliance to the 2008-Diabetic Ketoacidosis (DKA) National Protocol. To assess the need for improving the management of new cases without DKA.

**Methods:** Retrospective study. Clinical files were reviewed.

**Results:** 41 children were admitted, 3.4 new cases/year, with a modest increasing tendency. 61% females, median age 9 years. 90% previously healthy, only one obese child; 15% had type 2 diabetes in non-first degree relatives. All were admitted from the emergency department (44% referred with symptomatic hyperglycemia; 1 incidental finding). Classic new onset symptoms were the most common: polydipsia-93%; polyuria-83%; weight loss-68%; polyphagia-37%; lethargy-27%; 44% presented with DKA (severe in 10%). Median hospital stay was 2 days, with subsequent referral to endocrinology (66% to ward; 29% to consultation) and 5% to PICU. Concerning treatment after 2008 (n=13), insulin perfusion was administered to all ketoacidotic patients, with median duration of 6 hours. Insulin perfusion in non-ketoacidotic patients was variable (prescribed to 44%). All but 2 patients started IV iso-
tonic saline with potassium. Saline was replaced by 5-10% dextrose when initiating insulin (91% after at least one hour of IV hydration). One patient required HCO₃ correction before transference to PICU. Intermediate-acting insulin was always started after 24h.

**Conclusions:** These epidemiological and clinical aspects are according to published reports. Overall compliance with DKA guidelines is satisfactory. The lack of uniformity in the management of new cases without DKA highlights the need for implementing uniform procedures and improving the connection pathways between second and tertiary level hospital in the management of new onset diabetes.

**Objective and hypotheses:** This study was designed to review trends in presentation and incidence of childhood diabetes in the last 10 years in southwestern Iran.

**Methods:** During a detailed review of compiled records of Abuzar Children’s Hospital from Jan 2000 to Dec 2009, the following clinical information relevant to diabetes were extracted and analyzed: admissions for diabetes, all data regarding demographics, clinical status, laboratory findings, hospital course, morbidity, and mortality.

**Results:** Excluding 129 repeated admissions, 297 cases were enrolled for analysis: 223 new and 74 known cases. Among the new cases, 67.3% presented with DKA, without any gender bias. Among the DKA subjects, 45% had some degree of unconsciousness, and the mortality rate was 4%. The mortality risk was significantly higher in the <2-year group and in girls (boy:girl=1:7; p=0.039). Despite the increase in the number of medical centres that manage diabetic children, there is a regular increase (nearly 50.5% rises over 5 years—Figure) in the disease incidence.

**Conclusions:** Most of the new cases of T1DM presented with DKA, and this is similar to the trend seen in other developing countries. With an increasing incidence of DM, more attention to education of families and periodic retraining of health staff is essential to enable earlier diagnosis and management of new subjects, and to reduce morbidity and mortality rates associated with the disease.

**Trends in type 1 diabetes mellitus**

**Background:** Type 1 diabetes mellitus (T1DM) is the most common endocrine problem in childhood, with increasing worldwide incidence. The risk of developing diabetic ketoacidosis (DKA) is higher in children because of non-specific and non-classical signs and symptoms.

**Methods:** An analysis of diet 1 day in 28 children with type I diabetes. Energy expenditure determined by the computational method of WHO at a rate of physical activity. Actual energy consumption calculated on the menu layout. The data obtained was subjected to statistical analysis in Excel, Biostat.

**Results:** Table 1: Actual feeding of children

<table>
<thead>
<tr>
<th>Indicators</th>
<th>Excess (66.7%)</th>
<th>Lack (33.3%)</th>
<th>Excess (66.7%)</th>
<th>Lack (33.3%)</th>
<th>Excess (66.7%)</th>
<th>Lack (33.3%)</th>
<th>Excess (66.7%)</th>
<th>Lack (33.3%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Energy value</td>
<td>(33.3%)</td>
<td>(66.7%)</td>
<td>(33.3%)</td>
<td>(66.7%)</td>
<td>(14.3%)</td>
<td>(85.7%)</td>
<td>(14.3%)</td>
<td>(85.7%)</td>
</tr>
<tr>
<td>Proteins (%)</td>
<td>100</td>
<td>0</td>
<td>46.7</td>
<td>53.3</td>
<td>66.7</td>
<td>33.3</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>Fat (%)</td>
<td>33.3</td>
<td>66.7</td>
<td>20</td>
<td>80</td>
<td>66.7</td>
<td>33.3</td>
<td>28.6</td>
<td>71.4</td>
</tr>
<tr>
<td>Carbohydrates</td>
<td>66.7</td>
<td>33.3</td>
<td>20</td>
<td>80</td>
<td>0</td>
<td>100</td>
<td>14.3</td>
<td>85.7</td>
</tr>
<tr>
<td>Calcium (%)</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>100</td>
<td>67</td>
<td>93.3</td>
<td>42.9</td>
<td>57.1</td>
</tr>
<tr>
<td>Magnesium (%)</td>
<td>100</td>
<td>0</td>
<td>73.3</td>
<td>26.7</td>
<td>100</td>
<td>0</td>
<td>42.9</td>
<td>57.1</td>
</tr>
</tbody>
</table>

**Conclusions:** In children prepubertal period dominated by an increase in energy value, at puberty - a decline. Excessive intake of protein, including animals, in children prepubertal period. Carbohydrate intake increased in girls prepubertal period. Fat intake increased in boys prepubertal period. Girls prepubertal period, an increase calories by excess consumption of protein and carbohydrates, the boys - protein and fat. At puberty there is an increase calories from fat and carbohydrates. Girls and boys prepubertal period body mass index as normal 33.3% and 66.7%, and at puberty there is a tendency to increase 53.3% and 57.1%. Excessive food intake in boys and girls to dominate the dinner 83.3% and 100% respectively.

**Objective and hypotheses:** The aim of our study was to identify communication and the adequacy of the diet with the peculiarities of the clinical and metabolic status in children with type I diabetes.


**Results:** Table 1: Actual feeding of children

**Conclusions:** In children prepubertal period dominated by an increase in energy value, at puberty - a decline. Excessive intake of protein, including animals, in children prepubertal period. Carbohydrate intake increased in girls prepubertal period. Fat intake increased in boys prepubertal period. Girls prepubertal period, an increase calories by excess consumption of protein and carbohydrates, the boys - protein and fat. At puberty there is an increase calories from fat and carbohydrates. Girls and boys prepubertal period body mass index as normal 33.3% and 66.7%, and at puberty there is a tendency to increase 53.3% and 57.1%. Excessive food intake in boys and girls to dominate the dinner 83.3% and 100% respectively.

**Objective and hypotheses:** The study aimed to investigate the relation between skinfold thickness and serum leptin, ghrelin, adiponectin and resistin levels in infants of diabetic mothers.

**Methods:** We aimed to investigate the relation between skinfold thickness and serum leptin, ghrelin, adiponectin and resistin levels in infants of diabetic mothers. The mother two were diagnosed as having gestational diabetes by an Oral Glucose Tolerance Test (OGTT) performed between 24-28 gestational weeks, and their babies were included into this study. Mean HbA1C level between diabetic and control mothers were not significantly different. Mean Body Mass Index (BMI), abdominal circumference, upper extremity circumference, and biceps skinfold thickness was not significantly different between infants of diabetic mother and control infants. However, mean subscapular ad triceps skinfold thickness was significantly lower in infants of diabetic mother. Mean leptin, ghrelin, adiponectin and resistin levels were also not significantly different between infants and diabetic mother and control infants. Our results indicates that early diagnosis of gestational diabetes and control by appropriate diet or insulin treatment may be effective in protection of fetuses of diabetic mother from the negative effects of gestational diabetes.

**Conclusion:** The data obtained was subjected to statistical analysis in Excel, Biostat.

**Methods:** An analysis of diet 1 day in 28 children with type I diabetes. Energy expenditure determined by the computational method of WHO at a rate of physical activity. Actual energy consumption calculated on the menu layout.

**Results:** Table 1: Actual feeding of children

**Conclusions:** In children prepubertal period dominated by an increase in energy value, at puberty - a decline. Excessive intake of protein, including animals, in children prepubertal period. Carbohydrate intake increased in girls prepubertal period. Fat intake increased in boys prepubertal period. Girls prepubertal period, an increase calories by excess consumption of protein and carbohydrates, the boys - protein and fat. At puberty there is an increase calories from fat and carbohydrates. Girls and boys prepubertal period body mass index as normal 33.3% and 66.7%, and at puberty there is a tendency to increase 53.3% and 57.1%. Excessive food intake in boys and girls to dominate the dinner 83.3% and 100% respectively.

**Conclusion:** The study aimed to investigate the relation between skinfold thickness and serum leptin, ghrelin, adiponectin and resistin levels in infants of diabetic mothers. The mother two were diagnosed as having gestational diabetes by an Oral Glucose Tolerance Test (OGTT) performed between 24-28 gestational weeks, and their babies were included into this study. Mean HbA1C level between diabetic and control mothers were not significantly different. Mean Body Mass Index (BMI), abdominal circumference, upper extremity circumference, and biceps skinfold thickness was not significantly different between infants of diabetic mother and control infants. However, mean subscapular ad triceps skinfold thickness was significantly lower in infants of diabetic mother.

We aimed to investigate the relation between skinfold thickness and serum leptin, ghrelin, adiponectin and resistin levels in infants of diabetic mothers. The mother two were diagnosed as having gestational diabetes by an Oral Glucose Tolerance Test (OGTT) performed between 24-28 gestational weeks, and their babies were included into this study. Mean HbA1C level between diabetic and control mothers were not significantly different. Mean Body Mass Index (BMI), abdominal circumference, upper extremity circumference, and biceps skinfold thickness was not significantly different between infants of diabetic mother and control infants. However, mean subscapular and triceps skinfold thickness was significantly lower in infants of diabetic mother. Mean leptin, ghrelin, adiponectin and resistin levels were also not significantly different between infants and diabetic mother and control infants. Our results indicates that early diagnosis of gestational diabetes and control by appropriate diet or insulin treatment may be effective in protection of fetuses of diabetic mother from the negative effects of gestational diabetes.
PAO-232

Correlation of childhood obesity with obesity at late adolescence and young adulthood
Epila Vlachopapadopoulou; Fotini-Eleni Karachalios; Pelagia Soutoulou; Stefanos Michalakos
Children’s Hospital P.A. A. Kyriakou, Growth and Development, Athens, Greece

Aim: The aim of this study is to answer the question whether an obese child becomes an obese adolescent and/or obese young adult.

Methods: It’s a follow-up study of obese children followed in our department for the time period 1997-2006. We contacted 234 (109 M) of them during the last trimester of 2010, and they were asked to answer a semi-structured questionnaire. The questionnaire included questions regarding sociodemographic data of the family, current height and body weight of the index case, factors that in their opinion affect weight control. At present 141 cases were contacted, from them 43 were not available because of address change, 3 refused to participate and 22 were excluded because of young age (<16 yrs old). The response rate is 96.6%. To analyze the data we used descriptive statistics.

Results: The two sexes were equally represented in both the childhood sample (46.5 % M and 53.3 % F) and the follow up sample (46.7 % M, 53.3 % F). Of this cohort of obese children, follow up – 24.7 % were obese, 32.6 % were overweight and 42.7 % were of normal weight. More than half, 52.8 %, were overweight and obese at follow-up. Examining the sexes separately, 7.9 % of the women were obese and 22.5 % were overweight whereas 16.9 % of men were obese and 10.1 % were overweight.

Conclusions: These data, based on this particular sample of obese children, that they were investigated and received dietetic counseling in a tertiary center, suggest that more than half of this cohort have body mass index higher than normal, at young adulthood. Furthermore we conclude that obesity is more prevalent in men, whereas overweight is more prevalent in women. The limitations of the present study is the relative small sample size (the study is ongoing) and the absence of control group in order to assess whether early intervention has a positive effect on long term weight control.

PAO-233

Resistance to usual treatment in a patient with primary hypoparathyroidism: a coincident association with a celiac disease
Sanaa Abourazzak; Sanaa Chaouki; Mounia Idrissi; Samir Atmani; Abdelhak Bouharrou; Moustapha Hida
Mere-Enfants Hospital, Pediatrics, Fez, Morocco

Background: Hypocalcemia may present as an asymptomatic laboratory finding or as a severe, life-threatening condition. Chronic hypocalcemia may be well tolerated by the patient, but treatment nonetheless remains necessary in order to prevent long-term complications.

Objective: We present a case study of a patient with primary hypoparathyroidism who is surprisingly resistant to the usual treatment consisting of calcium and vitamin D supplementation.

Methods: We report the case of a 14-year old girl, in which the diagnosis of primary hypoparathyroidism was retained because of the association of low PTH coupled with severe hypocalcemia with seizure and brain calcifications.

Results: The patient was treated with intravenous calcium gluconate with a good response. Then, she was treated with oral calcium gluconate and alfalcidol with persistence of the clinical symptoms of hypocalcemia (paresthesia, good response). Then, she was treated with oral calcium gluconate and alfacalciol with persistence of the clinical symptoms of hypocalcemia (paresthesia, good response).

Conclusions: This finding suggests that coexisting celiac sprue is one of the mechanisms responsible for the malabsorption associated with idiopathic hypoparathyroidism concluding in a rare association.

PAO-234

Pseudohypoparathyroidism: monogenic obesity and tall stature
Filiz Mine Cizmecioglu; Elif Oztu; Gul Yesiltepe Mutlu; Sukru Hatun
Kocaeli University School of Medicine, Pediatric Endocrinology and Diabetes, Kocaeli, Turkey

Background and aim: Obesity is a common feature in patients with type 1a pseudohypoparathyroidism (PHP) and affected patients typically also have short stature. We describe a infant with PHP who developed morbid obesity with tall stature in early infancy.

Methods: 6 months female infant with history of abnormal weight gain and increased appetite was referred for endocrinological evaluation. She was born 38 week gestation with birth weight 4500 gram and rapid weight gain at 1 month. She was only breastfed from birth. Frequently nursed due to crying 3kg/last 1 month. Prenatal history unremarkable. No vitamin D taken by mother during pregnancy or child after birth. On physical examination at 6 months of age length was 70cm (1.4SD) weight was 13 kg (4.8SD) and head circumference was 48>(<2SD). She had no dysmorphic feature but she had a hard subcutaneous nodule in her lumbar area and umbilical hernia. Laboratory investigation showed the following values: serum calcium: 6.8 mg/dL (8.6-10.6mg/dL.), phosphorous: 7.6mg/dL (4.2-7mg/dL.), magnesium: 3.7 mg/dL (1.6-2.6mg/dL.), alkaline phosphatase:333 U/L(145-420U/L), parathyroid hormone:400 pg/Ml (9-69pg/mL), albumin: 3.7 mg/dL (4.5mg/dL.), 25(OH)D: 55 ng/m (15-80ng/mL), thryrotrpin: 6.87 mU/m (0.5-2.5mU/mL), free thryoxin: 0.69 ng/dL (0.8-1.8ng/dL), cortisol: 2.65 ug/dL (4.2Tgug/dL.), corticotropic: 12.9 pg/mL (10-60), leptin: 23 ng/mL. Excessive weight gain, mild hypothroidism and increased parathyroidism and decreased serum calcium suggested a diagnosis of Pseudohypoparathyroidism type 1a.

Conclusion: Hypothalamic G-protein coupled melancorin receptor may mediate the central effects of leptin. GNAS mutation result in underactivity of MCR4 It explains the obese, hyperphagic and tall stature phenotype and suggest that the genetic mutations which underlie PHP may be a more common cause of severe obesity.

PAO-235

Clinical evaluation of short children referred by school screening: an analysis of 2589 children according to the WHO norms of 2007
Ikram Louati1; Feriel Limam1; Ires Karmoun2; Bouzid Chiraz1; Zinet Turki1; Shihem Saed Allali1; Fatma Baalouch2; Claude Ben Slama2; Olfa Larbec1; Chiheb Ben Rayana1
1Hôpital Grombalia, Pédiatrie, Nabeul, Tunisia; 2Grombalia Hospital, Pediatric, Nabeul, Tunisia; 3National Institute of Nutrition, Endocrinology, Tunis, Tunisia; 4National Institute of Nutrition, Biology, Tunis, Tunisia

Background: An isolated delay in growth can reveal a treatable pathology. A school inquiry was launched. A prospective study was made during the school year 2008/2009 in the north of Tunisia.

Objective and hypotheses: To determine the prevalence of stunting growth and the etiologies.

Methods: All school children 5 to 8 years old: 2589 children have benefitted from a school screening. Infants with short stature (heights< -2SDs) have been identified for exploration. Exploration included: a detailed medical history, nutritional inquiry, physical examination and successive tests, according to primary results, of blood count, bone age, thyroid function, celiac serology, chromosome tests, and growth hormone screening. We use the new tables of the WHO published in 2007.

Results: 1.4% (36) infants have a pathological short stature: thyroid dysfunction (2 children), growth hormone deficiency (9 children), intra-womb short stature (8 children), Turner syndrome (1 child), bone constitutional disease (2 children), congenital hepatic disease (1 child) and 14 children with constitutional delay.

Conclusions: The majority of short stature in our region is due to either constitutional delay or endocrine causes. The screening for stunting growth in 5 to 8 year old children would allow treatment resulting in a more effective, and improved height development.
**PAO-236**

**Graves’ disease management with antithyroid drug (ATD) therapy - retrospective analysis of 35 children**

Paweł Matusik; Martyna Lopotacka; Anna Gronna; Agnieszka Bargielska; Aleksandra Januszek-Tzciakowska; Ewa Malecka-Tendera

1 Medical University of Silesia, Department of Paediatrics, Endocrinology and Diabetes, Katowice, Poland; 2 Medical University of Silesia, Scientific Society of Students, Katowice, Poland

**Background:** Graves’ disease is the most common cause of thyrotoxicosis in children, which can have many negative effects on both physical and psychological development. Antithyroid drug (ATD) therapy is recommended as the initial treatment but still exist many controversies concerning optimal duration of ATD therapy.

**Objectives and hypotheses:** The aim of our study was the retrospective evaluation of ATD therapy in children with Graves’ disease.

**Methods:** The medical history of 35 children (29 girls) in mean age of 12.1 years was analyzed. Total duration of treatment, time to initial remission, number of relapses, way of ATD therapy discontinuation and block and replace treatment were taken into consideration.

**Results:** Mean time of observation was 2.5 yrs (max. 5.83 yrs.). The initial hormonal remission was achieved in 30 (85.7%) children. Mean ATD therapy duration for hormonal remission was 4 months. Only in 14 (34.3%) discontinuation of ATD was possible and mean time free from ATD was 6 months.

Mean number of relapses 2.42 was observed. In 34.3% of children ATD dose reduction was fast (by 50% during a weeks), 34.3% of children had prolong ATD low dose therapy (form 1.25 to 2.5 mg/d for several months), in 54.3% of children combination of L-thyroxine with ATD was used.

No differences concerning time of initial remission, time and number of relapses depending on way of ATD dosage was found. 5 children from that group were qualified to radioiodine therapy.

**Conclusions:** ATD therapy in children is effective way to achieve initial clinical and hormonal remission in GD thyrotoxicosis but longer permanent remission (after ATD discontinuation) than 6 months is unusual. The late outcome of ATD therapy seems to have no relationship to way and duration of dosage.

**PAO-237**

**Results of Gn-RH analogs (triprotrelin) therapy in girls with idiopathic true precocious puberty**

Juliana Ghariani; Camelia Procopiuc; Cristina Patricia Dumitrescu; Nina Dumitriu; Corina Neamtu

3 „C. I. Parhon” National Institute of Endocrinology, Pediatric Endocrinology, Bucharest, Romania; 4 “M. S. Curie” Children Hospital, Endocrinology, Bucharest, Romania; 5 “C. I. Parhon” National Institute of Endocrinology, Ultrasonography, Bucharest, Romania

**Background:** True precocious puberty (PP) has negative psychological consequences and is often associated with a reduction of final adult height.

**Objectives and hypotheses:** To study the efficiency of triptorelin treatment (3.75 mg i.m. monthly) over clinical features, hormonal profile and predicted adult height (PAH) in girls diagnosed with idiopathic true PP.

**Methods:** We conducted a retrospective study over patients diagnosed with idiopathic true PP in the pediatric endocrinology department in the last 5 years; we only considered patients treated for at least 6 months continuously.

**Results:** We identified 42 patients (aged 3 to 8.6 years at the beginning of treatment), which were treated for an average period of 25 months (6-51 months). Growth velocity during treatment was between 3.8 cm/years and 11.8 cm/year, (average 6.4 cm/years); the bone age had a slow rate of progression during treatment (0.85 years bone age/1 year chronological age).

The predicted adult height (PAH) at the end of therapy was significantly higher than the predicted final height at the beginning of the therapy. The PAH at the last evaluation during triptorelin therapy was negatively and significantly correlated with the difference between bone age and statural age at the beginning of treatment; we also identified correlations between PAH and bone age at the beginning of therapy (negative correlation) and between PAH and midparental height. 8 patients were re-evaluated after cessation of therapy (between 3 months and two years, at a chronological age of 9.5 -12 years);

their growth velocity was between 5.5 and 8.2 cm/year (average = 6.9 cm/ano) and none of them was menstruate.

**Conclusions:** Triptorelin therapy has proved to be efficient in regression of pubertal signs, in restoring prepubertal hormonal profile and improving final height; it is mostly efficient in patients with high midparental height and low bone age at the beginning of therapy.

**PAO-238**

**Final height in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency**

Suely Keiko Kohara; Tatadzwa Makaya; Paul Dimitri; Neil Wright; Jerry Wales

1 UNIVILL, Pediatrics, Joinville, Brazil; 2 Sheffield Children’s Hospital, Endocrinology, Sheffield, United Kingdom

**Background:** Achievement of optimal growth is one of the major problems in the management of children affected by congenital adrenal hyperplasia (CAH) due to 21-hydroxilase deficiency (21-OHD). The current literature reports that patients with classic CAH often do not achieve their target height (TH) and that they are obese. Glucocorticoid replacement is vital for preventing adrenal crisis and reducing androgen excess, but results in growth inhibition when administered in larger doses. If the androgens are not suppressed, there is advancement of bone age with premature fusion of the epiphyses and ultimate short stature.

**Aim:** The aim of this study was to evaluate final height (FH) of patients with the classic form of 21-OHD and compare to TH.

**Methods:** We reviewed the growth charts of patients with CAH who had attained FH.

**Results:** We evaluated 14 patients who had attained FH. 7 salt-wasting (SW) and 7 simple virilizing (SV). Five patients were male. Mean age at onset of treatment was 2.6y. Target height was available in twelve patients and mean TH-SDS was -0.15±1.1. Mean FH-SDS was -0.58±1.24. Corrected FH (FH-SDS – TH-SDS) was -0.66. All the patients were treated with hydrocortisone. Two patients were overweight at FH. The last bone age done at a mean chronological age of 13 years were advanced more than 1 year in 6 patients.

**Conclusions:** We concluded that mean FH of our CAH patients was within normal range, but in 8 patients was below the genetic target, as reported in the literature. Only one patient was obese.

**PAO-239**

**Response of C-peptide/ insulin during a mixed meal test in combination with repaglinide to identify the diabetes type and the option for oral treatment**

Diemud Simm; Henk-Jan Veeze; Henk-Jan Aanstoot

Diabetes, National Center of Diabetes in Children and Young Adults, Diabetology, Rotterdam, Netherlands

**Background:** The aetiology and type of diabetes is not always clear in young diabetes patients. While clinical features, autoimmune antibodies (IC, GAD, IA2 and insulin) as well as molecular diagnostics for Mody 1 – 6 help to distinguish diabetes forms, a subgroup remains without a certain diagnosis.

**Objectives and hypotheses:** For such cases we aimed to develop a method to evaluate β-cell function and subsequent options of treatment by repaglinide, a short acting insulin secretagogue (maximum plasma concentration within 0.5 – 1h, half life 1 h) which also stimulates early insulin secretion and is thus suitable to be combined with a β-cell provocation. A mixed meal test combined with incremental dosages of repaglinide was previously applied by Lawrence S. Coma et al. to show the effectiveness of the medication in type 2 diabetes.

**Methods:** Seven patients with unclear aetiology of diabetes and 1 healthy control person underwent after an overnight fasting period a MMT with Sustacal 6 ml/kg (max.: 360 ml) ingested in combination with repaglinide 1 mg directly before the meal intake. Glucose, insulin and c-peptide were determined after fasting and 30, 60, 90, 120, 150 minutes after test start, i.e. repaglinide medication and start meal intake.

**Results:** In this pilot study we identified five patients who responded with sufficient insulin release to change medication from insulin to repaglinide.

**Conclusions:** We conclude that this test identifies individuals with repa-
glime responsive diabetes in whom traditional tests couldn’t clarify the aetiology and thereby were placed on insulin therapy. Using this test we can offer an oral treatment option despite in some of the cases the molecular diagnosis is not yet clear.

### Incidence and clinical characteristics of the new cases of type 1 diabetes in Galicia, Spain
Claudia Heredia1; Jesus Barreiro1; Aurora Pavor1; Pablo Lazaro1; Jose Luis Chamorro1; Pablo Faria1; Maria Mercedes Rodicio1; Alicia Cependado1; Maravilla Santos2; Ines Quintela2; Codo Lourdes2; Paloma Cabanas2; Maria Jose Pita2; Marian Rodriguez2
1Hospital de Santiago de Compostela, Universidad de Santiago de Compostela, Unidad de Endocrinologia Pediatrica, Creixonimento y Adolescencia, Santiago de Compostela, Spain; 2Hospital Provincial de Pontevedra, Pediatría, Pontevedra, Spain; 3Hospital Infantil Teresa Herrera, Pediatría, A Coruña, Spain; 4Hospital Xeral-Cies, Pediatría, Vigo, Spain; 5Hospital Cristal Piñor, Pediatría, Ourense, Spain; 6Hospital Da Costa, Pediatría, Burela, Spain; 7Hospital Xeral Calde, Pediatría, Lugo, Spain; 8Hospital Arquitecto Marcide, Pediatría, Ferrol, Spain; 9Hospital Virxe da Xunqueira, Pediatría, Cee, Spain; 10Hospital Comarcal Montforte, Pediatría, Monforte, Spain; 11Hospital del Barbanza, Pediatría, Viveira, Spain

**Objective:** Studying the epidemiology of childhood-onset type 1 diabetes (DM1) less than 15 years of age in hospitals of Galicia (Spain) during the period 2001-2010.

**Methods:** We identify new cases with DM1 criteria diagnosed by a paediatrician in Galicia Autonomous Community from January 2001 to December 2010 and conducted a data collection protocol to hospitalization include age, prior to the debut diabetic symptoms, duration, associated autoimmune disease, family history and biochemical parameters at diagnosis.

**Results:** We identified 559 subjects with childhood-onset DM1 during 2001-2010 and distributed by sex: 44.3% females and 55.6% males. The annual incidence rate was 17.2/100,000/year (range: 15.0-19.4); younger than 5 years-224 patients (40.8%). Nineteen patients (3.3%) had celiac disease, 15 patients (2.68%) autoimmune thyroiditis, 22 children (3.54%) developed diabetes before the age of 1 year, 104 patients (18.8%) were diagnosed during the first 5 years of life. The average age at diagnosis was 7.8-4.9 years. 11 males (52.4%), 10 females (47.6%), 2 prepubertal children (9,5%), 19 pubertal (90,5%).

<table>
<thead>
<tr>
<th>Years</th>
<th>Polyuria (%)</th>
<th>Polydipsia (%)</th>
<th>Enuresis (%)</th>
<th>Weight loss (%)</th>
<th>Average glycaemia (mg/dL)</th>
<th>HbA1c (%)</th>
<th>Diabetic ketoacidosis (DKA) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-4.9 years</td>
<td>14.7 (1-24)</td>
<td>97.6</td>
<td>94.9</td>
<td>59</td>
<td>475</td>
<td>8.9</td>
<td>34.4</td>
</tr>
<tr>
<td>5-9.9 years</td>
<td>24.6 (2-68)</td>
<td>96.4</td>
<td>100</td>
<td>78</td>
<td>386.3</td>
<td>10.9</td>
<td>29.6</td>
</tr>
<tr>
<td>10-14.9 years</td>
<td>28.7 (3-120)</td>
<td>97</td>
<td>64</td>
<td>87</td>
<td>536.4</td>
<td>11.8</td>
<td>24.1</td>
</tr>
</tbody>
</table>

**Conclusions:** The incidence peak was found in the 10 to 14 years age-group and a third of the children was diagnosed with DKA. The 0-4.9 years group was diagnosed in less time and with lower values of HbA1c. The most common symptoms were polydipsia, polyuria and weight loss. The incidence remained stable over the 10 years.

### Use of 70/30 premixed insulin in DM1 pediatric patients with a basal bolus regimen with multiple snacks
Marta Ferrer-Lozano1; Mercedes Rodriguez-Rigual2; Gracia M. Lou-Francés3; Maria D. Cañas-Redondo4; Jose I. Perales-Martinez1; Sofia Congost-Marin5
Children’s University Miguel Servet Hospital, Paediatric Diabetes and Endocrinology, Zaragoza, Spain

**Background:** Metabolic control is related with the number of short-acting analogs bolus administered, as we reported in a previous study [3 bolus (n:33) HBAlc: 8.54+/-0.8; And >4 bolus (n:73) HBAlc: 7.52+/-0.8; p<0.001]. In our country, children have 4-5 meals/d, with midmorning and midafternoon snacks. Some of them, especially adolescents, refuse to receive more bolus/d, and have snacks without insulin. In these patients a premixed 70/30 insulin at breakfast and/or lunch could better satisfy insulin requirements, improving glycaemic profile and HBAlc.

**Objective and hypotheses:** To analyze the characteristics of a regimen using a premixed insulin 70/(aspartic) 30(NPH), related to insulin requirements (U/kg/d), time of the injection and its effect on metabolic control.

**Methods:** 28 DM1 patients with a basal-bolus regimen, 3 short-acting analogs/d and poor metabolic control were proposed to change to 70/30 premixed insulin at breakfast and/or lunch. 21 patients were included. Mean age +/- DS: 15.14 +/- 2.49 years (range 9-17). Diabetes evolution: 7.52 +/- 4.19 years (1-16). 11 males (52,4%), 10 females (47,69%), 2 prepubertal (9,5%), 19 pubertal (90,5%).

**Results:**

<table>
<thead>
<tr>
<th>Insulin requirements (U/Kg/d)</th>
<th>Before change</th>
<th>After change</th>
<th>Mean of differences</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBAlc (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(range)</td>
<td>8.48 ± 0.85</td>
<td>7.8 ± 0.87</td>
<td>-0.68 ± 0.87</td>
<td>NS</td>
</tr>
<tr>
<td>(6.6-10)</td>
<td>7.92 ± 0.80</td>
<td>7.0 ± 0.87</td>
<td>-0.92 ± 0.87</td>
<td>NS</td>
</tr>
<tr>
<td>(6.6-9.7)</td>
<td>-1.01 ± 1.7</td>
<td>-0.9 ± 1.65</td>
<td>0.002 0.000</td>
<td></td>
</tr>
</tbody>
</table>

Premixed insulin administered at breakfast in 33% of the patients, at lunch in 42.9%, and at breakfast and lunch in 23.8%.

**Conclusions:** In DM1 patients having multiple snacks who refuse to receive more than 3 bolus, the change to a regimen with 70/30 premixed insulin at breakfast and/or lunch improve significantly their metabolic control, reducing HBAlc. The change from a short-acting analog to 70/30 premixed insulin does not vary total insulin dose significantly.

### Disorder of sex development in southern Nigeria: a report of four cases and constraints in management
Tamunoriye Jaja1; Iboro Yahaya1; Ifeoma Anochie2
University of Port Harcourt Teaching Hospital, Paediatrics, Port Harcourt, Nigeria

**Background:** Disorder of sex development (DSD) is a congenital condition in which development of chromosomal, gonadal, or anatomic sex is atypical. The prevalence of DSD is about 1% among live births and about 0.1-0.2% present with marked genital ambiguity. In most developing countries, the exact incidence is not known. This is because some cases are missed at delivery, which is mainly by traditional birth attendants and amongst clinicians, poor awareness is a major challenge.

**Objective and hypotheses:** To report four cases of DSD seen in a tertiary hospital in Southern Nigeria and highlight management constraints.

**Methods:** Case notes of patients with ambiguous genitalia seen at the Paediatric endocrine unit between January 2008 and December 2010 were analysed. Literature was reviewed for comparison with current trend in investigations and management. Parents were interviewed using a structured questionnaire and results analysed.
Results: Of 62 children seen with various endocrine disorders during the study period, 4 (6.4%) had ambiguous external genitalia. Their ages at presentation ranged from 6 days to 16 years. The commonest initial clinical diagnosis was congenital adrenal hyperplasia. Confirmatory diagnosis was not done in any of the patients due to financial constraint and non availability of facilities for performing the investigations in our centre. Three (75%) were lost to follow up while one patient died from chronic renal failure. Reasons for default were religious (2/50%), financial constraints in investigations (4/100%), lack of diagnostic tools (35%), and unwillingness to continue follow up (2/50%).

Conclusions: There is still delay in diagnosis of ambiguous genitalia in our environment. Lack of diagnostic facilities, belief in spiritual attacks and high cost of confirmatory test have led to high rate of loss to follow up.

PAO-243
The TRH test identifies hypothalamic defects of the thyroid axis in children within euthyroid state
Ana de la Puente Arévalo1; Julio Guerrero-Fernández1; R Morà2; Jose María Iturzaeta2; R. Gómez2; Antonio Buño2; María Antonia Molina1; Isabel González Casado1; Ricardo Gracia Bouthelier1; Jose Carlos Moreno2
1La Paz University Hospital, Pediatric Endocrinology, Madrid, Spain; 2La Paz University Hospital, Biochemistry and Clinical Analysis, Madrid, Spain; 3La Paz University Hospital, Molecular Thyroid Laboratory, ING EMM-Institute for Medical and Molecular Genetics, Madrid, Spain

Background: Congenital Central Hypothyroidism (CCH) has a prevalence of 1:16,000 neonates. 40% of cases are isolated pituitary or hypothalamic deficiencies. CCH is not screened for in Europe where TSH is mainly used as screening. Besides, it is not routine to discriminate between secondary or tertiary CCH using the TRH test. Pituitary CH is due to TSHB and TRHR genes mutations, while hypothalamic CH remains genetically “orphan”.

Objective and hypotheses: To test the discriminative capacity of the TRH test in the etiology of CCH.

Methods: After 7 µg/kg TRH, TSH and PRL were determined at -15, 0, 15, 30, 60, 120 and 180 min. and FreeT4 and TotalT3 at 0 and 180 min. We analyzed TSH peak, its return to basal levels and dynamics of TSH increase in both groups - mean age 14,02±2,8 y. and boys) - mean age 14,12±4,32 y. Control group was consist of 11 girls and 8 boys - mean age 14,02±2,8 y. We analyzed patients with good and bad compensation of diabetes type 1.

Results: Patients 1 and 2 had type 3 TSH response (hypothalamic defect) with 15’/0’ and 30’/0’ ratios and fall (ratios 30’/60’ and 180’/0’) upon Van Tijn. The test was performed in: 1. A 20 month old girl with postnatal progressive and severe growth retardation (-3.7 SD weight and height), hyperfagia and perthyrotropinemia (TSH 9.82 mU/L) and hyperglycemia (109 mg/dl) (TRH test suspect). 2. An 11 year old boy with hypothermia-bradichardia-sweating crises and sporadic electrocardiography examination in patients with diabetes type 1.

Conclusions: There is still delay in diagnosis of ambiguous external genitalia in our environment. Lack of diagnostic facilities, belief in spiritual attacks and high cost of confirmatory test have led to high rate of loss to follow up.

PAO-244
Type 1 diabetes mellitus in schools - monitoring of current practice
Cristina Matei1; Nadeem Abdullah2
1Norfolk and Norwich Hospital, Paediatrics, Newmarket, United Kingdom; 2Addenbrooke’s hospital, Paediatrics, Cambridge, United Kingdom

Background: It has been shown that by improving diabetes control, the rate of complications later in life is reduced. In the recent years, there is more interest in multiple injection therapy and continuous subcutaneous infusions compared to the conventional twice daily regimes.

Objective: We wanted to establish the level of support in school for children and young people with diabetes in our area.

Methods: We prospectively collected questionnaires, anonimised from parents or patients attending paediatric diabetes outpatient clinics over 2 months period, (July-September 2010). Our questionnaires included: who does blood glucose testing?, what insulin regimes children are on?, who does the insulin injection in school? and the patient’s views about different aspects of education and understanding of school staff of diabetes.

Results: We had a total of 78 questionnaires completed and returned. Most children had insulin given in school (44 out of total 78) In the overall sample, most injections were done by the children or young people with supervision from school staff.

Conclusions: We concluded that even in some schools there continues to be fear of managing diabetes. The main problem continues to be the administration of insulin in the young age group, who are most vulnerable group. However, insulin is only a part of the complex assistance children with diabetes need in school. We believe that our efforts should concentrate in improving schools’ understanding of diabetes and education in management of this condition.
Results: discovered according to standard medical protocols for this pathology. 397 children from 0 to 18 years of age with diagnose DM1 were

Methods: The patient was consulted by Pediatric Orthopedist, Nephrologists and Endocrinologist. The blood biochemical findings revealed normal pH, normal calcium (Ca)-, potassium (K)-, sodium (Na)-concentrations, very low phosphate (P)- with markedly elevated alkaline phosphatase (AP)- and slightly elevated parathyroid hormone (PTH)-concentration; urine test indicated impaired tubular function: mild glucosuria, proteinuria, erythrocyturia and markedly increased phosphaturia. Phosphate tubular reabsorption (PTR) was 52%, phosphate clearance/creatinine clearance 0,52, renal threshold phosphate concentration (TmP/GFR) 0,25mmol/l. Genetic tests results not available yet.

Results: The diagnosis of phosphate diabetes made on the basis of clinical-laboratory data. The therapy with Inorganic phosphate (100mg/kg/d) and 1,25(OH)2VitD 50-60ng/kg/d had been started. Childs walking abilities improved with treatment, the deformation of legs decreased, but O-legs and other skeletal deformations are still remarkable. Auxological parameters are not satisfactory. Physical growth is below the normal range (height SDS -3, 84); serum AP is still elevated. ing performed reguraly under the treatment, serum phosphate remains below the patient's predicted height less than target height. Biochemical monitoring performed regularly under the treatment, serum phosphate remains below normal, serum AP is still elevated.

Conclusion: This case is in line with other publications and indicates the need for additional treatment with growth hormone.

Background: Primary hypophosphatemic rickets is a rare disorder caused by inborn defect of renal tubular reabsorption and usually manifested in childhood and infancy with stunted growth and deformities of lower limbs.

Objective and hypotheses: The female patient from healthy parents, born without complications at term, normal weight and length. Psychomotor development until the age of 2 years was normal. Since the age of 2 years deformation of legs and difficulties with walking have been observed.

Methods: The Patient was consulted by Pediatric Orthopedist, Nephrologists and Endocrinologist. The blood biochemical findings revealed normal pH, normal calcium (Ca)-, potassium (K)-, sodium (Na)-concentrations, very low phosphate (P)- with markedly elevated alkaline phosphatase (AP)- and slightly elevated parathyroid hormone (PTH)-concentration; urine test indicated impaired tubular function: mild glucosuria, proteinuria, erythrocyturia and markedly increased phosphaturia. Phosphate tubular reabsorption (PTR) was 52%, phosphate clearance/creatinine clearance 0,52, renal threshold phosphate concentration (TmP/GFR) 0,25mmol/l. Genetic tests results not available yet.

Results: The diagnosis of phosphate diabetes made on the basis of clinical-laboratory data. The therapy with Inorganic phosphate (100mg/kg/d) and 1,25(OH)2VitD 50-60ng/kg/d had been started. Childs walking abilities improved with treatment, the deformation of legs decreased, but O-legs and other skeletal deformations are still remarkable. Auxological parameters are not satisfactory. Physical growth is below the normal range (height SDS -3, 84); the patient’s predicted height less than target height. Biochemical monitoring performed regularly under the treatment, serum phosphate remains below normal, serum AP is still elevated.

Conclusion: This case is in line with other publications and indicates the difficulty to achieve normal phosphate levels and normal growth without an additional treatment with growth hormone.

PAO-248
Thyrotoxicosis/thyroid storm in a previously asymptomatic pediatric patient: a case report
Carla Minutti; Rachel-Marie Cazeau
Loyola University Medical Center, Pediatrics, Maywood, Illinois, United States

Background: Thyroid storm is a rare but severe complication of thyrotoxicosis. The most common etiology of thyrotoxicosis is Graves’ disease, which is also the most common cause of hyperthyroidism in children. Typically pediatric patients present with thyromegaly, weight loss, or behavioral changes. Previously asymptomatic patients whose initial presentation is thyroid storm are not a typical finding.

Objective: To determine whether thyroid storm has been reported as the initial presentation in Graves’ disease in previously asymptomatic pediatric patients.

Hypothesis: Thyroid storm may be a more common initial presentation of thyrotoxicosis in pediatric patients then previously thought.

Methods: Literature search.

Results: Our patient was a 14 year-old previously healthy female hospitalized for thyroid storm. She was later diagnosed with Influenza and Graves’ disease. Prior to presenting to the hospital, this patient exhibited no symptoms of hyperthyroidism. She presented to the emergency room with a 3 day history of fever, diarrhea, sore throat, and cough, consistent with a viral illness. Physical exam revealed hyperthermia, diaphoresis, sinus tachycardia, hypertension, exophthalmos, Von Graefe’s sign, Dalrymple’s sign, thyromegaly,
tremors, and fluctuating mental status. Her thyroid function studies revealed a Free T3 of 747 pg/dl, Free T4 of 4.8 ng/dl, and TSH of <0.01 uu/ml. She was started on Methimazole, Propranolol, and Potassium Iodide for thyroid storm. Antibody testing revealed anti-TPO of 1355.5 iu/ml, anti-thyroglobulin of 291.8 iu/ml, and TSI of 335% baseline. She was diagnosed with Grave’s disease and continued treatment with Methimazole and Propranolol.

Conclusions: Graves’ disease accounts for 10-15% of all childhood thyroid disorders, with incidence ranging from 0.1-3.0 in 100,000 children. Approximately 1-2% of patients with hyperthyroidism progress to thyroid storm when physiologically stressed. To our knowledge cases of asymptomatic Grave’s disease with initial presentation of thyroid storm in pediatric patients are not commonly reported.

PAO-249

Complication of subcutaneous fat necrosis of the newborn
Nazanin Hazhir; Robabeh Ghergherehchi
Tabriz University of Medical Sciences, Students’ Research Committee, Tabriz, Islamic Republic of Iran

Background: Subcutaneous Fat Necrosis(SCFN) of the newborn is uncommon, self-limited disorder that occurs in full term infant who experienced a perinatal distress in the first weeks of life. It can be complicated by life threatening hypercalcemia and other rare complication such as hypoglycemia, thrombocytopenia, hypertriglyceridemia, anemia and fever. SCFN with hypercalcemia frequently has been reported.

Objectives: To describe a case of subcutaneous fat necrosis with all of the above complications.

Methods: We recorded risk factors concerning the mother, pregnancy and delivery, clinical aspects of SCFN and early and late outcomes.

Results: The child was born at term. Lesions appeared on the 22th day of life. Delivery was complicated by meconium aspiration. Complications were hypoglycemia, hypercalcemia, nephrocalcinosis, dyslipidemia, thrombocytopenia and fever.

Conclusions: Physicians caring for infants with subcutaneous fat necrosis of the newborn should be aware of the above associations in order to provide prompt and appropriate treatment to prevent associated, undesirable sequelae. Figure 1: The erythematous subcutaneous nodular plaque on the middle of the back and arm.

PAO-250

Nutritional status in PKU patients in Mazandaran province: is it acceptable or not?
Peiman Eshraghi1; Ali Abbaskhanian2; Sahar Taghavi3
1Mashhad University of Medicine, Pediatric Endocrinology, Mashhad, Islamic Republic of Iran; 2Sari University of Medicine, Pediatric Neurology, Sari, Islamic Republic of Iran; 3University of Pharmacy, Biotechnology, Mashhad, Islamic Republic of Iran

Background: Phenylketonuria is one of the most frequent metabolic diseases which is transmitted as autosomal recessive pattern. Appropriate diet with restricted phenylalanine is the base of treatment, so special formulas and diet replace phenylalanine containing foods. Limited native studies exist about the results of such treatment means protein limitation and replacing an expensive and unavailable foods. This study was designed to evaluate nutritional status the calorie, protein, carbohydrate and fat of patients’ diet and iron storage and iron deficiency anemia in PKU patients.

Objective and hypothesis: This is a cross sectional study which evaluated all of the PKU patients in Mazandaran province during 2009-2010 in metabolic clinics in Babol and Sari. Nutritional status was evaluated according to 72 hours diet recall sheet which is the method for recording nutrients eaten within 3 days. Nutritional and demographic information was studied according to questionnaire and blood sampling results and iron deficiency anemia.

Results: Twenty one PKU patients were studied which 7 ones (33.3%) were female and 14 ones (66.7%) were male with mean age of 7.26±6.64 years. Iron deficiency and iron deficiency anemia was present in respectively in 10 (47.1%) and 6 patients (28.6%). Five patients (23.8%) were underweight and 4 patients (19%) were short stature.

Conclusion: Energy, protein, carbohydrate, fat and iron deficiency was significant in patients; According to the price of special foods in our country, families cannot prepare enough foods. So, attention to nutritional demands in PKU patients to reduce malnutrition and iron deficiency is critical.